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INTRODUCTION 
 
Siddha system of medicine is an integrated part of Indian system of medicine, 
which is very potent and unique system when compared with other traditional 
systems in existence. Siddha system clearly lays down the general principles of 
body constituents in the classic Bootha system. Siddhars hold that the universe is a 
macrocosm made up of the 5 primordial elements or Boothas, viz Nilam (Earth), 
Neer (Water), Thee (Fire), Vali (Wind) and Veli (Space) and the human being made 
up of the same five elements.  
 
                   "«ñ¼ò¾¢ÖûÇ§¾  À¢ñ¼õ 
 
                    À¢ñ¼ò¾¢ÖûÇ§¾  «ñ¼õ 
 
                    «ñ¼Óõ À¢ñ¼Óõ ´ý§È 
 
                    «È¢óÐ¾¡ý À¡÷ìÌõ §À¡§¾" 
 
                                     -ºð¼ÓÉ¢ »¡Éõ. 
 
 Siddha system is not only deals with medicine but with spirituality, righteous way 
of living, rejuvenation and means of attains  perfection. One  who attainment  of  
perfection in life is called as SIDDHARS. They had thoroughly studied human 
body, all kinds of plants, minerals, metals, and poisonous drugs and their physical 
and  chemical properties. They are experts in Alchemy, Yoga, Kayakalpa and the 
science of Elixir and also in the field of literature, philosophy, astrology etc. 
 
Many chronic diseases considered incurable in western medicine, can be treated 
successfully in siddha medicine contributing much to the women healthcare. As per 
saint Agathiyar, One such disease GARPA VAAYU mentioned in Agathiyar 
aayulvetham 1200
(1)
can  be correlated to Polycystic ovarian syndrome. The 
classical siddha literature Agathiyar Ayulvedham 1200 cites that any imbalance in 
three humors may inhibit the release of ovum from  the ovaries. This may be related 
to the subinfertility due to ovulatory factors. 
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The symptoms of Garpavaayu are Amenorrhoea, Oligomenorrhoea followed by 
Menerrhogea, Dysmenorrhoea, Inferility, Missed abortion, Low back ache, 
Constipation and Obesity. It may be correlated with Poly cystic ovarian syndrome 
of modern science.   
 
PCOS is a common endocrine disorder of women in reproductive years with 
prevalence of 5 to 10% childbearing age ranged fom 18 to 40 years and 30% of 
women have some PCOS symptoms in world wide
(2)
. In India 1 in 40 of Indian 
adolescent needs hospitalization due to PCOS. Long term hormone replacement 
therapy for PCOS has been proved unsafe. Since it produces complication such as  
Deep vein thrombosis, Obesity etc.  
 
           Siddhars identified innumerable number of herbs in treating uterine 
disorders. One such siddha formulation by name Garpavaayu ilagam mentioned in 
Aatmarakshamirtham ennum vaithiya saarasangiragam
(3)
, Which is said to be 
cost effective, efficasious and simple formulation when compared to other 
medications. 
 
One of the cause of PCOS is  Insulin resistance.  The  ingridients in Garpavaayu 
ilagam are said to possesses Anti-diabetic activity, Anti spasmodic activity , Anti 
obesity activity and Anti hyperlipidemic activity   which supports the efficacy of the 
trial drug  and found to possess regulatory agent of menstrual cycle for women with 
irregular cycles. The above said references and the research works done on the 
individual ingredients of  Garpavaayu ilagam justify its benefit in the treatment of 
Garpa vaayu (PCOS).  
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AIM: 
        The evaluate the therapeutic efficacy of siddha formulation ―GARPAVAYU 
ILAGAM‖(Internal)  in the management  of Garpa vaayu (Poly cystic ovarian 
syndrome). 
PRIMARY OBJECTIVE: 
To study the Therapeutic efficacy of siddha formulation ―GARPAVAYU 
ILAGAM‖ (Internal medicine)  in the treatment of Garpa vaayu (Poly cystic 
ovarian syndrome). 
SECONDARY OBJECTIVE:  
 To prepare the trial drug as per SOP. 
 To evaluate the biochemical and physicochemical analysis of the  trial drug. 
 To study the efficacy of the trial drug through an open clinical trial. 
 To study the changes in USG before and after treatment. 
 To compare the BMI (Body mass index) before and after treatment. 
 To evaluate the infertility ratio among the study patients. 
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                            REVIEW OF LITERATURE 
 
SIDDHA ASPECT  - GARPA VAAYU 
 
¦¸÷ôÀ Å¡ÔÅ¢ý Ì½õ : (DEFENITION) 
 
As per Sage Agathiyar, specified Garpa vaayu  is characterized by Amenorhea, 
oligomenorrhoea, Menorrhagia, dysmenorhoea, missed abortion, low back ache, 
constipation and obesity. 
 
¦À¡ÕÁ¢ Ãò¾ó¾ý¨É ÁÈ¢òÐô §À¡¾ Á¢¸×õ ÅÄ¢Ôñ¼¡í 
 
ÌÕ¾¢§ºÃ¡ ÅÂ¢ÚÅÄ¢§À¡í ¦¸¡ûÙí ¸÷ôÀó¾ý¨ÉÂÆ¢ìÌõ 
 
ÅÕÊÂ¢ÎôÒì Ì¨¼óÐ¨ÇìÌõ ÁÄò¨¾Á¢¸× Á¢Úì¸¢Úì¸¢ 
 
¦ÀÕ¸ô À¨½ìÌ¦ÁÉô ¦ÀÃ¢§Â¡÷ §ÀÍí ¸÷ôÀ Å¡ÔÅ¢§¾. 
 
                          -«¸ò¾¢Â÷ ¬Ôû§Å¾õ 1200(2) 
 
¦¸÷ôÀ §Ã¡¸ò¾¢ý Ì½õ 
 
Yugi muni vaithiya kaviyam  specified  the  symptoms like pain in lower abdomen, 
generalised body pain and missed abortion  under  Garpa noigal (Uterine disorder  
 
¦À¡ÕÁ¢ò ¾¢ÃñÎ ¸£úÅÂ¢üÈ¢ø ÒñÀð¼Øó¾¢î º£ú¦¸¡ñÎ 
 
ÁÕ¼ôÀÆ¸¢ ¿¢ýÈì¸¡ø ÁÂí¸¢î ¦º¡ø§ÄÁ¡È¡Ð 
 
¯ÕÅ¢ôÀ¢Æ¢ó¾¡ü §À¡ø§ÁÉ¢ ¯ÕñÎ ¯¨ÄóÐ ´Îí¸¢ 
 
¸Õ¨Å «Æ¢ìÌõ ÐÊÂ¢¨¼Â¡÷ ¸ÕÐõ ¦¸÷ôÀ§Ã¡¸Á¢§¾. 
 
                          -ä¸¢ÓÉ¢ ¨Åò¾¢Â ¸¡Å¢Âõ(4) 
 
According to Sarabendrar Vaithiya muraikal  text  the  Garpa rogam can be elicit 
from the symptoms such as pain in lower abdomen, mild fever, head ache and 
generalised tiredness due to pain.           
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¦À¡ÕÁ¢ ¾¢ÃñÎ ¸£úÅÂ¢üÈ¢ø Òñ§À¡Ä¡¸ Á¢¸¦¿¡óÐ 
 
ÓÕÅìÌò¾¢ì Ì¨¼ó¦¾íÌõ ¦Á¡ì¸î ÍÃÓõ ¾¨ÄÅÄ¢Ôõ 
 
¦ÅÕÅìÌò¾¢î  ¦ºÂø ¸ðÊ ¦ÅÊòÐô ÒñÀð§¼¡Î ÀðÎò 
 
¾¢Õ¨Å ¦À¡Õ¾ §ÁÉ¢Â§Ã ¦ºöÔÁí ¸÷ôÀ §Ã¡¸Á§¾. 
 
-ºÃ§Àó¾¢Ã÷ ¨Å¾¢ÂÓ¨ü¸û ¸÷ôÀ¢½¢ À¡Ä§Ã¡¸ º¢¸¢î¨º(5) 
 
ACCORDING TO T.V. SAMBASIVAM PILLAI AGARATHY 
 
Garpa vaayu is a disease of the uterus attended with flatulence. It is marked by 
unusual bloody discharge from the vagina, excessive pain, abortion, pain in the loin, 
heaviness of the abdomen, constipation and other symptoms.    
¸÷ôÀ §¿¡ö¸û ÅÕõ ¸¡Ã½õ (AETIOLOGY) 
 
Siddha system attributes the etiology of garpa rogam as  increase of heat that leads  
to loss of semen, any kind of infanticide,taking the cow‘s milk completely without 
for calf, destroying of young crops    
      
¸Õ¾¢§Â ¸ÉÁ¡É ¦¸¡Î¨Á ¦ºöÐ 
 
   ¸ÉÅ¨É§Â ¿¢ó¾¨É¾¡ý ¦º¡ýÉ §ÀÕõ 
 
ÀÕ¾¢Â¢ý ÓýÁÄºÄò ¨¾Å¢ð¼ §ÀÕõ 
 
    ÀÃ§¾º¢ §Â¨Æ¸¨Çô ÀÆ¢ì¸¢ý §È¡÷ìÌõ 
 
ÌÕ¾¢§Â Â¢¨Ãì¸¢ýÈ ¸¡Äó ¾ýÉ¢ø 
 
    Üº¡Áü ÒÕ„ºí ¨¸ÀýÉ¢§É¡÷ìÌõ 
 
ÍÕ¾¢§Â ÀÃ§À¡¸õ Å¢ÕõÀ¢ §É¡÷ìÌõ 
 
   ÍÕì¸¢§Ä ¦ÀÕõÀ¡Îü ÀÅ¢ìÌó ¾¡§É. 
 
               -ä¸¢ Á¡ÓÉ¢Å÷ ¨Åò¾¢Â º¢ó¾¡Á½¢ 800(6) 
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¾¡¦ÉýÈ ¸¡Ãí¸û Á¢Ìì¨¸ Â¡Öõ 
 
   ºñ¼¡Çì §¸¡Àò¾¢ý ºÄ¢ôÀ¢É¡Öõ 
 
°¦ÉýÈ Á¡Á¢ºí¸û ¦À¡º¢ò¾ Ä¡Öõ 
 
   ¯Èì¸ÁýÈ¢ Å¢Æ¢ò¾Ä¡ æÆ¢ò ¾£Â¡ø 
 
À¡¦ÉýÈ Àº¢Â¢ýÈ¢ô ¦À¡º¢ì¨¸ Â¡Öõ 
 
     À¡ÃÁ¡ï Í¨Á¾¡í¸ø  À¸Ö Èì¸õ 
 
Ü¦ÉýÈ ÌÚì¸Ä¡ö Ó¼ì¸¢ò àí¸ø 
 
    ÌåÃÁ¡õ ¦ÀÕõÀ¡Î ÜÎó ¾¡§É. 
 
          -ä¸¢ Á¡ÓÉ¢Å÷ ¨Åò¾¢Â º¢ó¾¡Á½¢ 800(6) 
 
ÍÆÄ¡Áø Š¾¢Ã¢¸ÙìÌ ¸÷ôÀ §¿¡ö ¾¡ý 
 
    ÝúóÐ Åó¾ ¸¡Ã½ò¨¾î ¦º¡øÄì §¸Ç£÷ 
 
«ÆÄ¡§Ä Å¢óÐÅ¨¾ «Æ¢ò¾ À¡Åõ  
 
    «ïº¡Áø À¡Ä¸¨É ¦¸¡ýÈ À¡Åõ  
 
ÌÆÅ¢Â¢Çõ À¢ïÍ âôÀÈ¢ó¾ À¡Åõ 
 
    §¸¡Å¢ý ¸ýÚì¸¢ýÈ¢ À¡øÌÊò¾ À¡Åõ 
 
Å¢¨ÇÅ¡É Å¢Çõ ÀÂ¢¨Ã ÂÆ¢ò¾ À¡Åõ  
 
    §Á¾¢É¢Â¢øÁ¼Ä¡É Å¢ó¨¾ ¾¡§É. 
 
                -Á¡¾÷ ÁÕòÐÅõ (º¢¾õÀÃ¾¡ÏôÀ¢û¨Ç)(7) 
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¦¸÷ôÀ §Ã¡¸õ Å¨¸¸û (CLASSIFICATION) 
 
1. ACCORDING TO YUGIMUNI VAITHIYA KAAVIYAM 
(14)
 
         Garpa nooigal has been classified into five types. They are,  
1.Í§Ã¡½¢¾ Å¡ö× 
 
2.¦¸÷ôÀ Ý¨Ä 
 
3.¦¸÷ôÀ Å¡ö× 
 
4.¦¸÷ôÀ Å¢ôÒÕ¾¢ 
 
5.þÃò¾ Ý¨Ã Å¡ö× 
 
2. ACCORDING TO MEGA NOI, SOOTHAGA NOOL AND ARIVAIYAR 
CHINTHAMANI 
(15) 
       Garpa noigal is classified into six types . 
 
1.¦¸÷ôÀ Å¡Ô 
 
2.¦¸÷ôÀ Ý¨Ä ÅÄ¢ 
 
3.ºÄ Ý¨Ä 
 
4.þÃò¾ Ý¨Ä  
 
5.Ý¾¸ Å¡Ô   
 
6.Å¢ôÒÕ¾¢ Å¡Ô 
3.ACCORDING TO AGASTHIYAR AAYULVEDHAM – 1200 (2) 
Following   types of Garpa noigal   are described  in Agasthiyar Aayulvedham  
 
1.¦¸÷ôÀ Å¡Ô  
 
2.¸÷ôÀ Å¢ôÒÕ¾¢  
 
3.¸÷ôÀ Ý¨Ä   
 
4.þÃò¾ Ý¨Ä   
 
5.Ý¾¸ Å¡Ô (Ýº¢¸ Å¡Ô)  
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CLINICAL FEATURES OF GARPA VAAYU  
A. ACCORDING TO YUGIMUNI VAITHIYA KAAVYAM 
(4) 
 
¦À¡ÕÁ¢ Ãò¾ó¾ý¨Éî ¦º¡Ã¢Ôõ §À¡¾ Á¢¸×õ ÅÄ¢Ôñ¼¡õ 
 
ÌÕ¾¢ì¸Æ¢Â¢øÅÄ¢«ÁÕõ ¦¸¡ûÙõ ¸÷ôÀó¾ý¨ÉÂÆ¢ìÌõ 
 
¸Õ¸¢þÎôÒõ ¸ÎòÐ¨ÇÔõ ¸Éò§¾ÅÂ¢ÚÁÄõ¸ðÎõ 
 
¦ÀÕ¸ô À¨½ìÌõ ¾Éò¾¢É÷ìÌõ §ÀÍí ¦¸÷ôÀ Å¡ÔÅ¢§¾. 
 
Menorrhagia, dysmenorrhoea, pain subside when the menstrual flow increases, 
missed abortion, low back ache, obesity are the features of Garpa vaayu  
B. ACCORDING TO MEGA NOI, SOOTHAGA NOOL AND ARIVAIYAR 
CHINTHAMANI     
Å¡È¡É ¦¸÷ôÀ Å¡Ô Å¨¸§Â ¦¾ýÈ¡ø  
 
    ÅÇ÷ Á¡¾Å¢¨¼ ¸¡Äõ ÅÂ¢üÈ¢ø §¿¡Â¡õ 
 
ÜÈ¡É Í§Ã¡½¢¾õ ¾¡ý þ¨Èîº¢ ¿£÷ §À¡ø 
 
    ÜýÈ ºÃò¾¢ø þ¨¼Å¢ðÎ ÓØìÌñ¼¡Ìõ 
 
§ÀÈ¡É ÒÕ„Û¼ý ÜÎõ ¸¡Äõ 
 
    ¦ÀÕ Á¢¨Èîº¢ ¿£ÃÐ §À¡ø Ð½¢Â¢ø ¸¡Ïõ 
 
Å£È¡¸ §¾¸ÁÐ ¦ÅÙòÐ §À¡Ìõ 
 
    Å¢ÇíÌ ¾¢½ôÀ¾¢¸ Á¾¡Ôñ¼¡í ¸¡§½. 
 
                 -§Á¸§¿¡ö, Ý¾¸áø ÁüÚõ «Ã¢¨ÅÂ÷ º¢ó¾¡Á½¢(8) 
 
The following symptoms like discomfort in abdomen during menstruaton, passing 
big clots during menstruation, irregular menstruation and anaemia are present in 
garpa vaayu . 
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D. ACCORDING TO PARARASASEKARAM 
(9) 
 
¾¢ÕÅ¨ÉÂ¡ Õ¾ÃÁ¾¢ü ¦¸÷ôÀ §Ã¡¸ï 
 
    ¦ºôÀ¢É¦Ã¡ý ÀÐ§À¾ï ¦ºöÂ §º¡Ã¢  
 
ÁÕ×ÍÃï Ý¨ÄÁ¢Ì Å¡Ô §ÁÖõ  
 
    ÅÕòÐÒØ Å¢üÒÕ¾¢ ÅýÒ½÷îº¢ 
 
¸ÕÅ¢ÖÚ  Åïº¨ÉÔ ÁÕó¾¢ É£Îõ 
 
    ¸ÆÈ¢ÉÃ¢í ¸¢ÅüÚ¨ÇóÐõ ¾£Õ ¦ÁýÚ 
 
¦À¡ÕÅÃ¢Â ¾Á¢úÓÉ¢Å ÉýÚ ¨Ãò¾ 
 
¦À¡ÕÇ¡Ã¡öó ¾È¢¾ø¸¼ý ÒÄ¨Á §Â¡÷ì§¸. 
 
According to Pararasasekaram, Garpa vaayu is one among the nine types of Garpa 
noigal.  They are as follow 
1.Í§Ã¡½¢¾ ¦¸÷ôÀ Å¡Ô 
 
2.ÍÃò¾¢ý §Áø ¦¸÷ôÀ §Ã¡¸õ 
 
3.¦¸÷ôÀ Ý¨Ä 
 
4.¦¸÷ôÀ Å¡Ô 
 
5.¦¸÷ôÀ ¸¢ÕÁ¢ 
 
6.¦¸÷ôÀ Å¢ôÒÕ¾¢ 
 
7.¦¸÷ôÀ Ò½÷îº¢ 
 
8.¦¸÷ôÀ Åïº¨É 
 
9.¦¸÷ôÀ ÁÕó¾£Î 
 
¦¸÷ôÀ Å¡ÔÅ¢ý Ì½õ 
 
¦À¡ÕÓ  Ó¾Ãó ¾¨ÉÂ¼÷òÐô §À¡¾ Á¢¸×õ ÅÄ¢Ôñ¼¡öì 
 
ÌÕ†¢¸Æ¢Â¢ø ÅÄ¢¾£Õí ¦¸¡ûÙí ¦¸÷ôÀ  ÓÈÅÆ¢ìÌõ 
 
ÅÕÊ Â¢ÎôÒò Ð¨¼Ô¨ÇÔ ÁÂìÌ ÁÄò¨¾ Á¢¸Å¢Úì 
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¦ÀÕ¸ô À¨½ìÌõ Ó¾Ãò¾¢ü §ÀÍõ ¦¸÷ôÀ  Å¡ÔÅ¢§¾. 
 
 
§ÅÃ¡Á¢¼Ð À¡¸ò¾¢ý Á¢ñÊ ÅÄ¢ìÌ §Á§ÄÚõ 
 
º¡Õí ÌÕ¾¢ ¾½¢Â¡Ð ¾¨ÄÂ¡¦ÁÉ§Å ¾¨Ä ¾¢Á¢÷ìÌõ 
 
§¿§Ã ¾¢ÃÙ ¿¡À¢ì¸£ú ¿¢÷ìÌï º¡ö¨¸ Â¾¢üº¡Õõ 
 
¿¡Ã¢ ¸ÎìÌï ºóÐ¨ÇÔ ¿Äï§º Õ¾Ãó ¾É¢øÅÄ¢§Â 
 
Amenorrhoea, oligomenorrhoea followed by menorrhagia, dysmenorrhoea subsides 
as the flow increases, severe pain in low back region and in thigh, giddiness, 
constipation and obesity. 
ÍÃò¾¢ý §Áø ¦¸÷ôÀ §Ã¡¸õ 
 
¿£Úï ÍÃÁ¡ Ô¼õÒÄÕ ¿£Õï º¢ÅìÌ ÁÊÅÂ¢üÈ¢ø 
 
°Ú Á¢¸§Å ¸¨ÈÀÎõ§À¡ Ð¼§É ¿£Õ ¦Á¡ÎÅ¡Ìõ 
 
§¾Úí  ¸Õ¨Å ÂÆ¢ôÀ¢ìÌó ¾¢É§Á ¸¡ó¾ý Á¢Ìõ ¦À¡ÕÓõ 
 
ÜÚï §º¡Ã¢ Â¢Ä¾¡Ìí ¦¸¡ÊÂ ÍÃò¾¢ý Ì½Á¡§Á. 
 
Dryness of skin, hematuria, lower abdominal pain, menorrhagia, abortion are the 
features of above disease.     
 
Í§Ã¡½¢¾ ¦¸÷ôÀ Å¡Ô 
 
¾¢ÃñÎ ÒÃñÎ ¸£úÅÂ¢üÈ¢ø ¾¢¾Á¡ö Á¡¾Å¢¼¡ö §À¡Öõ 
 
ÁÕñÎ ÌÕ¾¢ Á¢ÌóÐÅÕõ Å¡ö¿£÷ ¦ÀÕòÐ ÁÂí¸¢ ÅÕõ 
 
«ÕñÎ º¢Ä¿¡û Å¢Ãò¾ §Ã¡¸¦ÁÉ ×Ú¾¢ ÂÐ¸ñ Î½÷Å£§Ã. 
 
 
¯ó¾¢ì¸£ Ø¾Ãõ Òì¸¢ ÔÄ¦ÁÉ Å¢ÕìÌ §Á¡Êî  
 
ºóÐ¸û Å¢ÕÅ¢ ÕòÐò ¾¡Û¼ø ¿Îí¸¢ ¦ÂíÌõ 
 
Áó¾Á¡ Ô¼õÒ ÆüÈ¢ ÁÚ¸¢Ôð ºò¾¢ §¾¡ýÈ¢ø 
 
þó¾Á¡ Ì½í¸û ¸ñ¼¡ Ä¢Ð¦¸÷ôÀ Í§Ã¡½¢ ¦Âý§È. 
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Lower abdominal discomfort followed by excessive bleeding like menstruation, 
excessive salivation, giddiness,  lower abdominal pain ,abortion , numbness in 
joints, nausea, giddiness, generalised body pain and prostration.  
¦¸÷ôÀ Ý¨Ä  
 
¾¢ÃñÎ¸£ú ÅÂ¢üÈ¢ü §È¡ýÈ¢î º¢ì¸¢¿¢ý  È¢Ãò¾õ Å£úóÐ 
 
À¢ÃñÎ¾¡Û¾Ã ¦ÁíÌõ À¢û¨Ç§À¡ Ä¡¸çÕõ 
 
«ÕñÎ¾¡ÉØì¸ ¾¡É¡Ä¾Û¼ý ÅÄ¢Ôó §¾¡ýÚõ 
 
¯ÕñÊÎí ¦¸÷ôÀ ÝÄó ¾¡¦ÉÉ ×¨Ãì¸Ä¡§Á 
 
 
¾¢ÃñÎ¸£ú ÅÂ¢ü¨Èô ÀüÈ¢î º¢ì¸¢¿¢ý È¢Ãò¾õ Å£úóÐ 
 
ÒÃñÎ¾¡ý ÅÄ¢ìÌ Á¡¸¢ü ¦À¡øÄ¡¾ ¦¸÷ôÀ Ý¨Ä 
 
ÅÃñÎ§Á ¦ÅÙòÐ ÅüÈ¢ ÁÂí¸¢¼ì ÌÕ¾¢ §º¡Ã¢ø 
 
¯ÕñÊ¼¡ Å¢Ãò¾ §Ã¡¸ ÓÚ¾¢Â¡ Ô¨Ãì¸Ä¡§Á 
 
Excessive painful bleeding during menstruation, abdominal distention as  in 
pregnancy, anaemia.    
 
¦¸÷ôÀ ¸¢ÕÁ¢ 
 
¦À¡ÕÁ¢ò ¾¢ÃñÎ ¸£úÅÂ¢üÈ¢ü ÒñÀð¼Øó¾¢î ¦ºÂø¦¸¡ñÎ 
 
ÁÕÅ¢ ÅÄ¢ìÌõ ¦Åû¨ÇÔñ¼¡õ Å¡ö¿£ ÕÚ ÓÅ¡ó¾¢ìÌõ 
 
¯ÕÅ¢ô À¢Æ¢ó¾¡ü ¦À¡ý§ÁÉ¢ ÔÄ÷óÐ ¾¢ÂíÌ ¦Á¡Î×ñ¼¡õ 
 
¸¢ÕÁ¢ò §¾¡„ ÁÐ¦ÅýÛí ¦¸÷ôÀ §Ã¡¸ì Ì½Á¡§Á. 
 
Severe abdominal pain , whitish discharge, nausea, vomiting and dryness of skin are 
present in Garpa kirumi. 
¦¸÷ôÀ Å¢ôÒÕ¾¢ 
 
«ÊÅÂ¢ È¨¾òÐ Å¢õÁ¢ÂØó¾¢Îõ Àñ§À¡ §É¡Å¡õ 
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¾¨¼«¼ Å¢Ãò¾ ¿¢ýÚ ºüÚîºü  È¡¸ Å£Øõ 
 
þÕ¼È ÅÄ¢ìÌ  Á¡¾ Å¢¨¼Â¢É¡ Ä¢Ãò¾ Á¢ø¨Ä 
 
Á¢¨¼ÀÎí Ì½§Á ¦¸÷ôÀ Å¢üÒÕ¾¢ ¦ÂýÉÄ¡§Á. 
 
 
ÅÂ¢ü¨È ÅÄ¢ìÌõ ¦Åû¦Çîº ÁÐ§À¡ü À¢¼¨Å ¾É¢üÀÎÁ¡õ 
 
¯Â¢÷ô¨Àî º¢Èó¾ ×¼ÖÕìÌ  ÓÅó¾ý Éò¾¢ É¡¼¡Ð 
 
¦ÅÂ¢ü¸ð ¦À¡È¡Ð ¾¡¸ÓÁ¡ Á¢¸§Å §ÁÉ¢  ¾Ç÷îº¢Ôñ¼¡õ 
 
ÌÂ¢ü¦º¡ü ÀÂ¢Öí ¦¸¡ÊÂ¢¨¼Â£÷  ÌÈ¢ìÌõ Å¢üÒÕ  ¾¢ìÌ½§Á 
 
Distention of abdomen due to tumour, pain in abdomen, irregular menstruation 
followed by oliguria, dysmenorrhea, whitish discharge, loss of appetite, thirst and 
generalised tiredness 
¦¸÷ôÀ Ò½÷îº¢ 
þó¾¢Ã¢ Âó¿£÷ §À¡Ä Å¢¨¼Å¢¼¡ ¦¾¡Ø¸¢ Å£Øõ   
 
¯ó¾§Å ¾íÌí ¦¸÷ôÀ Ó¨¼ÀÎ  Ó¾¢Ã Á¡¸î 
 
º¢ó¾¢§Â  §Â¡Îõ Å¡Ô  ¾¢Ãðº¢Â¡öî  ¦ºÚòÐ Å¢õÓõ 
 
Òó¾¢¨Â ÁÂìÌí ¦¸÷ôÀô Ò½÷îº¢Â¢ý Ì½Á¡ ¦Áý§É. 
 
Excessive vaginal discharge following intercourse and missed abortion . 
 
¦¸÷ôÀ Åïº¨É 
 
Àï¦ºÉ ¦ÅÙìÌ §ÁÉ¢ ÀÈ¢ó¾¢Îó ¾¨ÄÔ §Ã¡Áõ 
 
¦¿ïÍÈ ¦ÅÃ¢òÐ Å¡ö¿£ åÈ¢§Â ¿¢¾õÀí ¸¡öóÐ 
 
Á¢ïº§Å  §¸¡¨Ã º¡Ôõ §Å÷¨ÅÔ Á¢¸×ñ¼¡õ 
 
Åïº¨Éì Ì¨ÈÂ¡í ¦¸÷ôÀõ ÅÕò¾¢Îí Ì½í¸¼¡§Á. 
 
Anemia, loss of hair, burning sensation in chest, excessive body heat followed by 
menorrhagia, hyperhidrosis     
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¦¸÷ôÀ ÁÕó¾£Î 
 
«Õó¾¢Îõ ¦À¡º¢ôÒì ¸¡½¡ÅÃ×Ä÷ó ¾ò¾¢ Â¡Ìõ 
 
ÅÕó¾¢§Â  ¦¿ïÍ Ä÷óÐ ÅÈðº¢Â¡ Â¢ÕÁ Öñ¼¡õ 
 
¦À¡Õó¾¢§Â ¦¸÷ôÀ ¿£÷§À¡ü ¦À¡í¸¢§Â Ô¾¢Ãõ §À¡¸¡ 
 
ÁÕó¾¢É£ ¼¾É¡ø Åó¾ ¦¸÷ôÀ§¿¡ö Å¨¸Â¢ ¾¡§Á 
 
Loss of appetite, chest discomfort followed by dry cough, amenorrhoea are the 
symptoms in maruntheedu Garpa noi.   
 
ACCORDING TO PARARASASEKARAM 
(9) 
Of the 9 types of Garpa noigal five are curable and four are incurable i.e., it can be 
treated only after long term treatment 
Åïº¢ì  ¦¸¡ÊÂ¡ ÕòÃÁ¾¢ý ÁÕ×í ¦¸÷ôÀ §Ã¡¸ÁÐ 
 
Á¢ïÍï Í§Ã¡½¢ ÍÃïÝ¨Ã Á¢Ìó¾ Å¡Ô ¸¢ÕÁ¢¦Â¡Î 
 
¦ºï¦º¡ý Á¼ÅÅ£÷ Å¢üÒÕ¾¢ §ºÕõ Ò½÷îº¢ Åïº¨É§Â¡ 
 
¦¼¡ïÍ ÁÕò¾¢ ¦¼¡ýÀ¾¢É¡ ÖÚ§Á ¦¸÷ôÀ  §Ã¡¸Á§¾. 
 
 
þÃò¾ §Ã¡¸ Áò¾¢ÍÃò  ¦¾Îò¾ §¿¡× Ý¨ÄÂ¢Éõ 
 
¯Ãò¾ Å¡Ôò ¾¢Ãðº¢§Â¡ Î¨ÈÔí ¸¢ÕÁ¢ Å¢üÒÕ¾¢ 
 
ÅÕóÐõ Ò½÷îº¢ Åïº¨ÉÔ ÁÕó¾¢É£Î  ¦Á¡ýÀ¾Ûû 
 
¾¢Õò¾ Á¡¸  ÓýÉ¡ýÌó ¾£Ã¡ ¨¾óÐó ¾£ÕÁý§È. 
 
 
º¡ò¾¢Â Å¨¸¸û 
 
1. ¦¸÷ôÀ Å¢ôÒÕ¾¢ 
 
       2. ¦¸÷ôÀ Ò½÷îº¢ 
 
       3. ¦¸÷ôÀ Åïº¨É 
 
       4. ¦¸÷ôÀ ÁÕó¾£Î 
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«º¡ò¾¢Â Å¨¸¸û 
 
1. Í§Ã¡½¢¾ ¦¸÷ôÀ Å¡Ô   
 
2. ÍÃò¾¢ý §Áø ¦¸÷ôÀ §Ã¡¸õ 
 
3. ¦¸÷ôÀ Ý¨Ä 
 
4. ¦¸÷ôÀ Å¡Ô     
 
5. ¦¸÷ôÀ ¸¢ÕÁ¢  
 
ÓìÌüÈ §ÅÚÀ¡Î¸û (Pathology) 
 
In Siddha system the manifestations of all diseases are due to the derangement of 
tridoshas i.e., vaatham, pitham and kabam. 
§¿¡ö ¸½¢ôÒ Ó¨È 
 
In piniyari muraimaigal following principles are followed in Siddha system. They 
are      
 
o Poriyaaltherithal  - Inspection 
o Pulanaal arithal  - Palpation  
o Vinaathal - Interrogation    
Poriyaaltherithal - Porigal is the five sense organs of perception namely Nose, 
Tongue, Eye, Skin and Ear.    
Pulanaal arithal – Pulangal is the five senses namely smell, sound, taste, sight 
sensation. Physicians use their pori and pulan to examine the pori and pulan of the 
patient respectively.    
Vinathal – Getting informations about the history of the diseases from the patient 
or from the attenders of him, when the patient is not in a position to speak or if the 
patient is a child.    
ENVAGAI THERVUGAL: 
“¿¡Ê ŠÀÃ¢ºõ ¿¡¿¢Èõ¦Á¡Æ¢ Å¢Æ¢ ÁÄõ ãò¾¢Ãõ 
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­¨ÅÂ¨ÉòÐõ ÁÕòÐÅý ¬Ô¾õ”(10). 
 
1) Naadi: The three Uyirthaathukkal are formed by the combination of      
                             Edakalai + Abanan = Vatham  
                             Pinkalai + Piranan = Pitham  
                             Suzhumunai + Samanan = Kabam  
In Garpa vaayu   Vatha naadi or Vatha thontha naadigal were seen commonly  
Á¡¾÷ ¨¸ôÀ¢Êò¾ §À¡Ð Åó¾¢Îõ Å¡¾¿¡Ê 
 
¾£¾Ú¦ÅÊòÐ À¡öóÐ º¢¾È¢§Â º¢ÄõÀ¢¿¢ýÈ¡ü 
 
§À¨¾¾ýÅÂ¢üÈ¢ý ¯û§Ç ¦ÀÕÌ Í§Ã¡½¢¾§Á ¾í¸¢ 
 
Å¡¨¾¸û Àñ½ Á¡¾Å¢¨¼¸¡Äõ ÅÕò¾õ ¦ºöÔõ 
 
þÎô¦À¡Î ¸ÎòÐ ¦¿¡óÐ þ¨¼Å¢¼¡ì Ìò¾Öñ¼¡ö 
 
¾Îò¾¢¼¡ ¸÷ôÀó¾¨É ¾í¸¢¼¡ ÅñÉõ ¦ºöÔõ. 
 
            -À¾¢¦½ñ º¢ò¾÷¸û ¿¡Ê º¡Š¾¢Ãõ 
 
The deranged Vatha naadi produces painful menstruation, excessive bleeding and 
generalised body pain. Finally it leads to infertility.  
 
Å¡¾¿¡Ê 
 
Å¡¾¦ÁÛõ ¿¡ÊÂÐ §¾¡ýÈ¢ø  
 
     º£¾Áó¾¦Á¡Î ÅÂ¢Ú¦À¡ÕÁø ¾¢Ãðº¢Å¡Ô 
 
º£¾ÓÚí ¸¢Ã¡½¢ Á§¸¡¾Ãõ ¿£Ã¡¨Á 
 
     ¾¢ÃûÅ¡Ô Ý¨Ä ÅÄ¢ì¸ÎôÒò ¾£¨Ã 
 
¿£¾ÓÚí ¸¢ÕÁ¢ÌýÁõ «ñ¼ Å¡¾õ 
 
     ¿¢¨ÄÔõ ¿£÷ì ¸¢Ã¢îºÃí¸û ¾óÐ §Á¸õ 
 
§À¾¸Á¡Ó¾Ãô À¢½¢ ãÄ§Ã¡¸õ 
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    §Àº¦ÅÌ À¢½¢¸Ù§Á  ¦À¡ÕÇ ¾¡§Á. 
 
Å¡¾À¢ò¾ ¦¾¡ó¾õ 
 
¦À¡ÕÇ¡É Å¡¾ò¾¢ø À¢ò¾ï §º÷óÐ  
 
     ¦À¡ÕóÐ Ì½í¸Ç¡ Ó‰½Å¡Ô ºò¾¢ 
 
¦ºÃ¢Â¡¨Á ÒÇ¢ò§¾ôÀõ ¦À¡ÕÁø ¿£Ã¢ü 
 
     º¢ÅôÒÁÄõ À¢Êò¾ÖÕó ¾¡Ð¿ð¼õ 
 
¸ÕÅ¡É §¾¸Á¾¢Ö¨Çîºø §º¡õÀø 
 
     ¨¸¸¡ø ¾È¢ôÒ¿¡ì ¸ºìÌ ÁýÉõ 
 
ÀÃ¢Å¡É °ñÌ¨È¾ø Õº¢§¸¼¡¾ø  
 
    ÀÄ§¿¡Ôõ ÅÕò¾¢¨ÅìÌõ À¡íÌ ¾¡§É. 
 
¸ÀÅ¡¾ ¦¾¡ó¾õ 
 
¸ñ¼¡¦Â¡ º¢§ÄüÀÉò¾¢ø Å¡¾ ¿¡Ê 
 
    ¸Äó¾¢Î¸¢ø ÅÂ¢Ú ¦À¡ÕÁø ¸Éò¾ Å£ì¸õ 
 
¯ñ¼¡§Ä¡ µí¸¡Ãï ºò¾¢ Å¢ì¸ø 
 
     ¯Ú¾¢Ã¡ð¨º  Å¡ö×ÅÄ¢  ºó¿¢ §¾¡¼õ 
 
Å¢ñ¼¡§Ä  þ¨ÇôÀ¢ÕÁø §º¡¨À À¡ñÎ 
 
    Å¢¼À¡¸õ Å¢¼Ý¨Ä Àì¸Å¡¾õ 
 
¾¢ñ¼¡Î ¿¡º¢¸¡À£¼í ¸ì¸ø 
 
    º¢Ã§¿¡ö¸û ÀÄ×õÅóÐ º¢ìÌó ¾¡§É. 
 
                               -º¾¸¿¡Ê(10) 
 
2) Sparisam: Tenderness over lower abdomen and mild increase in temperature.   
3)  Naa: Coated, pallor and dryness.  
4) Niram: Depending on the body constitution it may be black, yellow, whitish or 
mixed colour.    
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5) Mozhi: Normal vocal resonance present.    
6) Vizhi: Conjunctival pallor present.    
7) Malam: May have constipation  
8) Moothiram: 
Neerkuri: The colour of Urine is straw colour in general and in some cases it was 
noted to beyellow.    
Neikuri: Patients were advised to collect the early morning urine in a glass 
container and is subjected to analysis without disturbing its nature and the neikuri 
should be noticed in direct sunlight within 3 hours. Neikuri shows the following 
shapes 
“«Ã¦Å½ ¿£ñÊø « §¾ Å¡¾õ 
 
¬Æ¢§À¡ø ÀÃÅ¢ø « §¾ À¢ò¾õ 
 
         Óò¦¾¡òÐ ¿¢ü¸¢ø ¦Á¡Æ¢Å¾ý ¸À§Á"(10). 
 
 
 When the oil drops lengthens like a snake it indicates ‗Vatha Neer‘  
 When the oil drops spreads like a ring it indicates ‗Pitha Neer‘  
 When the oil drops remains that of pearl it indicates ‗Kaba Neer‘  
 
MANAGEMENT   
Á¢ÌÛõ Ì¨ÈÂ¢Ûõ §¿¡ö ¦ºöÔõ á§Ä¡÷  
 
ÅÇ¢Ó¾Ä¡ ¦Âñ½¢Â ãýÚ. 
 
According to siddha system the main aim of treatment is the removal of udarpini 
and manapini by correcting the deranged doshas.   
 
 
 
18 
 
NEEKKAM   
Treatment is not only aimed at removal of disease, but also for preventing the 
disease and improving the immunity.    
The three humours which are responsible for organization, regulation and 
integration of the bodily structures and functions are always kept in a state of 
equilibrium by word, thought, deed, and food. The imbalanced doshas are balanced 
by administering internal medicine or emetic or eye application and also through 
appropriate systemic therapy. The general aetiological factors are said to be caused 
by changes in life style and stress.   So it is essential to know the disease and the 
cause for the onset of disease, the nature of the patient, the severity of illness and 
the time of occurrence of the diseases must be observed.    
The line of treatment is to bring down the deranged mukkutram by giving purgative 
which normalise the deranged vatham which is one of the cause for garpa vaayu, 
then treated with suitable medicine indicated in ancient siddha literature with proper 
diet regimen  
"Å¢§ÃºÉò¾¡ø Å¡¾ó¾¡Øõ 
Å¡ó¾¢Â¡ø À¢ò¾õ ¾¡Øõ 
 
 «ïºÉò¾¡ø ¸Àõ ¾¡Øõ" 
 
                                -º¢ò¾ ÁÕòÐÅ¡í¸ ÍÕì¸õ 
 
According to the siddha text medicines should be given to induce purgation before 
starting the treatment to bring the deranged doshas to normal.   
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Àò¾¢Âõ 
 
Àò¾¢Âò¾¢É¡§Ä ÀÄý ¯ñ¼¡Ìõ ÁÕóÐ 
 
Àò¾¢Âí¸û §À¡É¡ø ÀÄý§À¡Ìõ - Àò¾¢Âò¾¢ø 
 
Àò¾¢Â§Á ¦ÅüÈ¢¾Õõ ÀñÊ¾÷ìÌ - ¬¾Ä¢É¡ø 
 
Àò¾¢Â§Á ¯ò¾¢¦ÂýÚ  À¡÷ 
 
-§¾¨ÃÂ÷ ¦ÅñÀ¡ 
 
DIET AND ADVICE:    
o Plenty of Green vegetables, water, Goose berry, Fish, Sprouted black 
gram, Butter milk, Fig fruit, Honey, Tender brinjal, Bananna, Pome 
granate regularly.  
o Patients were advised to avoid Bitter gourd, Mango, sesban, 
Chicken, Meat,  Chocolate, Horse gram, Ghee, Tamarind Packaged 
food, Fatty food stuffs  Sweetened beverages, Preserved cool drinks, 
Baked food items, Oily food items, green plantain etc.,  
o Advise yogasanas like Sarvaangasana, Matsyaasana, Shirasasana, 
Shavasana, Haalasana, Patchimottaanaasana, Dhanurasana and 
Naadi shuddhi. All these asanas stimulate internal organs, endocrine 
glands governing menstruation.     
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                                               MODERN ASPECT 
 
ANATOMY AND PHYSIOLOGY OF FEMALE 
REPRODUCTIVE SYSTEM  
 
INTRODUCTION  
 
            All living things reproduce. Reproduction is the process by which organisms 
make more organisms like themselves. It is one of the things that sets living things 
apart from non-living matter. But even though the reproductive system is essential 
to keeping a species alive, unlike other body systems, it's not essential to keeping an 
individual alive.  
 
FEMALE REPRODUCTIVE SYSTEM  
 
The female reproductive system includes the ovaries, fallopian tubes, uterus, 
vagina, vulva, mammary glands and breasts. These organs are involved in  
 
 Production and transportation of gametes  
 Secretes sex hormones  
 Facilitates the fertilization of ova by sperm  
 Protects and nourishes the fertilized egg until it is fully developed  
 Delivers fetus through birth canal  
 Provides nourishment to the baby through milk secreted by mammary 
glands in the breast  
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Internal Genitals  
Ovaries  
The ovaries are a pair of small glands about the size and shape of almonds, located 
on the left and right sides of the pelvic body cavity lateral to the superior portion of 
the uterus. Ovaries produce female sex hormones such as oestrogen and 
progesterone as well as ova (commonly called "eggs"), the female gametes. Ova are 
produced from oocyte cells that slowly develop throughout a woman‘s early life 
and reach maturity after puberty. Each month during ovulation, a mature ovum is 
released. The ovum travels from the ovary to the fallopian tube, where it may be 
fertilized before reaching the uterus. 
 
Fallopian tubes 
             The fallopian tubes are a pair of muscular tubes that extend from the upper 
corners of the uterus to the edge of the ovaries. The fallopian tubes end in a funnel-
shaped structure called the infundibulum, which is covered with small finger-like 
projections called fimbriae. The fimbriae lies close to the ovary, but is not attached. 
The ovaries alternately release an egg. When an ovary does ovulate, or release an 
egg, it is swept into the lumen of the fallopian tube by the fimbriae if enough sperm 
are ejaculated during inter course fertilization will occur. The tiny hairs in the tube's 
lining help push it down the narrow passageway towards the uterus. 
Uterus 
The uterus is a hollow, muscular, pear-shaped organ located near the floor of pelvic 
cavity. Connected to the two fallopian tubes on its superior end and to the vagina 
(via the cervix) on its inferior end, the uterus is also known as the womb, as it 
surrounds and supports the developing foetus during pregnancy. The inner lining of 
the uterus, known as the endometrium, provides support to the embryo during early 
development or it is sloughed off during menses. The visceral muscles of the uterus 
contract during childbirth to push the foetus through the birth canal. These muscles 
also contract rhythmically during an orgasm in a wave like action. It is thought that 
this is to help push or guide the sperm up the uterus to the fallopian tubes where 
fertilization may be possible. 
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Vagina  
            The vagina is a fibro muscular tube that extends from the vaginal opening to 
the cervix. It is located between the urinary bladder and the rectum. The vagina is 
made up of three layers, an inner mucosal layer, a middle muscular layer, and an 
outer fibrous layer.  
 
Functions of the Vagina  
 
 Receptacle for the penis during sexual intercourse  
 Pathway for delivery of the foetus during child birth  
 Provides the route for the menstrual flow from the uterus, to exit the body.  
 May hold forms of birth control, such as a diaphragm, FemCap, Nuva Ring, 
or female condom.  
 
Cervix  
 
   The cervix is the lower, narrow portion of the uterus where it joins with the top 
end of the vagina. It is cylindrical or conical in shape and protrudes through the 
upper anterior vaginal wall.  Approximately half its length is visible with 
appropriate medical equipment; the retainder lies above the vagina byond view. It is 
occasionally called ―cervix uteri‖, or ― neck of the uterus‖. The portion projecting 
into the vagina s referred to as the portio vaginalis or ectocervix. The ectocervix‘s 
opening is called theexternal os. In women who have not had a vaginal birth the 
external os appears as a small circular opening. The passageway between the 
external os and the uterine cavity is referred to as the endocervical canal. The 
endocervical canal terminates at the internal os which is the opening of the cervix 
inside the uterine cavity. 
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                  ANATOMICAL REPRESENTATION OF UTERUS 
 
 
 
Vulva 
 
The vulva is the collective name for the external female genitalia includes the mons 
pubis (a fatty mound which covers the pubic bone), the labia majora (outer lips of 
the vagina), the labia minora (the inner lips of the vagina), the vaginal opening, 
the urethral opening (opening of the urethra, a tube which carries urine from the 
bladder outside of the body), the clitoris (a small structure with sensitive nerve 
endings located within the labia minora, the sole purpose of which is for sexual 
arousal and pleasure), and the perineum (the space between the anus (the rectal 
opening) and the vaginal opening) 
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Breasts and Mammary Glands  
 
The breasts are specialized organs of the female body that contain mammary 
glands, milk ducts, and adipose tissue. The two breasts are located on the left and 
right sides of the thoracic region of the body. In the center of each breast is a highly 
pigmented nipple that  releases milk when stimulated. The areola, a thickened, 
highly pigmented band of skin that surrounds the nipple, protects the underlying 
tissues during breastfeeding. Mammary glands are enlarged and modified sweat 
glands. Within each breast , 15 to 20 clusters of  mammary glands become active 
during pregnancy and remain active until milk is no longer  needed. The milk  
passes through milkducts on its way to the nipple, where it exist the body. 
 
HORMONES THAT CONTROL THE REPRODUCTIVE CYCLE  
 
Five hormones play important role in the reproductive cycle. Of these three are 
produced in the brain and the other two are made in the ovaries.  
 
 Gonadotrophin-releasing hormone (GnRH) is secreted by the 
hypothalamus. It controls the release of Follicle-stimulating hormone (FSH) 
and Luteinizing hormone (LH).  
 
 Follicle-stimulating hormone (FSH) is released by the anterior pituitary. 
FSH is carried by the blood stream to the ovaries. Here it stimulates the 
immature ova to start growing.  
 
 Luteinizing hormone (LH) is also released by the anterior pituitary and 
travels to the ovaries. LH triggers ovulation and encourages the formation of 
a special group of cells called the corpus luteum. 
 
 Oestrogen is produced by the growing ova and by the corpus luteum. In 
moderate amounts oestrogen helps to control the levels of GnRH, FSH and  
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LH. This helps to prevent the development of too many ova. Oestrogen also 
helps to develop and maintain many of the female reproductive structures.  
 
 Progesterone is mainly released by the corpus luteum. It works with 
oestrogen to prepare the lining of the uterus for the implantation of a 
fertilised ovum. It also helps to prepare the breasts for releasing milk. High 
levels of progesterone control the levels of GnRH, FSH and LH.  
 
FEMALE REPRODUCTIVE CYCLE 
 
          The female reproductive cycle is the process of producing an ovum and 
readying the uterus to receive a fertilized ovum to begin pregnancy. Approximately 
every 28 days , during ovulation an ovary sends egg into one of the fallopian tubes. 
Unless the egg  is fertilized by a sperm in the fallopian tube within two to three days 
following ovulation,  the egg dries up and leaves the body about two weeks later 
through the vagina. This process is called menstruation. 
 
Blood and tissues from the inner lining of the uterus (the endometrium) combine to 
form the menstrual flow, which generally lasts for four to seven days. During 
menstruation arteries that supply the lining of the uterus constrict and capillaries 
weaken. Blood spilling from the damaged vessels detaches layers of the lining, not 
all at once but in random patches. Endometrium mucus and blood descending from 
the uterus, through the liquid creates the menstruation flow. 
 
 
The Menstrual Cycle/ reproductive cycle can be divided into an ovarian cycle 
and a uterine cycle.  
 
UTERINE CYCLE  
The uterine cycle operates in synchronize with the ovarian cycle and is divided into 
three phases.  
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Menstrual phase:  
 
               It is named the menstrual phase because it corresponds with the shedding 
of the uterine lining. The corpus luteum degenerates causing plasma estrogen and 
progesterone levels to come down and in turn causes menstruation. Blood vessels in 
the outer most layer of the endometrium constrict and decrease blood flow to the 
tissues lead necrosis. After the tissues die they start to separate from the underlying 
endometrial tissues. Eventually the dead tissue is shed. This shedding of the tissues 
ruptures blood vessels and causes bleeding.  
 
Proliferative phase:  
 
               During this phase the uterus renews itself and prepares for pregnancy. It 
last until the 14th day of a 28 days cycle. It is also referred as oestrogenic phase. 
The endometrial tissue that is left after menstruation begins to grow. The 
endometrial glands grow and enlarge causing more blood vessels. The cervical 
canal has glands that secrete a thin mucous that helps deposited sperm. Estrogen 
promotes uterine changes in this phase.  
 
Secretory phase:  
 
             The secretory phase of endometrium begins on the 15th day and persists 
until the onset of menstruation. In this the endometrium is transformed to make it 
the best environment for  implantation and subsequent housing and nourishment of 
the developing embryo. By doing this the endometrium will have an enriched blood 
supply, begin to secrete fluids rich in glycogen, and even form a plug at the end of 
the cervical canal so that microorganisms cannot enter. These changes in the uterus 
caused by   progesterone, due to the corpus luteum. At the end of the secretory 
phase the corpus luteum degenerates and progesterone levels fall.  This will trigger 
menstruation. 
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OVARIAN CYCLE  
 
The Follicular Phase 
 
          Several follicles commence to develop in each menstrual cycle. Of these 
several follicles, one follicle grows faster than the rest and produces more FSH 
receptors and estrogen. The rising estrogen level stimulates LH receptor in the theca 
cell but causes a negative feedback to the anterior pituitary gland leading to a 
progressive fall in level of FSH and gonadotropic support to the other lesser 
developed follicle which atrophy. The dominant follicle develops into graffian 
follicle results in ovulation.  
 
Ovulation phase 
 
         Ovulation occurs around 14 days before the onset of menstrual bleeding, 
which means that a woman with a 28-day cycle will ovulate around the 14th day of 
her cycle. However, if she has a longer cycle, ovulation will occur later. Ovulation 
is provoked by another signal sent by the hypophysis, the luteinizing hormone (LH) 
peak. During ovulation, the oocyte is extruded from the follicle, whose wall breaks, 
and is aspirated into the Fallopian tube. The oocyte now starts its migration towards 
the uterus. 
 
Luteal phase 
 
         During this phase, the endometrium of the uterus is prepared for implantation 
of the embryo resulting from the fertilization of the oocyte by a spermatozoon. This 
processes dependent upon hormones released by the ruptured follicle from which 
the oocyte was expulsed. 
The follicle is transformed into a corpus luteum (which means yellow body) and 
start to secrete a new hormone, progesterone until the placenta can take over 
production of  progesterone. 
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                     ANATOMICAL REPRESENTATION OF OVARIES
 
 
       Hence, progesterone is "pro gestational" and maintains the uterine lining during 
the course of pregnancy. If fertilization does not occur, the corpus luteum shrinks into 
corpus albicans and levels of both estrogen and progesterone decrease. The fall in 
progesterone level causes the endometrial lining to ―break‖ resulting in vaginal 
bleeding. This is called menstruation. 
 
ROLE OF HORMONES DURING MENSTRUAL CYCLE 
 
        The hormonal cycle facilitates maturation and rupture of the ovarian follicle 
results in the release of an ovum (the female reproductive or germ cell). Each month a 
series of changes take place which prepares the uterus for pregnancy. This cycle 
(menstrual cycle) is described below:   
 The first day of menstruation (referred to as Day 1) occurs when levels of 
estrogen and progesterone are low. In response to these low levels, the 
hypothalamus  secretesGonadotrophin releasing hormone (GnRH) which 
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 FSH stimulates the development of many follicles within the ovary. One 
dominant follicle takes over. As it continues to grow, it produces increasing 
amounts of estrogen, which stimulates the release of LH, and inhibits FSH, 
which suppresses further follicular development.  
 When LH levels are highest (LH surge), the ovarian follicle ―ruptures‖ and 
releases an ovum, which is ―swept‖ into the fallopian tube by hair-like 
projections called cilia that line the fimbriae (the fringe-like end of the 
fallopian tube that is closest to the ovary). This process is called ovulation. 
Increasing estrogen levels causes the cervical mucous (vaginal secretions) 
to become clear and profuse and the os to dilate. These two actions may 
facilitate the transport of semen (containing sperm) from the vagina, through 
the uterus, and into the fallopian tube.  
 Following ovulation, the ruptured follicle is transformed into the corpus 
luteum, a glandular mass that continues to produce estrogen and higher 
levels of progesterone. The progesterone causes the endometrium to 
thicken, preparing it for implantation of a fertilized egg. If fertilization takes 
place during ovulation, progesterone level remains high, essential for the 
maintenance of the pregnancy.  
 If fertilization does not occur, the corpus luteum shrinks into corpus albicans 
and levels of both estrogen and progesterone decrease. The fall in 
progesterone level cause the endometrial lining to ―break‖ resulting in 
vaginal bleeding. This is called menstruation, which marks the low point 
for estrogen activity and this leads to new cycle. The average menstrual 
cycle is 28-35 days, and menstrual flow usually continues for three to seven 
days, although there are variations among women.  
 Following menstruation, estrogen and progesterone levels are low, 
triggering the hypothalamus to once again release GnRH, starting the entire 
cycle again. If fertilization does take place, menstruation will not re occur 
for the duration of the pregnancy 
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                   Graphical representation of The reproductive cycle 
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               Ovarian and Uterine Cycles in the Non pregnant Woman  
 
Ovarian Cycle Events Uterine Cycle Events 
Follicular phase 
 
(1-13 days) 
 
FSH secretion 
begins. 
 
Follicle 
maturation 
occurs 
 
Estrogen 
secretion is 
prominent. 
Menstruation 
 
(2-5 days) 
 
Proliferative 
phase 
(6-13) days 
 
Endometrium 
breaks down. 
 
Endometrium 
rebuilds. 
Ovulation  
 
(15-28 days) 
 
 
LH spike occurs. 
 
 
--------- 
 
 
--------- 
Luteal phase 
 
(15-28 days) 
 
LH secretion 
continues. 
 
Corpus luteum 
forms. 
 
Progesterone 
secretion is 
prominent. 
Secretory phase 
 
(15-28 days) 
 
Endometrial 
thickens, and 
glands are 
secretory. 
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POLYCYSTIC OVARIAN SYNDROME 
 
INTRODUCTION:  
       Polycystic ovarian syndrome (PCOS) was first described by valisnere in 1721 
as ―Young, married peasant women, moderately obese, and infertile with two larger 
than normal ovaries, bumpy, shiny and whitish, just like pigeon eggs‖. The cyst 
related changes to the ovaries were described in 1844 
(11)
. 
  In 1953, Stein and Leventhal described a symptom complex with anovulation and 
it called it polycystic ovarian disease (POD) 
(12)
. 
PREVALANCE OF PCOS  
      PCOS occurs in 5% to 10% of women, making it one of the most common 
endocrine disorder
(13)
. PCOS is a heterogeneous endocrine disorder that affects 
about 1 in15 women worldwide
(14)
. The prevalence of Polycystic ovaries in Indian 
sub-continent Asian women was 52%
(15)
. PCOS exists commonly among women at 
reproductive age with an incidence rate of 6–10% (16).   
       Polycystic morphology seen in ultrasound is approximately 22% of women 
(17)
.  
Hirsutism is a common problem in India as elsewhere in the world. Idiopathic 
hirsutism 38.7%, PCOS 37.3%. In India nearly 40% of women are affected by 
PCOS. But among them only 60% come to hospitals for treatment, when they 
recognize that they have got infertility 
(18)
. 
 
DEFINITION  
PCOS is a syndrome, which can be defined as a group of recognizable patterns of 
symptoms or abnormalities that indicate a particular medical situation. The current 
definition of PCOS requires the presence of two of the following three conditions: 
(i) Oligo and /or anovalation,    (ii) Clinical and/or biochemical signs of hyper 
androgenism, and (iii) Polycystic ovaries-and the exclusion of other etiologies.  
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CAUSE  
 
PCOS is a heterogeneous disorder of uncertain etiology such as 
(19,20) 
1. Genetic cause: There is strong evidence that it is a genetic disease. Although 
specific gene associated with the condition have not yet been identified. 
2. Hormonal imbalance: An imbalance in the release of the luteinizing hormone 
(LH) and the follicle stimulating hormone (FSH) from the pituitary has been 
implicated.  
The LH / FSH ratio is altered and the secretion of LH is higher than that of FSH 
resulting in increased androgen, testosterone and dehydroepiandrosterone (DHEA) 
productions.  
3. Insulin resistance: It is not solely a consequence of increased visceral obesity. 
Rather, obesity and hormonal abnormalities are thought to make additive 
contributions to insulin resistance. Functional insulin resistance is considered as 
consequence of defects in insulin-mediated glucose transport and signaling in 
adipocytes and myocyte. This may be the result of dysregulation in adipokine 
production and signaling from adipose tissues but the mechanism is incompletely 
understood.  
4. Intrauterine exposures: Exposure to testosterone in utero may predispose to the 
later development of PCOS.  
5. Environment / lifestyle factors: Several lifestyle factors and environmental 
exposures have been associated with more severe PCOS phenotype.  
6. Obesity: Although obesity is not believed to cause PCOS, it is known to 
exacerbate the symptoms of the disease.  
 
CLINICAL SYMPTOMS:  The principle features of PCOS includes,  
1. Irregular menstrual periods:  
       PCOS mostly produce oligomenorrhoea (few menstrual periods) or 
amenorrhoea (no menstrual periods) but other types of menstrual disorders may also 
occur 
(21)
.  
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2. Central obesity (22): BMI > 30kg/cm2, waist line. ‖  
 
 
3. Reproductive manifestation 
(23)
: 
     Subfertility or infertility this generally results directly from chronic an ovulation  
4. Clinical hyperandrogenism:  
      The most common signs are acne and hirsuitism (male pattern of hair growth on 
face, chest, stomach or back) but it may produce hypermenorrhoea (very frequent 
menstrual periods), androgenic alopecia (Male-pattern baldness or thinning hair) or 
other symptoms 
(24)
. Approximately three-quarters of patients with PCOS (by the 
diagnostic criteria of NIH/NICHD 1990) have evidence of hyperandrogemia 
(25)
.   
5. Acanthosis nigricans:  
      It is due to insulin resistance (IR). Thick pigmented skin over the nape of neck, 
inner thigh and axilla. 
      HAIR-AN syndrome has been coined to describe the constellation symptoms of 
hyper androgenism, insulin resistance and acanthosis nigricans  
6. Metabolic syndrome:  
      It is a cluster of endocrine disturbances like IR, dyslipidemia, obesity, 
hypertension, type 2 diabetes mellitus, atherosclerosis and endothelial dysfunction.  
PCOS women have an 11 fold higher risk of having above metabolic syndromes 
compared to age matched controls. Homocysteine levels are higher in women with 
PCOS 
(26)
.  
7. Psychological problems:  
      It includes reduced quality of life, poor self-esteem, depression, anxiety.
(27,28) 
 
COMPLICATIONS OF PCOS  
 
 Type 2 diabetes mellitus  
 Hypertension  
 Dyslipidemia - elevated triglycerides or decreased high-density lipoprotein 
(HDL),  
 Cardiovascular disorder  
 Anxiety and depression  
 Sleep apnea  
 Endometrial carcinoma  
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 Premature delivery  
 Early miscarriage  
 Gestational hypertension – pre eclampsia,  
 Low birth weight or macrosomia.  
 Gestational diabetes mellitus  
PATHOPHYSIOLOGY 
      The ―cysts‖ in polycystic ovaries are not true cysts, but rather antral follicles 
which have arrested in development. This is thought to occur because of hormonal 
abnormalities:                             
PATHOPHYSIOLOGY  OF  PCOS                                                                                                                                                                                                        
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Hyperandrogenism: Arrest occurs when the granulosa cells of the ovaries normally 
begin to produce estrogen by aromatizing androstenedione produced by the theca 
cells; excess 5a-reduced androgens in the ovaries are thought to inhibit the action of 
aromatase and therefore reduce estradiol synthesis, which is required for further 
maturation.  
      Hyperinsulinemia: Exacerbates ovarian hyperandrogenism by (1) increasing 
17a-hydroxylase activity in theca cells and promoting androstenedione and 
testosterone production; (2) promoting LH- and IGF1-stimulated androgen 
production; and (3) elevating free testosterone by decreasing the production of sex 
hormone binding globulin (SHBG).       
 
INVESTIGATIONS:  
There is no single diagnostic test for PCOS. The diagnosis of PCOS is based on 
hyperandrogenism or chronic anovulation in the absence of specific pituitary and/or 
adrenal disease.  
Ultrasonogram:  
Ultrasound findings are confirmative of PCOS. Pelvic ultrasonography may be very 
helpful in the evaluation as well, but polycystic ovaries are not specific for PCOS 
with over 20% of ―normal‖ women having this finding (29). The number of follicles 
and ovary volume are important in the ultrasound evaluation.  
The criteria for PCOS put forth by Adams et al. are the most often cited: The 
presence of ≥10 cysts measuring 2–8 mm around a dense core of stroma or 
scattered within an increased amount of stroma 
(30)
. 
A recent proposal to modify these criteria has been put forth by Jonard et 
al.―Increased ovarian area (>5.5cm2) or volume (>11 mL) and/or presence of ≥12 
follicles measuring 2 to 9 mm in diameter (mean of both ovaries)‖ (31). 
These criteria had a specificity of 99% and a sensitivity of 75% for the diagnosis of 
PCOS.  
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Hormonal test:  
 Prolactin  
 Thyroid Function Test – Both are the key investigations to exclude other 
disorders.  
 Testosterone level in patients with PCOS seldom exceeds 4.8 nmol/l. If it is 
greater than 4.8 nmol/l then further endocrinological investigation to 
exclude other causes of androgen hypersecretion eg., cushing syndrome, 
adrenal gland or ovarian tumour 
(32)
.  
 FSH (Follicle Stimulating Hormone)  
 LH (LH:FSH ratio may not be elevated in obese is suggestive of PCOS)  
 Free androgen index (FAI) is the ratio of testosterone to sex hormone-
binding globulin (SHBG) to assess androgen status 
(14)
. If FAI level is above 
5 it is an indicative for PCOS
(33)
.  
 Rarely DHEAS (Dehydroepiandrosterodione) values ≥800 μg/dL (21.7 
μmol/L) highly suggestive of an adrenal dysfunction (34). 
 24-hour urine free cortisol - Mild elevations can be seen in PCOS with 
values ≥2 times the upper limit of normal more consistent with Cushing's 
syndrome.  
 17-hydroxyprogesterone - A morning, fasting, unstimulated level of <200 
ng/dL (<6 nmol/L) in the follicular phase reliably excludes late-onset 21-
hydroxylase deficiency.  
 Further evaluation of levels ≥200 ng/dL involves adrenocorticotropic 
hormone (ACTH)-stimulation with an intravenous 250 μg dose and a 30 
minute value (stimulated values ≥1,000 ng/dL (≥30 nmol/L) confirm the 
diagnosis)
(35)
. 
 
Biochemical Study:  
 Fasting blood sugar  
 Lipid Profile – HDL, LDL, VLDL and Triglyceride level  
 Fasting insulin level – insulin resistance can be observed in 50-80% of 
people with PCOS.  
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 OGTT - It is extremely useful in categorizing patients' risk of type 2 diabetes mellitus 
may indicate impaired glucose tolerance in 15-33% of women with PCOS.  
 
Laproscopy:  
       It is not only diagnostic but also therapeutic in destroying the cyst. Many patients with 
PCOS, particularly those who are having trouble becoming pregnant will have a laparoscopy.                            
A laparoscopy is an operation whereby the patient is given a short general anaesthetic, a small 
cut is made in the umbilicus, and a telescope is inserted to acess the health of pelvic contents 
including the uterus, tubes, ovaries and to look for any associated endometriosis. At laparoscopy 
PCOS ovaries look rather like ping-pong balls.   
 
Hysteroscopy:  
 
Hysteroscopy is an operation whereby a fine telescope is used to look inside the cavity of the 
womb (uterus). This is particularly important where the patient has had significant abnormal 
bleeding. Abnormal areas in the uterus can be seen and specific biopsies taken to assess for 
cancerous or pre-cancerous changes.  
 
Differential diagnosis  
Other causes of irregular or absent menstruation and hirsutism should be investigated such as,  
 Hypothyroidism  
 Congenital adrenal hyperplasia (21-hydroxylase deficiency)  
 Cushing syndrome  
 Hyperprolactinemia 
 Androgen secreting neoplasms  
 Pituitary or adrenal disorders  
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          PCOS has been reported in other insulin-resistant situations such as 
acromegaly 
 
DIAGNOSIS:  
The diagnosis of PCOS has been based on the history of oligomenorrhoea and/ or 
hyperandrogenism, either clinical or biochemical and / or polycystic ovaries on 
ultrasound.  
 
TREATMENT  
 
Metformin: Treatment of glucose intolerance, hyperinsulinemia, and anovulation. 
Reducing circulating insulin levels may secondarily reduce ovarian androgen 
synthesis.  
Clomiphene citrate: For inducing ovulation.  
Estrogen and progestin oral contraceptive (OCP) therapy: Treatment of acne, 
hirsutism and irregular menstrual cycles.  
Lifestyle modification: May help attenuate all symptoms of PCOS and reduce the 
long-term risk of infertility, CVD and T2DM.  
Anti-androgens (e.g. spironolactone, finasteride, flutamide): Treatment of acne 
and hirsutism.  
Gonadotropin therapy: Recombinant FSH and hCG can be used to induce 
ovulation in cases where treatment with clomiphene citrate and metformin has been 
unsuccessful  
Ovarian drilling: A laparoscopic surgical procedure that may be used to treat 
clomiphene citrate-resistant anovulation.  
In vitro fertilization (IVF): Used for the treatment of infertility in women who 
have not responded to other therapies to induce  ovulation. 
 
Management:  
It is the most effective and inexpensive approach, without adverse reactions. It 
consists in the practice of regular physical activity and in the adoption of a balanced 
diet. The loss of only 2-7% of weight improves almost all the parameters of PCOS 
by reducing androgen levels and improving ovarian function
(36)
 . These effects are 
related to the reduction in insulin levels and improvement of insulin resistance 
(37)
.  
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DRUG  REVIEW 
 
The formulation Garpa vaayu ilagam contains eighteen ingredients. The properties 
of each ingredient were explained under the following headings like Suvai, 
Thanmai, Pirivu, Pothu gunam, Pharmacological action and Traditional uses.  
 
1.¦Åñº¢Å¨¾-Operculina Turpethum,Linn 
 
Í¨Å- ¨¸ôÒ; ¾ý¨Á- ¦ÅôÀõ; À¢Ã¢×-¸¡÷ôÒ 
 
¨¸ôÒó ÐÅ÷ôÒí ¸Äó¾¢ÕìÌõ À¢ò¾ò¨¾ 
 
þôÒÅ¢Â¢ø ¿¡¦¼¡ð¼¡ ¾¢ùÅÇ§Å¡-¦ºôÒ¾Ãò 
 
¦¾¡û¨Çì ¸¢ÕÁ¢ ¦¾¡¨ÄìÌÁ¢Ì §À¾¢¾Õõ 
 
¦Åû¨Çî º¢Å¨¾¾¨É Å¢û. 
 
Phytochemicals: Turpethin resin 4 to 10%, Glucoside, Turpethin 
(39)
. 
 
Action: Purgative 
(38) 
 
Pharmacological action: Anti-diabetic activity 
(40)
 , Immuno modulatory 
(39)
, Anti 
oxidant,  
Anti cancer 
(39)
 , Anti microbial activity.  
 
2.¿¢ÄÅ¡¨¸ - Cassia senna, Linn. 
 
Í¨Å- ¨¸ôÒ; ¾ý¨Á- ¦ÅôÀõ; À¢Ã¢×-¸¡÷ôÒ 
 
¿¢ÄÅ¡¨Ã Â¢ýÌ½ó¾¡ý ¿£§¸û ÁÂ¢§Ä! 
 
ÀÄãÄ Å¡Ô¦ÅôÒ À¡¨Åî-º¢Ä¸¢Ãó¾¢ 
 
¦À¡øÄ¡¾ ÌýÁõ ¦À¡ÕÓÁÄì ¸ðÎÓ¾ø 
 
±øÄ¡ Á¸üÚ¦ÁÉ ±ñ. 
 
Phytochemicals: Anthroquinone glycoside 
(41)
( emodin, sennaside A & B, rhein), 
sodium potassium tartarate, salisilic acid, crisophanic acid, volatile oils, resin, 
calcium oxalate 
(42)
. 
Action: Laxative 
(38) 
Pharmacological action: Anti oxidant ,Anti diabetic, Anti hyperlipidemic activity. 
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3.§¸¡¨Ãì¸¢ÆíÌ - Cyperus rotundus,Linn. 
 
º£¾ ÍÃó¾£÷ìÌï ¦ºõÒÉøÀ¢ò ¾õ§À¡Ìõ 
 
Å¡¾ ÍÃó¾½¢ìÌõ ¨ÅÂ¸ò¾¢ø- §Å¨¾¦ºöÂ 
 
Åó¾  À¢½¢¨Â ¦ÂøÄ¡õ Å¡ðÎÓò ¾ì¸¡Í 
 
¦¸¡óÐÄ×õ Å¡÷ÌÆ§Ä! ÜÚ. 
 
Phytochemicals:Alkaloids, Flavonoids, Tannins, Starch, Glycosides, 
Sesquiterpenes, Sitosterol, Fatty oils, Cyperene 
(45) 
. 
 
Action:Astringent, Emmenagogue, Vermifuge, Stimulant, Tonic, Diuretic
(38)
. 
 
Pharmacological action: Anti diabetic, Anti diarrhoeal, Cyto protective, Anti 
oxidant
(45)
. 
 
4.ÍìÌ - Zingiber officinale, Rosc. 
 
Í¨Å - ¸¡÷ôÒ; ¾ý¨Á - ¦ÅôÀõ; À¢Ã¢× -¸¡÷ôÒ 
 
Ý¨ÄÁó¾õ ¦¿ï¦ºÃ¢ôÒ §¾¡¼§Áô ÀõÁÆ¨Ä 
 
ãÄõ þ¨ÃôÀ¢ÕÁø ãìÌ¿£÷- Å¡Ä¸À 
 
§¾¡¼Á¾¢ º¡Ãó ¦¾¡¼÷Å¡¾ ÌýÁ¿£÷ò 
 
§¾¡¼õ¬ Áõ§À¡ìÌï ÍìÌ. 
 
Phytochemicals: Alkaloids, Flavanoids, Glycosides, Saponins, Carbohydrates, 
Proteins, Steroids, Terpenoids. 
 
Action: Carminative, Stimulant, Stomachic 
(38) 
. 
 
Pharmacological action: Hypolypidemicactivity 
(46)
, Anti-diabetic, Anti oxidant. 
 
Traditional uses: Remove the outer covering of garlic, then boiled with ginger 
juice and mixed with sugar and make it into a paste and given with coconut oil will 
regularise the menstruation.   
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5.Á¢ÇÌ - Piper nigrum.Linn 
 
Í¨Å- ¨¸ôÒ,¸¡÷ôÒ; ¾ý¨Á- ¦ÅôÀõ; À¢Ã¢× -¸¡÷ôÒ 
 
º£¾ÍÃõ À¡ñÎ º¢§ÄòÁí ¸¢Ã¡½¢ÌýÁõ 
 
Å¡¾õ «Õº¢À¢ò¾õ Á¡ãÄõ-µÐºýÉ¢ 
 
Â¡ºÀŠ Á¡Ãõ «¼ý§Á¸õ ¸¡ºÁ¢¨Å 
 
¿¡ºí ¸È¢Á¢Ç¸¢É¡ø. 
 
Phytochemicals: Alkaloids, Phenols, Tannins, Coumarins, Essential oil, 
Carbohydrates, Proteins, Amino acids. 
 
Action: Anti-vatha, Carminative, Resolvent, Stimulant 
(38) 
 
Pharmacological action: Anti oxidant, Anti-diabetic 
(47)
. 
 
 
6.¾¢ôÀ¢Ä¢ - Piper longum 
 
Í¨Å- þÉ¢ôÒ; ¾ý¨Á - ¦ÅôÀõ; À¢Ã¢× -þÉ¢ôÒ 
 
þÕÁø ÌýÁõ þ¨ÃôÒ ¸ÂôÀ¢½¢ 
 
     ®¨Ç À¡ñÎ ºó¿¢Â¡ºõ «§Ã¡º¸õ 
 
¦À¡ÕÁø °¨¾ º¢ÃôÀ¢½¢ ã÷î¨º§¿¡ö 
 
     âÃ¢ì ÌïºÄ §¾¡¼õ À£Ä¢¸Óõ 
 
ÅÕÁ Äô¦ÀÕì §¸¡Î Á§¸¡¾Ãõ 
 
    Å¡¾õ ¬¾¢Óò §¾¡¼ï ÍÃíÌÇ¢÷ 
 
¦ÀÕÁ¡¨ÄôÒÃ¢ §Á¸ô À¢¼¸Óõ 
 
    §ÀÕó ¾¢ôÀ¢Ä¢ô §ÀÃíÌ¨Ãì¸§Å. 
 
Phytochemicals: Alkaloids, Tannins, Coumarins, Carbohydrates, Proteins, 
Aminoacids, Phenols, Essential oil. 
 
Action: Carminative, Stimulant 
(38) 
 
Pharmacological action: Anti-diabetic, Anti oxidant 
(49)
, Anti hyperlipidaemic 
(50)
. 
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7.¸Îì¸¡ö - Terminalia chebula.Retz 
 
Í¨Å - ÐÅ÷ôÒ, þÉ¢ôÒ,ÒÇ¢ôÒ,¸¡÷ôÒ,¨¸ôÒ; ¾ý¨Á - ¦ÅôÀõ; À¢Ã¢× -
þÉ¢ôÒ 
 
¾¡¨¼ ¸Øò¾ì¸¢ ¾¡Ö ÌÈ¢Â¢Å¢¼ô  
 
À£¨¼ º¢Ä¢À¾Óü §À¾¢Ó¼õ- ¬¨¼¦Âð¼¡ò 
 
àÄÁ¢Ê ÒñÅ¡¾ §º¡½¢¸¡ Á¡¨ÄÂ¢Ãñ 
 
¼¡ÄÁ¢Ê §À¡õÅÃ¢ì¸¡Â¡ø. 
 
Phytochemicals: Tannins, Triterpenoids, Phenolic. 
 
Pharmacological action: Anti-diabetic, Anti oxidant 
(51)
, Hypolipidaemic activity. 
 
8.¦¿øÄ¢ì¸¡ö - Phyllanthus emblica.Linn 
 
Í¨Å - ÒÇ¢ôÒ,ÐÅ÷ôÒ,þÉ¢ôÒ; ¾ý¨Á - ¾ðÀõ; À¢Ã¢× -þÉ¢ôÒ 
 
À¢ò¾ÁÉ ¨ÄÂõ À£É¢ºõÅ¡ö ¿£÷ Å¡ó¾¢ 
 
Áò¾ÁÄì ¸¡Îõ ÁÂì¸Ó¸¢ø-´ò¾×Õ 
 
Å¢øÄ¢ì¸¡ ÂõÁÕí¸¡ ¦ÁýÉ¡ð¸¡ Äó§¾÷ó§¾ 
 
¦¿øÄ¢ì¸¡ ÂõÁÕó Ð½£. 
 
Phytochemicals: Alkaloids, Steroids, Flavanoids, Saponins, Anthroquinones, 
Tannins. 
Actions: Astringent, Laxative, Refrigerant, Diuretic.  
Pharmacological acions: Anti oxidant, Anti-diabetic, Spasmolytic action, Lipid 
lowering effect. 
 
9.¾¡ýÈ¢ì¸¡ö - Terminalia bellerica.Roxb. 
 
Í¨Å - ÐÅ÷ôÒ; ¾ý¨Á - ¦ÅôÀõ; À¢Ã¢× -þÉ¢ôÒ 
 
º¢Äó¾¢Å¢¼õ ¸¡Á¢ÂôÒñ º£Æ¡É §Á¸í 
 
¸ÄóÐÅÕõ Å¡¾À¢ò¾í ¸¡§Ä¡-¼Ä÷óÐ¼Ä¢ø 
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°ýÈ¢ì¸¡ö ¦ÅôÀ Ó¾¢ÃÀ¢ò Ðí¸ÃìÌó 
 
¾¡ýÈ¢ì¸¡ö ¨¸Â¢¦ÄÎò ¾¡ø. 
 
Phytochemicals: Tannins, Anthroquinone, Alkaloids, Glycosides, Phytosterols, 
Triterpenoids, Flavanoids, Carbohydrates, Proteins, Amino acids, Cardiac 
glycosides. 
Actions: Laxative, Tonic, Astringent, Expectorant. 
Pharmacological actions:Anti-fertility, Anti hypercholestrolemic 
(52)
, 
Hypoglycaemic. 
 
10.¸ñ¼¾¢ôÀ¢Ä¢ - Piper longum 
 
Í¨Å - ,¸¡÷ôÒ; ¾ý¨Á - ¦ÅôÀõ; À¢Ã¢× -þÉ¢ôÒ 
 
¾¡¸À¢ò¾ï §º¡¸ó ¾½¢Â¡î ÍÃÁ¢ÕÁø 
 
§Á¸í ÌÃü¸õÁø ¦Áöì¸ÎôÒõ- ²Ìí¸¡ñ 
 
¾¢ôÀ¢Ä¢ã Äí¸ñ¼ò ¾¢ôÀ¢Ä¢Â ¾¡õ¿ÚìÌò 
 
¾¢ôÀ¢Ä¢¦Âý §È¦Â¡Õì¸¡ü ¦ºôÒ. 
 
 
11.þóÐôÒ - Sodium chloride impure 
 
§ÅÚ¦ÀÂ÷ - ºó¾¢ÃÛôÒ, Á¾¢ÔôÒ  
 
«ð¼ÌýÁõ Áó¾õ «º¢÷ì¸ÃïÝ÷ º£¾ôô¢ò¾õ 
 
Ðð¼¨ÅÂõ ¿¡ÊôÒñ §¾¡¼í¸û- ¦¸ð¼ÁÄì 
 
¸ðÎÅ¢¼ Å¢óÐô¨Àì ¸¡Á¢Â§¿¡ö Åý¸ÃôÀ¡ý 
 
Å¢ðÎÅ¢¼ Å¢óÐô¨À Å¢û (53). 
 
Actions: Laxative 
 
12.µÁõ - Carum copticum Benth&Hook.f 
 
Í¨Å - ¸¡÷ôÒ; ¾ý¨Á - ¦ÅôÀõ; À¢Ã¢× - ¸¡÷ôÒ 
 
º£¾ÍÃí ¸¡ºï ¦ºÃ¢Â¡Áó ¾õ¦À¡ÕÁø 
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§À¾¢Â¢¨Ãî ºø¸ÎôÒ §ÀÃ¡Áõ-µ¾¢ÕÁø 
 
Àø¦Ä¡ÎÀø ãÄõ À¸Á¢¨Å§¿¡ ¦Âý¦ºÔ§Á¡? 
 
¦º¡ø¦Ä¡Î§À¡õ µÁ¦ÁÉî ¦º¡ø. 
 
Phytochemicals: Thymol 
 
Actions: Antispasmodic, Carminative, Stomachic, Stimulant, Tonic, Antiseptic, 
Sialogogue. 
 
Pharmacological actions: Antioxidant 
(54)
, Anti-diabetic 
 
13.Ì§Ã¡º¡½¢ µÁõ - Hyoscyamus niger Linn 
 
Í¨Å - ¸¡÷ôÒ, º¢Ú¨¸ôÒ; ¾ý¨Á - ¦ÅôÀõ; À¢Ã¢× - ¸¡÷ôÒ 
 
¦ÅÌãò ¾¢ÃõÅ¡¾õ Å£Ã¢Â¿ð ¼õÒñ 
 
¯Ì§À¾¢ Ôð¸ÎôÀ¢§É¡§¼-Á¢Ì¸ÃôÀ¡ý 
 
¾£Ã¡ì ¸ÀÁ¢¨Å§À¡õ ¦ºöÂÌ §Ã¡º¡É¢¦ÂýÈ¡ø 
 
Å¡Ã¡ ÁÂì¸ÓÚ Á¡ø. 
 
Phytochemicals: Hyoscyamine 
 
Actions: Hypnotic, Sedative, Anodyne, Antispasmodic, Mild diuretic 
 
Pharmacological actions: Anti tumor, Antioxidant. 
 
Traditional uses: It is used also as a pessary in painful affections of the uterus  
 
 
14.Å¡öÅ¢Çí¸õ - Embelia ribes.Burm.f 
 
Í¨Å - ¨¸ôÒ; ¾ý¨Á - ¦ÅôÀõ; À¢Ã¢× - ¸¡÷ôÒ 
 
À¡ñÎÌð¼õ ÌýÁõ ÀÕóàÄ §¿¡öÅ¡¾ó 
 
¾£ñÎ ¾¢Ã¢Å¢¼ï º¢ÃóÐñ¼õ-âñ¼ÁÊ 
 
§¿¡Å¢Çí¸ì ¸¡ð¼¡¾ Ññ¸¢ÕÁ¢ Â¡ºÉôÒñ 
 
Å¡öÅ¢Çí¸í¸¡ð¼Å¢ÕÁ¡÷. 
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Phytochemicals: Phenolic compounds, Tannins, Alkaloids, Saponins, 
Carbohydrates, Proteins, Oil, Fats, Mucilage 
 
Actions: Anthelmintic, Carminative, Stomachic, Stimulant. 
 
Pharmacological actions: Anti-diabetic, Anti oxidant 
(55)
, Oestrogenic action. 
 
 
15.«¾¢Å¢¼Âõ - Aconitum hetrophyllum Wall-ex Royle 
 
Í¨Å - ¨¸ôÒ; ¾ý¨Á - ¦ÅôÀõ; À¢Ã¢× - ¸¡÷ôÒ 
 
«¾¢Å¢ ¼Âõº÷ì¸ Ã¡üÒ¾§¿¡ö ¦ÅôÒ   
 
¦¸¡¾¢ÁÕ× §À¾¢¦Â¡Î §¸¡¨Æ- ±¾¢÷Å¡ó¾¢ 
 
±ýÚ¨ÃìÌõ §¿¡öìÜð¼õ þøÄ¡ ¾¸üÈ¢Å¢Îõ 
 
Ìý¨È ¿¢¸÷Ó¨ÄÂ¡ö! ÜÚ. 
 
Phytochemicals: Alkaloids, Saponins, Tannins, Flavanoids, Phenols and Lipids 
 
Actions: Stomachic, Astringent, Febrifuge, Aphrodisiac, Tonic, Aniperiodic 
 
Pharmacological actions: Anti inflammatory
(56) 
 
16.Á¡º¢ì¸¡ö - Quercus infectoria oliver 
 
Í¨Å - ÐÅ÷ôÒ; ¾ý¨Á - ¾ðÀõ; À¢Ã¢× - ¸¡÷ôÒ 
 
«ì¸Ãí¸û §À¡ì¸¢Å¢Îõ Á¡È¡¾ ¦ÅôÀ¸üÚõ 
 
¦ÁöìÌÚ¾¢ Á¡º¢ì¸¡ö ¦Áý§ÁÖõ - ¾ì¸¦¾¡Õ 
 
À¡Ä÷¸½ §¿¡ö§À¡ìÌõ Àý§Á¸ Óó¦¾¡¨ÄìÌõ 
 
§ÅÄ¨ÉÂ ¸ñ½¡ö! Å¢ÇõÒ. 
 
Phytochemicals:Tannins  (50-70%), Gallic acid, Ellagic acid, Syringic acid and 
Methyl  
 
betulate. 
 
Actions: Astringent, Styptic, Tonic 
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Pharmacological actions: Anti-inflammatory, Anti bacterial 
(57)
, Emollient 
 
 
17.º¢üÈ¡Á½ìÌ ±ñ¦½ö - Ricinus communis,Linn 
 
Í¨Å - º¢Ú¨¸ôÒ; ¾ý¨Á - ¦ÅôÀõ; À¢Ã¢× - ¸¡÷ôÒ 
 
¬Á½ìÌ ¦¿öÂ¡ø ¿ÄÓñ¼¡õ Â¡Å÷ìÌõ 
 
âÁ½ìÌ §ÁÉ¢ ÒÃ¢ÌÆ§Ä- Å¡öÁ½ì¸ì 
 
¦¸¡ûÇ¢ø ÅÂ¢ÚÅ¢Îí §¸¡ÃÓûÇ Å¡ÔÅÚõ 
 
¯ûÇ¢øÅÕ ÌýÁõ§À¡ §Á¡Ð. 
 
Actions: Laxative, Antivatha, Emollient 
(38).
 
 
Pharmacological actions:Anti-inflammatory, Anti-bacterial, Laxative, Emollient 
 
Traditional uses: 30 ml of castor oil mix either with milk or ginger juice and drink. 
This will result in loose motion. This will cure loss of appetite and menses 
problems.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
 
MATERIALS AND 
METHODS 
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MATERIALS AND METHODS:   
1. Authentication of raw drug  
          The raw drugs were purchased from a well reputed indigenous drug shop. 
The raw drugs were identified and authenticated by the Asst. Professor in Medicinal 
botany, NIS and Indhuppu (Sodium chloride impura), from Dept. of 
Pharmacognosy in Siddha Central Research Institute, Chennai. 
 2. Purification of raw drugs 
The following drugs were purified as per the siddha literature ; 
1. Root of Sivathai (Operculina turpethum.Linn(59) 
.- steamed with milk  anddried. 
 
2. Root of Nilavagai (Cassia senna,Linn)(60) 
-  steamed with milk  and dried.  
3. Koraikizhangu (Cyperus rotandus)(61) 
- Remove the outer skin  and  shadow dry.  
4. Sukku (Zingiber officinalis.Rosc) (60) 
 - Peel off the outer skin      
5. Milagu (Piper nigrum.Linn)(60) 
-Soak it in butter milk for three hours and dry it. 
6. Thippili(Piper longum.Linn)(60) 
 -Soak it in butter milk for three hours and dry  it. 
7. Kadukkai (Terminalia chebula.Retz)(61) 
 -Discard the seed and collect the rinds  alone for use. 
8. Thaantrikkai (Terminalia bellarica.Roxb) (61) 
- Discard the seed and collect the rinds alone for use. 
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9. Nellikkai (Phylanthus embilica.Linn) (60) 
- Remove the seed and collect the rinds alone for use. 
10. Kanda Thippili(Piper longum.Linn)(59) 
-Soak it in butter milk for three hours &  dry.   
11. Indhuppu (Sodium chloride impura)(53) 
-soaked in viniger for three days and dried in sunlight.  
12. Omam (Carum coptium.Benth&Hook.f)(60) 
-Soak it in clear calcium carbonate filtrate and dry it. 
13. Kadugu Rogini (Picrorhiza scrophulariflora,Pennell)(60) 
 -Dry it in shade.  
14. Vaaivilangam (Embelia ribes.Burm) (60) 
-Remove the waste from it and dry it in shade. 
15. Athividayam (Aconitum heterophyllum Wall-ex Royle)(60) 
-Dry it in shade 
16. Maasikai (Quercus infectoria.Oliver)(60) 
-Dry it in shade. 
17. Raipur Sugar (Brown sugar)(59) 
-
Dissolved in water and filter it. 
18. Sitramanakku ennai (Ricinus communis.Linn)(60) 
-Filter it. 
19. Water-Filter it. 
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3.Preparation of trial drug
 
Garpavaayuilagam: Ref: Vaithiya saarasangiragam,P.no-59 
Ingredients:
 
1. Sivathai vaer  (Operculina turpethum.Linn)   -  150 varagan (630 gm)  
2. Nilavagaivaer(Cassia senna,Linn)      -  150 varagan (630gm) 
3. Koraikizhangu(Cyperusrotandus,Linn)          - 33 varagan (138.2 gm) 
4. Sukku (Zingiber officinalis.Rosc)                     -  1.7 gm 
5. Milaghu (Piper nigrum.Linn)      -  1.7gm 
6. Thippili (Piper longum.Linn)                            -  1.7 gm 
7. Kadukai (Terminalia chebula.Retz)                  -  1.7 gm 
8. Thaantrikkai (Terminalia bellarica.Roxb)       -  1.7 gm 
9. Nellikkai ( Phylanthus embilica.Linn)             -  1.7 gm 
10. Kanda Thippili(Piper longum.Linn)                 -  1 kazhanju (5.1 gm) 
11. Indhuppu (Sodium chloride impura)       -  1 kazhanju (5.1 gm) 
12. Omam (Carum coptium.Benth&Hook)     -  1 kazhanju (5.1 gm) 
13. KaduguRogini(Picrorhizascrophulariflora,Pennell)  -  1 kazhanju (5.1gm)  
14. Vaaivilangam (Embelia ribes.Burm)             -  1 kazhanju  (5.1gm) 
15. Athividayam (Aconitum heterophyllum Wall-ex Royle -  1 kazhanju (5.1 gm) 
16. Maasikai (Quercus infectoria.Oliver)             -  1 kazhanju (5.1 gm) 
17. Raipur Sugar(Brown sugar)      -  5 palam (175 gm) 
18. Sitramanakkuennei(Ricinuscommunis,Linn)    - 1 padi (1.3 litre) 
19. Water                                     -  Suffiecient quantity  
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Method of preperation: The purified raw drugs from 1 to 16 were made into fine 
powder. The powder were added to the sugar syrup (i.e 175 gms of powdered sugar 
required quantity of water was added and boiled till it reache syrup consistency) and 
mix it well until it reach to ilagam consistency. Then Castor oil-1.3litre were added 
to the above mixture.   The prepared drug was stored in air tight glass container . 
 
4. Physiochemical analysis of trial drug  
     Sample discription: Garpavaayu ilagam. 
COLOUR   
          About 5 gm of Garpavaayu ilagam  was taken in a clean glass beaker and 
tested for its colour by viewing again a white opaque back ground under direct 
sunlight.  
 ODOUR   
        About 5 gm of the Garpavaayu ilagam  was placed in 100 ml of beaker and 
tested for its odour by wafting the air above the beaker. 
LOSS ON DRYING AT 100 ºC  
       5 gms of Garpavaayu ilagam  was heated in a hot oven at 100º c to a constant 
.The percentage of loss of weight was calculated.  
pH 
       The pH of the Garpavaayu ilagam  was estimated as per the method prescribed 
in the Indian standard (IS) -6940(1982). One gram of the Garpavaayu ilagam was 
taken in to a 100ml graduated cylinder containing about 50 ml of water and filled 
up to the mark with water. The cylinder was stopped and shaken vigorously for two 
minutes and the suspension was allowed to settle for hour at 25ºc to 27ºC about 25 
ml of the clear aqueous solution was transfered in to a 50 ml beaker and tested for 
pH using DIGISUN digital pH meter (DIGISUN electronics, Hyderabad, India)  
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DETERMINATION OF ASH VALUE   
     Weighed accurately 2gms of the Garpavaayu ilagam  in tarred platinum or  silica 
dish and incinerate at a temperature not be exceeding  450ºC until free from corban 
cooled and weighed calculate the percentage of ash with reference of the air dried 
drug was then calculated.  
WATER SOLUBLE ASH  
       To the Gooch crucible containing to the total ash, added 25 ml of water and 
boiled for 5 minutes. Collected the insoluble matter in a sintered glass crucible for 
15 minutes at a temperature not exceeding 450º c subtract the weight off the 
insoluble matter from the weight of the ash the difference of the weight represents 
the water soluble ash. Calculate the percentage of water soluble ash with the 
reference to the air dried drug.  
ACID INSOLUBLE ASH 
          Boiled ash 5minutes with 25 ml of 1:1 dil. Hcl collect the insoluble matter 
Gooch crucible on an ash less filter paper wash without water and ignited, cooled in 
a desiccators and weighed , calculated the percentage of insoluble ash with 
reference to the air dried  drug.  
STANDARDISATION OF REPORTS 
S.NO PARAMETER MEAN 
1. Loss on Drying at 105 C 11.77% 
2. Total ash 3.33% 
3. Water soluble  Ash 1.27% 
4. Acid insoluble  Ash 0.48% 
5. Water Soluble extractives 52.17% 
6. Alcohol soluble  extractives 44.31% 
7. pH 5.6 
8. Total solid 88.23% 
9. Fat content 12.18% 
10. Reducing sugar Nil 
11. Total sugar 30.78% 
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HPTLC DOCUMENTATION  
 
Stationary Phase - Silica Gel 60 F254 
Mobile Phase - Toluene : Ethyl Acetate : Formic Acid (5: 2: 0.5 v/v/v) 
 
 
 
λ = 254 nm 
 
 
λ = 366 nm 
 
λ  = 575 nm (Derivatized) 
 
Color Rf  value(s) Color Rf  value(s) Color Rf value(s) 
Green 0.32 Light pink 0.24 Purple 0.04 
Green 0.35 Dark pink 0.32 Purple 0.19 
Green 0.42 Bluish grey 0.41 Blue 0.37 
Green 0.50 Light pink 0.55 Pink  0.53 
Green 0.58 Light pink 0.58 Purple 0.61 
Green 0.76 Light Grey 0.62   
  Light Pink 0.65   
  Light Pink 0.71   
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3D Chromatogram @ 254 nm: 
 
 
HPTLC Chromatogram @ 254 nm:  
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Peak Table @ 254 nm:  
 
BIOCHEMICAL ANALYSIS 
S.No EXPERIMENT OBSERVATION INFERENCE 
 1.Test For Acid Radicals   
1. Test For Sulphate :  
       2ml of the above prepared extract is 
taken in a test tube to this added 2ml of 
4% ammonium oxalate solution. 
 
No cloudy     
appearance present 
 
Absence of 
Sulphate 
2. Test For Chloride: 
      2ml of the above prepared extract is 
added with 2ml of dil- HNO3 till the 
effervescence ceases. Then 2 ml of silver 
nitrate solution is added. 
 
Cloudy appearance 
present 
 
Presence of 
Chloride 
S Test For Phosphate: 
      2ml of the extract is treated with 2ml 
of ammonium molybdate solution and 
2ml of con.HNO3 
 
 No cloudy yellow    
appearance present. 
 
Absence of  
Phosphate     
4. Test For Carbonate:  
    2ml of the extract is treated with 2ml 
magnesium sulphate solution 
 
No Cloudy appearance 
present 
 
Absence of  
Carbonate 
5. Test For Fluoride & Oxalate: 
    2ml of extract is added with 2ml of 
dil. Acetic acid and 2ml calcium 
No cloudy appearance 
present. 
 
 Absence  of     
fluoride and   
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chloride solution and heated. oxalate 
6. Test For Nitrate: 
   1gm of the substance is heated with 
copper turning and concentrated H2So4 
and viewed the test tube vertically down 
 
No  Brown   gas   is 
evolved 
 
Absence   of   
Nitrate 
7. Test For Sulphide:  
      1gm of the substance is 
treated with 2ml of con. HCL 
No Rotten Egg 
Smelling gas  evolved 
Absence of   Sulphide 
8. Test For Nitrite: 
    3 drops of the extract is 
placed on a filter paper, on 
that - 2 drops of acetic acid 
and 2 drops of Benzidine 
solution is placed. 
No   Characteristic    
changes 
Absence  of  Nitrite 
9. Test For Borate: 
     2 Pinches of the substance 
is made into paste by using 
sulphuric acid and alcohol 
(95%) and introduced into the 
blue flame. 
Bluish  green  colour  
flame  not  appeared 
Absence   of   Borate 
 II. Test For Basic Radicals   
1. Test For Lead: 
2ml of the extract is added 
with 2ml of potassium iodine 
solution. 
No yellow precipitate 
is obtained. 
Absence  of   Lead 
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5. Test For Zinc:  
To 2ml of the extract sodium 
hydroxide solution is added in 
drops to excess  
 
White  precipitate   is   
not formed 
Absence of  Zinc 
6. Test For Calcium:  
2ml of the extract is added with 
2ml of 4% ammonium oxalate 
solution  
Cloudy appearance and 
white precipitate is  
obtained 
 
  Presence of  Calcium 
7. Test For Magnesium:  
     To 2ml of extract sodium 
hydroxide solution is added in 
drops toexcess. 
White precipitate is  not 
obtained 
Absence    of Magnesium 
2. Test For Copper: 
     2ml of extract is added 
with excess of ammonia 
solution. 
No blue color    
precipitate formed. 
 
Absence   of   Copper 
 
3. Test For Aluminium: 
    To the 2ml of extract 
sodium hydroxide is added in 
drops to excess. 
No characteristic 
changes.  
  Absence   of Aluminium 
4. Test For Iron: 
a.       To the 2ml of extract 
add 2ml of  ammonium 
thiocyanate solution 
b.    To the 2ml of extract 2ml  
ammonium  thiocyanate 
solution and 2ml  of con 
HNO3 is added 
Mild red colour appear 
Blood red colour 
appeared. 
Presence of Iron 
 
Presence of iron 
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8. Test For Ammonium: 
To 2ml of extract few ml of 
Nessler's reagent and excess of 
sodium hydroxide solution are 
added. 
No Brown colour 
appeared 
 
Absence     of Ammonium 
9. Test For Potassium: 
   A pinch of substance is treated 
with 2ml of sodium nitrite solution 
and then treated with 2ml of cobalt 
nitrate in 30% glacial acetic acid. 
 
No Yellowish 
precipitate is obtained. 
 
Absence of  Potassium 
10. Test For Sodium: 
    2 pinches of the substance is 
made into paste by using HCl and 
introduced into the blue flame of 
Bunsen burner. 
 
Yellow   colour    
flame appeared 
 
Presence  of   Sodium 
11. Test For Mercury:  
      2ml of the extract is treated 
with 2ml of sodium hydroxide 
solution.  
 
No yellow precipitate 
is obtained 
 
Absence of  Mercury 
12. Test For Arsenic:  
2ml of the extract is treated with 
2ml of sodium hydroxide solution. 
 
No brownish red 
precipitate is obtained 
 
Absence  of   Arsenic 
 III. Miscellaneous   
1.  Test For Starch: 
  2ml of extract is treated with 
weak iodine solution  
 
No Blue   colour 
developed 
 
 Absence of   Starch 
2.  Test For Reducing Sugar:  
5ml of Benedict's qualitative 
solution is taken in a test tube and 
allowed to boil for 2 minutes and 
 
Brick   red  colour 
developed 
 
 Presence of  Reducing 
sugar 
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added 8 to 10 drops of the extract 
and again boil it for 2 minutes. 
The colour changes are noted. 
3.  Test For The Alkaloids: 
a)  2ml of the extract is treated 
with 2ml of potassium lodide 
solution. 
b)  2ml of the extract is treated 
with 2ml of picric acid. 
c)  2ml of the extract is treated 
with 2ml of phosphotungstic acid. 
 
 
 
Yellow   colour 
developed 
 
 
 
  Presence of   Alkaloid 
4.  Test For Tannic Acid:  
2ml of extract is treated with 2ml 
of ferric chloride solution  
 
Black precipitate   is 
obtained 
 
 Presence of  Tannic acid 
5.  Test For Unsaturated 
Compound:   
To the 2ml of extract 2ml of 
Potassium permanganate solution 
is added.  
 
Potassium 
permanganate is  not 
decolourised 
 
Absence   of     unsaturated 
compound  
6.  Test For Amino Acid: 
    2 drops of the extract is placed 
on a filter paper and dried well.. 
 
 No Violet   colour 
developed 
 
Absence  of  Amino acids 
7. Test For Type Of Compound: 
2ml of the extract is treated with 2 
ml of ferric chloride solution.  
 No Brown    colour 
developed 
 
No red colour 
developed  
Absence of  Oay  quinole, 
Pinephrine  and  Pyro 
catechol 
 
Anti pyrine,Alipathic 
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No violet colour 
developed  
 
No Blue colour 
developed. 
amino acids and meconic 
acid are absent. 
 
Salicylate and resorcinol 
are absent. 
 
Morphine, Phenol cresol 
and hydroquinone are 
absent 
 
Preliminary Qualitative Phytochemical tests procedure and inter 
pretation of results 
s.no Constituents Inference 
1.  Calcium  Present 
2.  Sulphate  Absent 
3.  Chloride  Present  
4.  Carbonate  Absent  
5.  Sodium  Present  
6.  Iron  Present  
7.  Phosphate  Absent  
8.  Tannic acid  Present  
9.  Sugars  Present  
10.  Alkaloids  Present  
11  Fluoride  Absent  
12  Oxalate  Absent  
13  Aluminium  Absent  
14  Zinc  Absent  
15  Magnesium  Absent  
16  Ammonium  Absent  
17  Mercury  Absent  
18  Arsenic  Absent  
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19  Silicate  Absent  
20  Lead  Absent  
21  Copper  Absent  
22  Starch  Absent  
 
The bio chemical analysis of Garpavaayu ilagamhad shown the presence of 
Calcium, chloride, Iron,  Sugars, Alkaloid, Tannic acid, Unsaturated compound. 
 Clinical trial  
Screening of PCOD patients:  
Patient reporting at the NIS, OPD of Maruthuvam with clinical features of 
amenorrhoea, oligomenorrhoea, obesity, irregular menstruation, and infertility will 
be subjected to screening test and documented using screening proforma. The 
patients who are enrolled are informed about the study trial drug, possible outcomes 
and the objectives of the study in their own language and terms understandable to 
them and the informed consent would be obtained from them in the consent form.  
Patient recruitment  
Inclusion  
 Age: 20-40 years 
 Patients who are having the clinical symptoms of Oligomenorrhoea (or) 
Amenorrhoea (or) Dysmenorrhoea. 
 Patient willing to undergo Ultrasound abdomen &  routine blood 
investigation. 
 USG pelvis showing polycystic ovaries.   
 Patient  willing to participate in trial and signing in consent form  
Exclusion  
 H/O hypertension  
 H/O Diabetes mellitus 
 H/O cardiac disease 
 Pregnancy and lactation 
 H/O thyroid dysfunction  
 Chronic kidney disease  
 Fibroid uterus 
 H/O use of HRT in one year before. 
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 Presence of any systemic illness (e.g.Anaemia,)  
Conduct of clinical trial  
Study design 
Study type: An Open Clinical trial 
Study Place: 
             OPD & IPD Of theAyothidass Pandithar Hospital , 
             National Institute of Siddha, 
             Tambaram sanatorium, 
Chennai-47. 
Study Period     : 12 months  
Sample size     : 40 patients 
Conduct of the study  
The trial drug was given by the investigator in the OP department of Maruthuvam, 
NIS,  Chennai. On the first day  the trial drug Garpa vaayu ilagam was given for 7 
days medicine-7days drugholiday.  The patients were asked to have a regular 
treatment in the OP department once in 14 days for 3 months. In every visit the 
clinical assessment was recorded in the prescribed Proforma (form no:II A). The 
laboratory investigation was done before and after treatment and recorded in the 
prescribed format (form no: III).  
                At the end of the trial the patients were advised to come for follow up for 
2 months for observation.   
 
Data Management: 
 After enrolling the patient in the study, a separate file for each patient will 
be opened and all forms will be filed in the file. Study No. and Patient No. 
will be entered on the top of file for easy identification.  Whenever the study 
patient visits OPD during the study period, the respective patient‘s file will 
be taken and necessary recordings will be made at the assessment form or 
other suitable forms. 
 The screening forms will be filed separately. 
 The Data recordings will be monitored for completion by Guide (HOD, 
Dept. of Maruthuvam), SRO (Statistics) and the adverse event will be 
monitored by  
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the members of the Pharmacovigilance department of NIS. All forms will be 
further scrutinized in presence of Investigator by Sr.Research Officer 
(Statistics) for logical errors and incompleteness of data to avoid any bias. 
No modification in the results is permitted for unbiased reports.   
Data analysis  
     All collected datas will beentered into the computer and manually cross checked 
the correctness of the data entry. The clinical symptoms and laboratory 
investigation of blood and urine will be analysed by comparing the data before and 
after treatment by paired test and chi-square test will be employed to study the 
efficacy of treatment. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
 
OBSERVATION 
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OBSERVATION AND RESULTS 
 
 
1. Age incidence  
2. Marital status  
3. Parity  
4. Religion distribution  
5. Distribution of cases by Paruvakaalam  
6. Distribution of cases by Thinai  
7. Dietary habits  
8. Distribution of cases based on incidence of infertility  
9. Body built (based on BMI)  
10. Occupational distribution  
11. Positive family history for the disease  
12. Chronicity of illness       
13. Treatmental history other than siddha treatment  
 
a) For treating infertility  
 
b) For irregular menstruation  
 
14. Thegi  
15. Derangement in mukkutram  
 
        15. a Derangement in Vatham  
 
        15. b Derangements in Pitha kutram  
 
        15. c Derangements in Kaba kutram  
 
16. Kanmenthiriyam involvement  
 
17. Kosangal  
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18. Disturbance in Udal thathukkal  
19. Envagai thervu  
 
      19. a. Naadi  
 
      19. b. Neikkuri (oil on urine sign)  
 
20. Clinical symptoms before treatment  
      20.a. Intermenstrual score before treatment 
21. Out Come Measurement Before And After Treatment  
      21. a. Changes in USG after treatment   
      21.b. IMP score Before and After treatment      
22. Clinical symptoms before and after treatment  
23. BMI before and after treatment  
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1.AGE INCIDENCE 
 
Table: 1 
 
Age  (Year)             No of cases      Percentage 
20-24 18 45% 
25-29 16 40% 
30-34 5 12.5% 
35-40 1 2.5% 
         Total    40 100% 
 
 
 
 
 
 
 
 
Observation: Among 40 cases, 18 cases(45%)  were in the age group of 20-24 
years, 16 cases(40%)  in the age group of 25-29 years, 5 cases(12.5%)  were in the 
age group of 30-34 years and 1case (2.5%) were in the age group of 35-40 yrs. 
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 2. MARITAL STATUS 
Table : 2 
           Marital status             No of case      Percentage 
Single 24 60% 
Married 16 40% 
Total 40 100% 
 
 
 
 
Observation:  
Among the 40 patients selected, 24 cases (60%) were married and 16 cases(40%) 
were single.  
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3.PARITY 
   Table: 3 
Parity             No of case      Percentage 
Multiparous 3 7.5% 
2 nd child 10 25% 
Nulliparous 27 67.5% 
Total 40 100% 
 
 
 
Observation: Out of 40 cases, 27 cases (67.5% ) were found to be Nulliparous,10 
cases  (25% ) were seeking for second child and 3cases(7.5% ) were in Multiparous.  
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4. RELIGION DISTRIBUTION: 
 
    Table: 4   
Religion             No of case      Percentage 
Hindhu 36 90 % 
Christian 2 5 % 
Muslim 2 5 % 
Total 40 100 % 
 
 
 
Observation: Among 40 patients, 36 cases (90%) were Hindu, 2cases(5%)  were 
christian and 2 cases(5%)  were Muslim.  
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5. PARUVA KAALAM (SEASON)  
 
    Table: 5  
SI.No                  Paruva Kaalam        No. of cases        Percentage 
1 Kaar Kaalam (Aug 17- Oct 17) 0 0 % 
2              Koothir Kaalam (Oct 18 – Dec 15) 1 2.5 % 
3 Munpani Kaalam (Dec 16 – Feb 12) 20 50 % 
4 Pinpani Kaalam( Feb 13 – Apr 13) 19 47.5 % 
5 Elavenil Kaalam (Apr 14 – Jun 16) 0 0 % 
6 Muthuvenil Kaalam (Jun 17 – Aug 
16) 
0 0 % 
 Total 40 100 % 
 
 
Observation: Out of 40 cases, 20 cases(50%)  the treatment period was Munpani 
kaalam, 19 cases(47.5%)  Pinpani kaalam and 1case(2.5%)  koothirkaalam. 
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6. THINAI:  
 
Table: 6  
Thinai (Land) No of cases Percentage 
   Kurinji (Hill) 19 47.5 % 
   Mullai (Forest) 4 10 % 
   Marutham (Fertile) 1 2.5 % 
   Neithal(Coastal) 16 40 % 
   Paalai(Desert) 0 0 % 
            Total 40 100 % 
 
 
 
  
 
 
 
 
Observation: Out of 40 cases, 19cases  (47.5%) were from the land Kurinji, 16 
cases (40%) were from Neithal, 4 cases(10%)   were from Mullai and 1 case (2.5%) 
from Marutham. 
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7. DIET  
 
Table: 7  
Dietery Habit         No of cases Percentage 
               Vegetarian 2 5 % 
           Non - vegetarian 38 95 % 
                 Total 40 100 % 
 
 
 
 
 
Observation: Among 40 patients, 38 (95%) cases were non vegetarian, and 2 (5%) 
cases were vegetarian.  
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8. CASE DISTRIBUTION  
 
     Table: 8 
Case distribution   No of cases   Percentage 
PCOS 27 67.5 % 
PCOS along with infertility 3 7.5 % 
PCOS and for 2 nd child 10 25 % 
Total 40 100 % 
 
 
 
Observation: All the 40 patients had PCOS. Among them 27 cases (24 single and 3 
married women) ie., 67.5% were diagnosed as PCOS only, 3cases (3 married 
women ie., 7.5%) were PCOS with Maladu (1º infertility) and 10 cases were PCOS 
with kathalimaladu (seeking for second child ie., 25%).   
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9. BODY BUILT:  
    Table: 9 
BODY BUILT  
Based on BMI  
 
No of cases Percentage 
Obese (>30)  
 
16 40 % 
Over weight (25-30)  
 
16 40 % 
Normal weight (21-25)  
 
7 17.5 % 
Under weight (Below 20)  
 
1 2.5 % 
Total 40 100 % 
 
 
 
 
Observation: Among the 40 cases, 16 cases(40%)  were obese, 16 cases(40%)  
were of  over weight, 7 cases (17.5%) were normal weight and 1case(2.5%)  comes 
under  under weight category. 
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10. OCCUPATIONAL DISTRIBUTION  
 
      Table: 10  
          Nature of work   No of cases   Percentage 
Home Maker 10 25 % 
Standing work style 2 5 % 
Sedentary work style 19 47.5 % 
Student 19 22.5 % 
Total 40 100 % 
 
 
 
Observation: Among the 40 patients the incidence were more in sedentary workers 
ie., 19 cases(47.5 %) , next in home working 10 cases(25%) , next in students 9 
cases  (22.5%) and finally in standing workers 2 cases(5%). 
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11. POSITIVE FAMILY HISTORY FOR THE DISEASE  
 
     Table:11 
Family history for the disease  
 
       No of case      Percentage 
In 1 st degree relationship  
 
2 5 % 
No positive family history  
 
38 95 % 
Total 40 100 % 
 
 
 
Observation: Positive familial history was seen in only 2 cases (5%) of patients 
and the other 38 cases (95%) have no relevant family history. 
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12. CHRONICITY OF ILLNESS: 
a) Irregular menstruation:  
       Table: 12 (a)  
Chronicity of illness  
 
       No. of cases        Percentage 
Less than six months 2 5 % 
6 months - 1 year 21 52.5 % 
Above 1 - 2 year 6 15 % 
Above 2 – 5 year 4 10 % 
Above 5 – 10 year 5 12.5 % 
More than  10 year 2 5 % 
Total 40 100 % 
 
 
 
Observation: Among 40 patients, 21 cases (52.5 % ) the duration of illness was 
between 6months – 1 yr, 2 cases(5%)  was less than 6 months, 6cases(15%) were 
between 1-2 years, 4 cases(10%)  the duration was between 2-5 yrs, 5 cases(12.5%)  
between 5-10 yrs and 2 cases (5%) the duration was more than 10 years.  
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13. TREATMENTAL HISTORY OTHER THAN SIDDHA:  
 
Table: 13a (For treating infertility)   
Various treatmental history  
 
  No of cases   Percentage 
Ovulation induction  
 
1 33.33 
Ovulation induction + IUI  
 
0 0 % 
Not undergone any treatment 
before 
2 66.66 % 
Total 3 100 % 
  
 
 
 
Observation: Among the 3 patients, 1 case (33.33%) only underwent ovulation 
induction 
And 2 cases (66.66%) has not taken any treatment.  
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Table: 13b (For irregular menstruation) 
Various treatmental history  
 
  No of cases   Percentage 
Menstruation induction  
 
4 11.42 % 
Oral hypoglycemic drug  
 
2  5.71 % 
Not undergone any treatment before  
 
29  82.85 % 
Total 35 100 % 
 
 
 
 
 
Observation: Among the 35 patients, 29 cases (82.85%) were not taken any 
treatment, 4 cases (11.42%) underwent menstruation induction and 2 cases(5.71%) 
were under oral hypoglycaemic drug.  
.  
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 14. THEGI  
 
Table: 14 
Thegi No of cases Percentage 
        Vatham 16 40 % 
        Pitham 8 20 % 
       Kapham 16 40 % 
       Total 40 100 % 
 
 
 
Observation: In the study, 16 cases(40%) were Vatha thegi, 16 cases(40 %)  were 
Kapha thegi and another 8 cases(20 %) were Pitha thegi.  
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  15. DERANGEMENT OF MUKKUTRAM 
 
        15. a. DERANGEMENT IN VATHAM: Table:  
SI.No       Classification of vatham No of cases Percentage 
     1             Praanan 0 0 % 
     2            Abaanan 40 100 % 
     3            Udhaanan 0 0 % 
     4            Samaanan 40 100 % 
     5            Viyaanan 16 40 % 
     6            Naagan 0 0 % 
     7            Koorman 0 0 % 
     8            Kirukaran 0 0 % 
     9            Devathathan 31 77.5 % 
    10            Dananjayan -- -- 
 
 
 
Observation: Abanan and Samanan were affected in all the 40 Patients(100%). In 
31 cases (77.5%) Devathathan was affected, Viyanan was affected in 16 cases(40%) 
. 
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15. b. DERANGEMENTS IN PITHA KUTRAM:  
 
     Table: 15. b 
SI.No      Classification of Pitham          No of cases Percentage 
      1      Anarpitham 0 0 % 
      2      Ranjagam 2 5 % 
      3      Saathagam 40 100 % 
      4      Alosskam 0 0  % 
      5      Prasakam 2 5 % 
 
 
 
Observation: Among the 40 cases, Sathagam was affected in 40 cases(100%). 
Ranjagam was affected in 2 cases(5%)  and Prasagam was affected in 2 cases(5%).  
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15.c DISTURBANCES IN KABA KUTRAM:  
Table: 15.c 
SI.No Classification of Kabam No of cases Percentage 
    1                  Avalambagam 0 0 % 
    2                   Kelethagam 2 5 % 
    3                    Pothagam 0 0 % 
    4                  Tharpagam 0 0 % 
    5                  Santhigam 16 40 % 
 
 
 
Observation: Among 40 cases, Santhigam was affected in 16 cases(40%)  and 
Klethagam was affected in 2 cases(5 %) . 
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16. KANMENTHIRIYAM INVOLVEMENT:  
 
      Table: 16  
Kanmenthiriyam No of cases Percentage 
Kai  0 0 % 
Kaal 16 40 % 
Vaai 0 0 % 
Karuvaai 40 100 % 
Eruvaai 31 77.5 % 
 
 
 
Observation:  
Among the 40 cases, Karuvaai was affected in all 40 cases(100%) . Eruvaai was 
affected in 31 cases(77.5 %)  and Kal was affected in 16 cases(40%).  
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17. KOSANGAL:  
 
      Table: 17  
Kosam No of cases             Percentage 
      Annamaya kosam 1 2.5 % 
      Pranamaya kosam 2 5 % 
      Manomaya kosam 35 87.5 % 
      Vignanamaya kosam 1 2.5 % 
      Anandamaya kosam 40 100  % 
 
 
 
OBSERVATION: Among the 40 cases, all the 40 cases (100%) Ananthamaya 
kosam was affected, in 35 cases(87.5%)  Manomaya kosam was affected and 
Vignanamaya kosam was affected in 1 cases(2.5%) . 
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18. DISTURBANCE IN UDAL THATHUKKAL  
 
     Table: 18 
Udal Kattugal No of cases Percentage 
Saaram 3 7.5 % 
Senneer 2 5 % 
Oon 16 40 % 
Kozhuppu 17 42.5 % 
Enbu 16 40  % 
Moolai 0 0 % 
Sukkilam/ Suronitham 40 100 % 
 
 
 
Observation: Among 40 cases, Suronitham was affected in all the 40 cases(100%) 
, Saaram was affected in 3 cases(7.5%) , Kozhuppu was affected in 17 cases(42.5%)  
and  Oon was affected in 16 cases(40 %)  , Enbu was affected in 16cases (40%) and  
Senneer was affected in 2 cases(5%).  
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19. ENVAGAI THERVUGAL (EIGHT DIAGNOSTIC 
METHODS)  
 
      Table 19  
En Vagai  Thervugal  No of cases Percentage 
 Naa 0 0 % 
Niram 0 0 % 
Mozhi 0 0 % 
Vizhi 0 0 % 
Sparisam 2 5 % 
Malam 31 77.5 % 
Mothiram 5 12.5 % 
Naadi (Thontham) 40 100 % 
 
 
 
 
Observation: Malam was affected in 31 cases(77.5%) . Moothiram was affected in 
5 cases(12.5%) , Sparisam was affected in 2 cases (2%)  . In all the cases, 
examination of Naadi nadai revealed thontham.  
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19. a NAADI  
 
Table: 19. a 
Naadi No of cases Percentage 
        Vatha pittham 30 75 % 
        Pitha vatham 5 12.5 % 
       Kapha pittham 5 12.5 % 
       Total 40 100 % 
 
 
 
Observation: Majority of the cases 30 (75%) revealed Vatha Pitha naadi. 5 cases 
(12.5%) show Pitha vatham and 5 of the cases (12.5%)  showed Pitha kaba naadi  
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19. b NEIKKURI (Oil on urine sign)  
 
Table: 19. b 
            Types              No of cases               Percentage 
 
Aravenaneendathu  
Vathaneer (Spreading like a 
snake) 
 
20 50 % 
 
Aazhipolparaviathu  
Pitha neer (Spreading like a 
ring)  
 
8 20 % 
 
Muththothu Ninrathu  
Kabaneer (Stands like a pearl)  
 
8 20 % 
Thontha neer 4 10 % 
Total 40 100 % 
 
 
Observation: Among the 40 cases, 20 cases(50%)  had Vatha neer, 8 cases(20%)  
had Pitha neer, 8 cases (20%) had Kabha neer and 4 cases (10%)  had Thonta neer.  
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20. BEFORE TREATMENT ASSESSMENTS  
 
20. a. INTER MENSTRUAL PERIOD ASSESSMENT SCORE  
 
GRADE BEFORE TREATMENT 
LENGTH OF CYCLE Cases Percentage 
0 28 days Nil 3 7.5% 
1 28 – 45 days Mild 11 27.5 % 
2 45 – 60 days Moderate 18 45 % 
3 Above 60 days Severe 8 20 % 
 Total  40 100 % 
 
 
 
Observation: Among the 40 cases, 3 cases(7.5%)  had 28 days cycle, 11 
cases(27.5%)  had 28-45 days cycle, 18 cases (45 %) had 45-60 days cycle and 8 
cases (20 %) had above 60 days cycle.  
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20.b CLINICAL SYMPTOMS BEFORE TREATMENT:  
     Table: 20.c 
Clinical symptoms No of cases Percentage 
Irregular menstruation 40 100 % 
Oligomenorrhoea 10 25 % 
Amenorrhoea 8 20 % 
Dysmenorrhoea 8 20 % 
Constipation 31 77.5 % 
Weight gain 32 80 % 
Infertility 3 7.5 % 
Acanthosis nigricans 12 30 % 
Hirsuitism 12 30 % 
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Observation:  
Out of the 40 cases, all 40 cases(100%)  had irregular menstrual cycle (IMP or 
Duration of bleeding).  
Weight gain was found in 32 cases (80 %), Constipation was seen in 31 cases(77.5 
%)                                                                                                                                                         
Acanthosis nigricans was found in 12cases  (30 % ),  
Hirsuitism had 12 cases (30 %)  , 8 cases (20%) had amenorrhoea, 8 cases(20 %)  
had dysmenorrhea, 
10 cases(25%)  had oligomenorrhoea and   3 cases (7.5 %) had infertility. 
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RESULTS     
21. OUTCOME MEASUREMENTS:  
       Out of 45 cases, 5 cases with drawn from the study due to long term absence. 
So the outcome was given for 40 cases before and after treatment. 
21.a ULTRASONOGRAPHY REPORT IN BEFORE AND AFTER TREATMENT 
S.NO OPD NO NAME AGE BEFORE TREATMENT AFTER TREATMENT 
1 G91843 Mangaiyarkarasi 21 B/L POLYCYSTIC OVARIES NORMAL  STUDY 
2 G99429 Sharly louisa 25 B/L POLYCYSTIC OVARIES NORMAL  STUDY 
3 H00862 Nandhini 23 B/L POLYCYSTIC OVARIES NORMAL  STUDY 
4 G92647 B.Anitha 30 B/L POLYCYSTIC OVARIES NORMAL  STUDY 
5 H08939 Abarna 30 B/L POLYCYSTIC OVARIES B/L POLYCYSTIC OVARIES 
6 G93856 Anandhi 23 LEFT  CYSTIC OVARY NORMAL  STUDY 
7 H08424 Sudha 24 B/L POLYCYSTIC OVARIES B/L POLYCYSTIC OVARIES 
8 H08496 Aswathy 27 B/L POLYCYSTIC OVARIES B/L POLYCYSTIC OVARIES 
9 H01889 Mageshwari 28 B/L POLYCYSTIC OVARIES NORMAL  STUDY, 
10 H13948 Benazir 23 B/L POLYCYSTIC OVARIES B/L POLYCYSTIC OVARIES 
11 H14793 Suganthi 21 B/L POLYCYSTIC OVARIES REDUCED SIZE OF  CYST 
12 H15049 Chitra 36 B/L POLYCYSTIC OVARIES REDUCED SIZE OF  CYST 
13 H16320 Shakila  banu 29 B/L POLYCYSTIC OVARIES REDUCED SIZE OF CYST 
14 H16297 Deepa 20 B/L POLYCYSTIC OVARIES NORMAL  STUDY 
15 H08207 Thenmozhi 29 B/L POLYCYSTIC OVARIES  
BULKY UTERUS 
NORMAL  STUDY 
16 H19521 S.Pavithra 23 B/L POLYCYSTIC OVARIES B/L POLYCYSTIC OVARIES 
17 G49654 Thulasi 29 B/L POLYCYSTIC OVARIES REDUCED SIZE OF CYST 
18 H08313 Rathika 26 B/L POLYCYSTIC OVARIES NORMAL  STUDY 
19 H07725 Amudhavalli 28 B/L POLYCYSTIC OVARIES B/L  POLYCYSTIC OVARIES 
20 H16246 Suriyakala 32 B/L POLYCYSTIC OVARIES REDUCED SIZE OF CYST 
21 G97934 Ranjitham 25 B/L POLYCYSTIC OVARIES NORMAL  STUDY 
22 H26029 Geetha 32 RIGHT CYSTIC OVARY NORMAL  STUDY 
23 H25763 P.Pavithra 20 B/L POLYCYSTIC OVARIES REDUCED SIZE OF CYST 
24 H26007 Kasthuri 21 B/L POLYCYSTIC OVARIES REDUCED SIZE OF CYST 
25 H28179 Sandhiya 24 LEFT  CYSTIC OVARY NORMAL  STUDY 
26 H05923 Mohanalakshmi 21 B/L POLYCYSTIC OVARIES NORMAL  STUDY 
27 H28333 Suguna 23 B/L POLYCYSTIC OVARIES REDUCED SIZE OF CYST 
28 H31190 Sadhana 28 B/L POLYCYSTIC OVARIES B/L POLYCYSTIC OVARIES 
29 H19738 V.Anandhi 26 B/L POLYCYSTIC OVARIES REDUCED SIZE OF CYST 
30 H08744 J.Anitha 28 B/L POLYCYSTIC OVARIES NORMAL  STUDY 
31 H30678 Akila 23 LEFT  CYSTIC OVARY REDUCED SIZE OF CYST 
32 H24781 Preetha 20 B/L POLYCYSTIC OVARIES REDUCED SIZE OF CYST 
33 H30919 S.Janani 26 B/L POLYCYSTIC OVARIES NORMAL  STUDY 
34 G91734 Kanimozhi 23 B/L POLYCYSTIC OVARIES REDUCED SIZE OF CYST 
35 G96488 Saraswathy 31 B/L POLYCYSTIC OVARIES NORMAL  STUDY 
36 H35170 R.Janani 26 B/L POLYCYSTIC OVARIES REDUCED SIZE OF CYST 
37 H27777 Gayathri 28 B/L POLYCYSTIC OVARIES REDUCED SIZE OF CYST 
38 H20486 Sapna 24 B/L POLYCYSTIC OVARIES REDUCED SIZE OF CYST 
39 H36263 Vidhya 30 B/L POLYCYSTIC OVARIES NORMAL  STUDY 
40 H00601 Keerthana 22 B/L POLYCYSTIC OVARIES REDUCED SIZE OF CYST 
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21.a CHANGES IN USG ABDOMEN AFTER TREATMENT:  
Table:21.a 
IMPROVEMENT  
 
USG ABDOMEN 
CHANGES  
NO. OF 
CASES  
PERCENT
AGE  
GOOD Complete clearance of cyst 17 42.5 % 
MODERATE Changes in the size of the cyst  16 40 % 
POOR No changes  in the size of the 
cyst 
7 17.5 % 
 TOTAL 40 100 % 
 
 
 
Observation: Out of 40 patients, All 40 cases show polycystic changes in both 
ovaries Out of which, 17 patients (42.5%) showed complete clearance of cyst after 
treatment. Moderate changes seen in 16 (40%) case. No significant improvements 
were seen in the remaining 7 (17.5%) cases.  
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 21.b  INTERMENSTRUAL SCORE IN BEFORE AND AFTER TREATMENT 
S.NO OPD NO AGE IMP SCORE 
BEFORE TREATMENT AFTER TREATMENT 
1 G91843 21 2 0 
2 G99429 25 2 0 
3 H00862 23 1 0 
4 G92647 30 1 0 
5 H08939 30 3 2 
6 G93856 23 0 0 
7 H08424 24 1 0 
8 H08496 27 1 0 
9 H01889 28 1 0 
10 H13948 23 2 1 
11 H14793 21 3 2 
12 H15049 36 0 0 
13 H16320 29 2 1 
14 H16297 20 3 1 
15 H08207 29 0 0 
16 H19521 23 3 3 
17 G49654 29 2 0 
18 H08313 26 1 0 
19 H07725 28 3 3 
20 H16246 32 1 0 
21 G97934 25 2 0 
22 H26029 32 3 0 
23 H25763 20 2 1 
24 H26007 21 2 1 
25 H28179 24 1 0 
26 H05923 21 2 0 
27 H28333 23 2 1 
28 H31190 28 2 1 
29 H19738 26 2 0 
30 H08744 28 2 0 
31 H30678 23 2 1 
32 H24781 20 1 0 
33 H30919 26 1 0 
34 G91734 23 3 3 
35 G96488 31 2 1 
36 H35170 26 2 1 
37 H27777 28 2 2 
38 H20486 24 3 0 
39 H36263 30 1 0 
40 H00601 22 3 2 
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21.b) INTER MENSTRUAL PERIOD ASSESSMENT SCORE  
GRADE BEFORE 
TREATMENT 
AFTER TREATMENT 
LENGTH OF CYCLE Cases Percentage Grade Cases Percentage 
0 28 days Nil 3 7.5 % 0 23 57.5 % 
1 28 – 45 days Mild 11 27.5 % 1 10 25 % 
2 45 – 60 days Moderate 17 42.5 % 2 4 10 % 
3 Above 60 
days 
Severe 9 22.5 % 3 3 7.5 % 
 Total  40 100 % Total 40 100  % 
 
 
 
 
 
Observation:  
        Intermenstrual periods were found to be normal in 3 (7.5) patients and severe 
in 9 (22.5 %) cases before treatment. At the end of the treatment it was found 
normal in 23 (57.5%) number of cases and the severity was present only in 3 (7.5 
%) case.  
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22. CLINICAL SYMPTOMS  AFTER  TREATMENT:                                                                                                                                    
     Table: 22 
Clinical symptoms   No of cases 
observed      
No of cases  
improved 
Percentage 
Irregular menstruation 40 40 100 % 
Oligomenorrhoea 10 10 100 % 
Amenorrhoea 8 4 50 % 
Dysmenorrhoea 8 7 87.5 % 
Constipation 31 31 100 % 
Weight gain 32 10 31.25 % 
Infertility 3 2 66.6 % 
Acanthosis nigricans 12 1 8.3 % 
Hirsuitism 12 1 8.3 % 
 
 
Observation:    Out of the 40 cases, all the 40 cases the menstrual cycle was 
irregular (IMP or Duration of bleeding) before treatment. Secondly, weight gain 
was found in (80 %) large number of patients before treatment.  
After treatment there was a considerable reduction in all symptoms particularly 
irregular menstruation, oligomenorrhoea, Dysmenorrhoea and amenorrhoea.  
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After treatment there was a complete relief in the symptom like constipation and 
There was  changes in the body weight (31.25%). 2 infertility  with PCOS patients 
normal study in USG abdomen and regularized menstrual cycle after treatment 
 
23.BMI   IN BEFORE AND AFTER TREATMENT 
S.NO OPD 
NO 
AGE BT AT 
1 G91843 21 17 17 
2 G99429 25 25.5 25 
3 H00862 23 31.5 30.5 
4 G92647 30 31 30 
5 H08939 30 30.4 30.5 
6 G93856 23 28.5 28 
7 H08424 24 22.9 22.8 
8 H08496 27 25.4 25 
9 H01889 28 27.8 26 
10 H13948 23 33.4 33 
11 H14793 21 26.3 25 
12 H15049 36 32.1 32 
13 H16320 29 34 34 
14 H16297 20 34.2 34 
15 H08207 29 26.3 26 
16 H19521 23 28.2 26 
17 G49654 29 30.1 30 
18 H08313 26 25 25 
19 H07725 28 28 28 
20 H16246 32 28 28 
21 G97934 25 33.8 30.8 
22 H26029 32 28 27 
23 H25763 20 25 25 
24 H26007 21 35.5 34 
25 H28179 24 30 30 
26 H05923 21 42 40 
27 H28333 23 26 26 
28 H31190 28 29 29 
29 H19738 26 32 30 
30 H08744 28 26.8 24 
31 H30678 23 25 25 
32 H24781 20 24 24 
33 H30919 26 36.9 35.8 
34 G91734 23 25 25 
35 G96488 31 28 28 
36 H35170 26 32 32 
37 H27777 28 31 31 
38 H20486 24 32 33 
39 H36263 30 25.5 25.4 
40 H00601 22 25 25 
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STATISTICAL ANALYSIS:  
1. INTERMENSTRUAL PERIOD (IMP) SCORE BEFORE AND AFTER 
TREATMENT  
 
 (IMP SCORE BT and AT) 
Variable No Mean±Std T value P value 
BT 40 1.8±0.88  
9.39 
P<0.0001 
AT 40 0.675±0.94 
 
 The mean± standard deviation of pain score at before and after treatment 
were 1.8±0.88  and0.675±0.94 (t= 9.39 p <0.001).The % of improvement 
i.e,Regular menstrual cycle  is 63% from 1.8 to 0.675. Respectively which is 
statistically significant. 
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DISCUSSION 
           Advancement in the modern technology has enabled our present day society 
to exist in a world where the constant of hard work even moderate work is absolute 
and infashionable. Though the modern medicine has advanced in its development it 
still lacks proper medicine in some disease such as PCOS, Psoriasis, etc. The 
physical inactivity, sedentary life style, food habits, environment pollution have 
caused so many diseases, especially in women of child bearing age with  menstrual 
abnormalities, one such abnormality is Garpa vaayu.  
          Garpa vaayu is a disease characterized by abdominal discomfort, 
dysmenorrhoea, low back ache, constipation, amenorrhea, and heaviness of thigh. It 
may be correlated with Polycystic Ovarian Disease of modern science.  
           The main aim of the study is to document the effectiveness of the siddha 
medicine ―Garpa vaayu ilagam (Internal medicines)‖ in the management of Garpa 
vaayu (Polycystic ovarian syndrome).  
           The standardization of the trial drug and the safety of the trial drug were 
ensured during the study through physicochemical analysis.  
           The drug was prepared as per standard operating procedure mentioned in the 
protocol in Gunapadam laboratory of National Institute of Siddha after getting 
authentication of the raw drugs.  
           The standardization of trial drug was carried out in biochemistry lab of NIS 
and CSRI, Chennai respectively. It revealed the presence of effective minerals.  
          The clinical study was conducted with a well defined protocol and a proper 
proforma after the approval of the Institutional Ethical Committee (IEC NO: 
NIS/IEC/8-14/6-26-08-2014). Out of 91 cases reported at the OPD of Maruthuvam 
and Magalir & sool maruthuvam, 40 cases were selected for induction to the trial. 
Before enrollment into the trial the informed consent was obtained from the 
patients.   
       Treatment was mainly aimed at balancing the elevated humors and treating the 
disease through siddha line of treatment – Purgation and Internal medication. 
      The trial drug   Garpavaayu ilagam was given for 7 days medicine – 7 days drug 
holiday i.e (Total duration of drug administration  is  42 days for the study period of 
3 months).  Which is referred in the Siddha literature Vaithiya saarasangiragam. 
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       For OP  patients,  they should visit the hospital once in 14 days. At each 
clinical  visit clinical assessment was done and prognosis was noted. 
       Laboratory investigations and radiological investigation were done before and 
after the trial. All the patients were put under observation for 2 months follow up 
period without the trial drug treatment.  
The observations are summarized below.  
1. Distribution of cases by age:  
Among 40 cases 
 18 cases (45%)  were in the age group of 20-24 years 
 16 (40%) cases in the age group of 25-29 years 
 5 (12.5%) cases were in the age group of 30-34 years   
 1(2.5%) case were in the age group of 35-40 yrs. 
Inference:    
     In this study the prevalence of the disease was found to be higher in 18 cases 
(45%) in the age group of 20-24 years. Many women who have PCOS are very 
frustrated with their lives and ignore the symptoms and do not try to treat 
themselves until it is too late.  
2. Distribution of cases by marital status:  
       Among the 40 patients selected,  Prevalence of the disease was found to be 
higher in married females i.e.24 cases (60%) and 16 (40%) cases are single.  
Inference: PCOS is a very common disorder that many women first learn about 
while seeking the cause of their infertility. 
3.Distribution of case by Parity: 
Out of 40 cases, 67.5% (27 cases) were found to be Nulliparous, 25% (10 cases) for 
PCOS  and for second child and 7.5% (3cases) were in Multiparous.  
Inference: PCOS is a very common disorder that many women first learn about 
while seeking the cause of their infertility  
4. Distribution of cases by religion:  
Among 40 patients, 36 (90%) cases were Hindu, 2(5%) cases were christian and 2 
(5%) cases were Muslim. 
5. Distribution of cases by Paruvakaalam:  
Out of 40 cases, 20 cases (50%)  the treatment period was Munpani kaalam, 19 
(47.5%) cases Pinpani kaalam and 1(2.5%) case koothirkaalam.  
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6. Distribution of cases by Thinai:  
Out of 40 cases, 19 (47.5%) were from the land Kurinji, 16 (40%) were from 
Neithal, 4 (10%)  cases were from Mullai and 1 (2.5%) case from Marutham. 
7. Distribution of cases by Diet:  
Among 40 patients, 38 (95%) cases were non vegetarian, and 2(5%) cases were 
vegetarian.  
Inference:  
In this study most of the patients were observed to be non vegetarians.  
8. Case distribution:  
        All the 40 patients had PCOS. Among them 27 cases (24 single and 3 married 
women) ie., 67.5% were diagnosed as PCOS only, 3cases (3 married women ie., 
7.5%) were PCOS with Maladu (1º infertility) and 10 cases were PCOS with 
kathalimaladu (seeking for second child ie., 25%).     
9. Distribution of cases by body built:  
        Among the 40 cases, 16 (40%) cases were obese, 16 (40%) cases were of  over 
weight, 7 (17.5%) cases were normal weight and 1(2.5%) case comes under weight.  
Inference:  
In this study most of the subjects are Obese and overweight. Obesity, particularly 
the abdominal phenotype, may be partly responsible for insulin resistance and 
associated hyperinsulinemia in women with PCOS. Therefore, obesity-related 
hyperinsulinemia may play a key role in favouring hyperandrogenism in these 
women. These obviously emphasize the role of obesity in the pathophysiology of 
PCOS.  
10. Distribution of cases by Occupation:  
Among the 40 patients the incidence were more in sedentary workers ie., 19 (47.5 
%) cases, next in home working 10 (25%) cases, next in students 9 (22.5%) and 
finally in standing workers 2 (5%) cases.  
Inference: In this study most of the patients are sedentary workers. The incidence 
appears to be increase due to change in life style and stress. Sedentary workers are 
distressed by both physical aspects and psychological aspects  
11. Distribution of cases by positive familial history:  
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         Among the 40 cases observed, Positive familial history was seen in only 2 
(5%) of patients and the other 38 (95%) cases has no family history for the 
incidence of the disease.   
12. Distribution of cases by chronicity of illness:  
Among 40 patients 
21 cases (52.5 % ) the duration of illness was between 6months – 1 yr,  
2 (5%) cases was less than 6 months  
6(15%)cases were between 1-2 years  
4 (10%) cases the duration was between 2-5 yrs  
5 (12.5%) cases between 5-10 yrs  
2 (5%) cases the duration was more than 10 years.  
Inference: In this study majority of the subjects are between 6months-1year 
chronicity. 
13.Treatment history:  
Among the 3 Infertility patients, 1 (33.33%) case only underwent  ovulation 
inductionand 2 (66.66%) cases had not taken any other treatment. 
       Among the 35 PCOS patients, 29 (82.85%) cases were not taken any treatment, 
4 (11.42%) cases underwent menstruation induction and 2 (5.71%) cases were 
under oral hypoglycaemic drug. 
14. Thegi: 
In the study, 16 (40%) cases were Vatha thegi,  16 (40 %) cases were Kapha thegi 
and another 8 (20 %) cases were Pitha thegi.  
Inference: In this study most of the cases were Vatha and  Kabha thegi.  
15. Condition of Mukkuttram:  
15.a. Derangement in Vatha kutram:  
Among the 40 cases,  
Abanan was affected in 40 (100%) cases which resulted in irregular menstruation.  
Samanan was affected in all 40 (100%) cases which resulted in irregular 
menstruation.  
Viyanan was affected in 16 (40%) of cases which resulted in low back ache.  
Devadhathan was affected in 31 (77.5%) cases, which resulted in Constipation and 
lethargy.  
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Pranan, Udhanan, Nagan, Koorman,  Kirukaran and Dhananjeyan remained normal 
in all 40 cases.  
15.b. Derangement in Pitha Kutram:  
Among the 40 cases 
Sathagam was affected in 40 (100%) cases which resulted in irregular menstruation. 
Ranjagam was affected in 2 (5%) cases,  which  resulted in reduced level of Hb.  
Prasagam was affected in 2 (5%) cases which  resulted in hyperpigmentation of the 
skin. Anarpitham and Alosagam remained normal in all cases.  
15.c. Derangement in Kabha kutram:  
Among 40 cases, Santhigam was affected in 16 (40%) cases which resulted in low 
back ache.  
Klethagam was affected in 2 (5 %) cases which is resulted in Abdomen discomfort 
and Belching. All others remained normal  
16.Distribution of cases by Kanmendrium:  
Among 40 cases,  
Karuvai was affected in all 40 (100%) cases leading to irregular periods  
Eruvai was affected in 31 (77.5%) cases leading to constipation.  
Kal (Lower limb) was affected in 16 (40%) cases leading to pain in lower limb  
Kai and Vai were normal in all the 40 (100%) patients.  
17. KOSANGAL:  
Among the 40 cases, In all cases Ananthamaya kosam was affected resulted in 
irregular periods.  
In 35 (87.5%) cases Manomaya kosam was affected resulted in mental depression.  
In 1 (2.5%) cases Vignanamaya kosam was affected resulted in pain in joints.  
In 1 (2.5%) cases the Annamaya kosam was affected resulted in Abdomen 
discomfort.  
In 2 (5%) cases the Pranamaya kosam was affected resulted in dyspnoea.  
18. Distribution of cases by Udal thathukkal:  
Among 40 cases, 
Suronitham was affected in all the 40 (100%) cases resulted in irregular 
menstruation 
Saaram was affected in 3 (7.5%) cases that produced the symptoms  like lethargy  
and mental depression. 
Kozhuppu was affected in 17 (42.5%) cases that produced the symptoms like 
increased body weight  
105 
 
Oon was affected in 16 (40 %) cases resulted in joint pain  lower limbs.  
Enbu was affected in 16(40%) cases resulted in low back ache and hair fall. 
Senneer was affected in 2 (5%) cases that produced symptoms like loss of strength, 
skin manifestation,reduced level of Hb. 
Moolai  was not affected in all the case concerned to the disease. 
19. Distribution of cases by Envagai thervugal: 
Malam was affected in 31 (77.5%) cases resulted in constipation. 
Moothiram was affected in 5 (12.5%) cases resulted in Itching and Burning 
micturition.  
Sparisam was affected in 2 (2%)  cases resulted in hyperpigmentation of skin.  
In all cases the type of Naadi was thontha naadi  
All other remained normal.  
19.a. Distribution of cases by Naadi type:  
All the 40 cases showed Thontha naadi.  
Vadha pitha naadi was predominant in 30 (75%) cases.  
Pitha Vatha naadi was found in 5 (12.5%) cases.  
Pitha Kabham naadi was found in 5 (12.5%) case.  
19.b. Distribution of cases by Neikuri:  
Among 40 cases,  
20 (50%) cases had Vatham pattern of Neikuri i.e. Aravenaneendathu (Spreading 
like a snake)  
8 (20%) cases had Kapham pattern of Neikuri. i.e Muththothu Ninrathu (Stands like 
a pearl).  
8 (20%) cases had Pitham pattern of Neikuri .i.e. Aazhipolparaviathu (Spreading 
like a ring)  
4 (10%) cases had Thontha neer.   
 
20. BEFORE TREATMENT ASSESMENT 
20.a.Intermenstrual Period Assesment Score before treatment  : 
Among the 40 cases  
3 (7.5%) cases had 28 days cycle 
11 (27.5%) cases had 28-45 days cycle  
18 (45 %) cases had 45-60 days cycle  
8 (20 %) cases had above 60 days cycle.   
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Inference: In this study most of the patients i.e.18 (45%) cases fall under 60 days 
cycle.  
20.b. Clinical symptoms before treatment: 
Out of the 40 cases, all 40 (100%) cases had irregular menstrual cycle (IMP or 
Duration of bleeding).  
Weight gain was found in 32 (80 %) cases , Constipation was seen in 31 (77.5 %)                                                                                                                                                         
cases,   Acanthosis nigricans was found in 12 (30 % ),  
Hirsuitism had 12 (30 %)  , 8 (20%) cases had amenorrhoea, 8 (20 %) cases had 
dysmenorrhea, 
10 (25%) cases had oligomenorrhoea and   3 (7.5 %) cases had infertility. 
OUTCOME MEASURES: 
PRIMARY  OUTCOME OBSERVATIONS: 
21.a CHANGES IN USG ABDOMEN BEFORE AND AFTER TREATMENT : 
 Out of 40 patients,  
All 40 cases show polycystic changes in both ovaries 
 Out of which, 17 patients (42.5%) showed complete clearance of cyst after 
treatment. 
 Moderate changes seen in 16 (40%) case.  
 No significant improvements were seen in the remaining 7 (17.5%) cases.  
21.b.INTERMENSTRUAL  PERIOD ASSESMENT  SCORE 
Intermenstrual periods were found to be normal in 3 (7.5) patients and severe in 9 
(22.5 %) cases before treatment.  
At the end of the treatment it was found normal in 23 (57.5%) number of cases and 
the severity was present only in 3 (7.5 %) case.  
SECONDARY OUTCOME OBSERVATIONS:  
CLINICAL SYMPTOMS:  
22. Observation with reference to other Clinical symptoms: 
Out of the 40 cases, all the 40 cases the menstrual cycle was irregular (IMP or 
Duration of bleeding) before treatment.  
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Secondly, Out of 32  patients,  weight gain was found in (80 %) large number of 
patients before treatment  and about 10 cases there was moderate significant in BMI 
after treatment.  
After treatment there was a considerable reduction in all symptoms particularly 
irregular menstruation, oligomenorrhoea, Dysmenorrhoea and amenorrhoea.  
After treatment there was a complete relief in the symptom like constipation and 
There was  changes in the body weight (31.25%).  
Out of 3 infertility with PCOS patients, 2 patients were reported normal study in 
USG abdomen and regularized menstrual cycle after treatment and one patient 
conceived after treatment.  
STATISTICAL ANALYSIS:  
BIO STATISTICAL ANALYSIS  
      The effectiveness of the clinical trial drug Garpa vaayu ilagam was assessed by 
using paired comparison test (paired t test). The responses (IMP) of the patients to 
the drug were analyzed.  
Assessment of the effectiveness of drug:  
     The effectiveness of the drug was assessed by the improvement of the patients 
from irregular menstruation, which is measured using assessment score.  
Inference: The test drug is statistically significant (p>0.0001) and hence effective 
in the treatment of Garpa vaayu   
BIOCHEMICAL ANALYSIS:  
     Preliminary phytochemical analysis of Garpa vaayu ilagam (GVL) was done in 
NIS biochemical laboratory showed the presence of minerals like Calcium, 
chloride, Iron,  Sugars, Alkaloid, Tannic acid, Unsaturated compound. 
PHYSICOCHEMICAL ANALYSIS  
1. pH% 5.6 
2. Ash (%w/w) 3.33% 
3. acid insoluble ash (%w/w) 0.48%  
4. Loss on drying @105o C 11.77%  
5. Water soluble extractive values 52.17%  
6. Alcohol soluble extractive values 44.31%  
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SUMMARY  
 The aim of the study is to evaluate the therapeutic efficacy  of siddha 
formulation Garpa vaayu ilagam (Internal medicine) in the management of 
Garpa vaayu (polycystic ovarian disease). 
 The Study Protocol was approved by Institutional Ethical committee (IEC 
approval number:   NIS/IEC/8-14/6-26-08-2014)   
 Before initiating the clinical trial, it was registered in Clinical trial registry 
of India (CTRI- REF/2016/06/0111463)  
 The raw drugs were authenticated by the Assistant professor of medicinal 
botany and the trial drug was prepared by the investigator in the Gunapadam 
laboratory of National Institute of Siddha.  
 The qualitative and quantitative phytochemical studies were done at the bio 
chemistry laboratory of National Institute of Siddha and physio chemical 
analysis in SCRI Chennai.  
 For the clinical study, 40 cases were recruited for the trial as per the 
inclusion and exclusion criteria and the informed consent was obtained from 
the patients. All these cases were treated in OPD of Ayothidoss pandithar 
hospital of NIS, Chennai.  
 The trial medicine Garpavaayu ilagam 6gm was given in the morning for 7 
days and next 7 days drug holiday   for 3 months.                                  
 Laboratory investigations were carried out before and after the treatment 
and the concerned data was recorded in the proforma.  
 USG abdomen was also done before and after treatment.  
 Clinical assessments were done once in 14 days in all the patients.  
 During the study period, there was no adverse event reported. 
 During the study period out of 45  cases 5 cases were withdrawn from the 
study due to long term absence.  
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 In this study out of 40 cases, the therapeutic efficacy of the trial drug by 
showing, USG report shows complete clearance of cyst in   17(42.5%) 
cases.  
 Regular menstrual cycle ie., 28 days intermenstrual period in 23 (57.5%) 
cases.  
 As per the Siddha Literature and recent research articles, the ingredients of 
the trial drug was found to have anti- oxidant, anti- diabetic, anti- 
hypercholesterolemia properties owing to the disease manifestations.  
 Statistical analysis showed significant changes in the Intermenstrual period 
score before and after treatment.  
 This ensures the safety usage of the drug as per the literature.  
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CONCLUSION  
 
 Clinical study revealed the therapeutic efficacy of the trial drug by showing, 
regular menstrual cycle ie., 28 days intermenstrual period in 23 (57.5%) 
cases USG shows complete clearance of cyst in 17(42.5%) cases.  
 No adverse drug reactions were noticed during the course of treatment.  
 Expenditure of the trial drug is cost effective, easily preparable and highly 
effective in Garpa vaayu. Because of the encouraging clinical and laboratory 
results, the study may be undertaken with the same medicines for a 
prolonged period in a large number of cases for the treatment of Garpa 
vaayu.  
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LABORATORY REPORTS 
HEMATOLOGY AND BIOCHEMISTRY REPORTS BEFORE AND AFTER 
TREATMENT 
S.NO 
 
OP.NO 
 
Hbgms% TC cells/Cumm RBC 
10
6
Cells/cu.mm 
ESR/hr 
BT AT BT AT BT AT BT AT 
 
1 
G91843 
12.7 11.8 6700 5900 4.4 4.3 22 6 
 
2 
G99429 
12.6 12.4 8000 8000 4.8 4.8 34 36 
 
3 
H00862 
14 14.4 11900 8900 4.6 4.7 4 4 
 
4 
G92647 
13.9 13.7 7660 8000 5.1 5 8 4 
 
5 
H08939 
12.2 12.5 8800 10900 4.5 4.4 22 26 
 
6 
G93856 
13.2 12.6 8000 9900 4.5 4.4 22 24 
 
7 
H08424 
13.7 13.5 10600 8800 4.6 4.3 22 12 
 
8 
H08496 
10.9 11 7400 6800 4.7 4.9 42 4 
 
9 
H01889 
12.4 12.5 7800 8200 4.5 4.6 22 12 
 
10 
H13948 
12 12.4 9600 8900 5.0 5.2 80 64 
 
11 
H14793 
13.1 13 8300 7800 4.8 4.4 32 12 
 
12 
H15049 
12.4 12.2 9600 10200 4.6 4.3 12 10 
 
13 
H16320 
11.9 12 8800 8800 4.6 4.8 28 12 
 
14 
H16297 
11.4 11.6 9800 9800 3.4 3.8 26 10 
 
15 
H08207 
10.2 9.7 5900 5000 4.5 4.4 24 32 
 
16 
H19521 
13.5 13.8 7100 7200 4.9 5.1 22 20 
 
17 
G49654 
13.7 1 3.3 11000 10300 4.7 4.5 26 6 
 
18 
H08313 
11.3 11.5 11200 10400 4.6 4.7 24 16 
 
19 
H07725 
13.0 13.1 10800 10900 4.8 4.9 102 40 
 
20 
H16246 
13.8 13.6 9500 6800 4.7 4.7 32 12 
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S.NO 
 
OP.NO 
 
Hbgms% TC cells/Cumm RBC 
10
6
Cells/cu.mm 
ESR/hr 
BT AT BT AT BT AT BT AT 
 
21 
G97934 
12.9 12.9 8700 7300 3.9 3.9 22 20 
 
22 
H26029 
13 13 8900 9000 4.2 4.2 20 16 
 
23 
H25763 
12.1 12.2 9200 7800 4.1 4.3 46 22 
 
24 
H26007 
11 11 11100 11000 4.6 4,4 20 16 
 
25 
H28179 
11.7 12 8600 8500 4.4 4.4 12 10 
 
26 
H05923 
11.6 11.4 9200 9400 4.6 4.4 42 22 
 
27 
H28333 
10.8 10.6 7700 8900 3.8 3.9 26 12 
 
28 
H31190 
13.6 13.5 10000 10200 4.9 4.8 12 10 
 
29 
H19738 
11.4 11.3 7000 7200 4.4 4.4 6 6 
 
30 
H08744 
10.2 10.1 8700 10300 4.7 4.7 20 20 
 
31 
H30678 
12.8 12.9 7100 8700 4.8 4.8 12 10 
 
32 
H24781 
13.5 14 6200 8200 4.4 4.6 6 6 
 
33 
H30919 
12.2 12.4 8200 8700 3.8 4.0 24 18 
 
34 
G91734 
11.6 11.7 10300 10200 4.4 4.4 12 10 
 
35 
G97488 
12.1 12 7400 8400 4.2 4.2 22 16 
 
36 
H35170 
12.8 13 8500 8600 4.6 4.8 44 22 
 
37 
H27777 
13.1 13 7100 7800 4.5 4.4 20 18 
 
38 
H20486 
11.8 12.5 5800 6500 4.1 4.5 10 10 
 
39 
H36263 
12.5 12.5 5600 7000 4.3 4.1 14 10 
 
40 
H00601 
12 12 9100 9200 4.1 4.0 16 14 
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S.N
O 
 
OP.NO Poly morphs 
% 
Lymphocytes 
% 
Mono Cytes 
% 
Eosinophils  
% 
BT AT BT AT BT AT BT AT 
 
1 
G91843 
73 67 23 27 1 2 3 4 
 
2 
G99429 
51 57 43 37 2 1 4 5 
 
3 
H00862 
60 59 35 36 1 1 4 4 
 
4 
G92647 
61 60 35 36 1 1 3 3 
 
5 
H08939 
52 57 44 37 0 1 4 5 
 
6 
G93856 
58 72 37 23 1 1 4 4 
 
7 
H08424 
68 57 25 37 2 2 5 4 
 
8 
H08496 
58 59 38 35 2 2 4 4 
 
9 
H01889 
65 68 31 26 1 2 3 4 
 
10 
H13948 
70 61 24 33 2 2 4 4 
 
11 
H14793 
72 62 22 31 2 1 4 6 
 
12 
H15049 
65 70 30 26 1 1 4 3 
 
13 
H16320 
60 60 37 36 0 1 4 4 
 
14 
H16297 
62 61 35 35 0 1 3 3 
 
15 
H08207 
51 40 43 52 2 0 4 8 
 
16 
H19521 
59 60 36 35 1 1 4 4 
 
17 
G49654 
68 70 27 2 4 1 1 4 5 
 
18 
H08313 
70 67 26 29 1 1 3 3 
 
19 
H07725 
62 61 34 32 1 1 4 6 
 
20 
H16246 
72 60 24 34 1 1 3 5 
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S.N
O 
 
OP.NO Poly morphs 
% 
Lymphocytes 
% 
Mono Cytes 
% 
Eosinophils  
% 
BT AT BT AT BT AT BT AT 
 
21 
G97934 
60 65 35 29 1 1 4 5 
 
22 
H26029 
61 64 33 30 1 1 5 5 
 
23 
H25763 
64 65 31 30 1 1 4 4 
 
24 
H26007 
60 60 36 34 1 2 3 4 
 
25 
H28179 
58 59 38 35 2 2 4 4 
 
26 
H05923 
72 60 24 34 1 1 3 5 
 
27 
H28333 
73 67 23 27 1 2 3 4 
 
28 
H31190 
65 70 30 26 1 1 4 3 
 
29 
H19738 
68 66 26 29 2 1 4 4 
 
30 
H08744 
72 60 24 34 1 1 3 5 
 
31 
H30678 
51 57 43 37 2 1 4 5 
 
32 
H24781 
68 70 27 2 4 1 1 4 5 
 
33 
H24781 
68 57 25 37 2 2 5 4 
 
34 
H30919 
59 60 36 35 1 1 4 4 
 
35 
G96488 
60 60 37 35 0 1 4 5 
 
36 
H35170 
59 60 36 35 1 1 4 4 
 
37 
H27777 
52 57 44 37 0 1 4 5 
 
38 
H20486 
72 62 22 31 2 1 4 6 
 
39 
H36263 
59 60 36 36 1 1 4 3 
 
40 
H00601 
62 61 35 35 0 1 3 3 
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S.NO 
 
OP.NO Blood 
Sugar(F) 
 
Blood 
Sugar(PP) 
BT AT BT AT 
 
1 
G91843 
88 106 99 120 
 
2 
G99429 
91 140 96 149 
 
3 
H00862 
93 86 110 106 
 
4 
G92647 
105 90 95 110 
 
5 
H08939 
80 80 86 125 
 
6 
G93856 
82 80 110 110 
 
7 
H08424 
90 86 120 110 
 
8 
H08496 
82 80 132 120 
 
9 
H01889 
95 88 102 100 
 
10 
H13948 
93 94 110 100 
 
11 
H14793 
88 86 84 100 
 
12 
H15049 
89 87 102 100 
 
13 
H16320 
104 80 130 110 
 
14 
H16297 
95 90 100 90 
 
15 
H08207 
77 84 93 100 
 
16 
H19521 
104 90 90 95 
17 
G49654 
71 89 102 100 
 
18 
H08313 
90 80 110 100 
 
19 
H07725 
119 90 130 110 
 
20 
H16246 
82 80 128 120 
121 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
S.NO 
 
OP.NO Blood 
Sugar(F) 
 
Blood 
Sugar(PP) 
BT AT BT AT 
 
21 
G97934 
95 90 100 98 
 
22 
H26029 
100 95 120 100 
 
23 
H25763 
90 80 130 110 
 
24 
H26007 
84 80 120 110 
 
25 
H28179 
98 80 99 90 
 
26 
H05923 
104 92 94 116 
 
27 
H28333 
82 80 128 120 
 
28 
H31190 
95 90 100 90 
 
29 
H19738 
119 90 130 110 
 
30 
H08744 
94 86 120 110 
 
31 
H30678 
119 90 130 110 
 
32 
H24781 
95 90 100 90 
 
33 
H24781 
88 86 84 100 
 
34 
H30919 
96 88 117 100 
 
35 
G96488 
91 140 130 119 
 
36 
H35170 
88 87 90 100 
 
37 
H27777 
89 86 84 100 
 
38 
H20486 
110 90 130 109 
 
39 
H36263 
87 80 98 90 
 
40 
H00601 
96 85 100 90 
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S.NO 
 
OP.NO Urea mg/dl 
 
Creatinine             
mg/dl 
 
Uric Acid 
mg/dl 
BT AT BT AT BT AT 
 
1 
G91843 
12 0.8 18 0.9 2.8 2.1 
 
2 
G99429 
18 16 0.8 0.8 4.6 4.6 
 
3 
H00862 
07 18 0.7 0.8 6.2 5.5 
 
4 
H08939 
18 28 0.9 0.9 6.5 6.3 
 
5 
G92647 
14 14 0.9 0.9 5.4 5.4 
 
6 
G93856 
15 14 0.9 0.8 2.9 3.3 
 
7 
H08424 
13 14 1.0 0.8 2.1 2.9 
 
8 
H08496 
17 14 0.9 1.0 3.4 4.7 
 
9 
H01889 
13 16 0.9 0.8 2.2 4.5 
 
10 
H13948 
16 17 1.7 0.9 3.7 4.2 
 
11 
H14793 
19 27 1.3 0.7 5.4 4.8 
 
12 
H15049 
20 24 0.8 0.8 4.9 4.9 
 
13 
H16320 
20 24 0.8 0.8 4.8 4.8 
 
14 
H16297 
18 18 0.8 0.8 4.8 4.8 
 
15 
H08207 
16 17 0.7 0.7 3.5 3.7 
 
16 
H19521 
10 10 0.7 0.7 3.9 3.9 
 
17 
G49654 
17 16 0.9 0.9 4.0 4.0 
 
18 
H08313 
20 28 1.0 1.0 4.1 4.6 
 
19 
H07725 
19 19 0.9 0.9 5.3 5.0 
 
20 
H16246 
17 12 1.0 0.8 3.1 3.7 
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S.NO 
 
OP.NO Urea mg/dl 
 
Creatinine             
mg/dl 
 
Uric Acid 
mg/dl 
BT AT BT AT BT AT 
 
21 
G97934 
13 19 0.9 0.7 4.7 5.5 
 
22 
H26029 
14 14 0.8 0.8 4.8 4.6 
 
23 
H25763 
15 13 0.9 0.9 5.0 4.8 
 
24 
H26007 
11 16 0.9 0.8 4.2 5.1 
 
25 
H28179 
26 24 0.9 0.9 3.5 3.8 
 
26 
H05923 
19 21 0.9 0.9 3.7 3.7 
 
27 
H28333 
13 16 0.8 0.8 3.7 3.8 
 
28 
H31190 
13 15 0.6 0.6 3.1 3.5 
 
29 
H19738 
18 24 0.7 0.9 3.5 3.3 
 
30 
H08744 
18 24 0.8 0.8 2.2 2.2 
 
31 
H30678 
18 20 0.7 0.7 3.5 3.2 
 
32 
H24781 
25 24 0.9 0.8 3.5 3.8 
 
33 
H24781 
12 10 0.7 0.7 3.9 3.9 
 
34 
H30919 
28 24 1.0 1.0 4.1 4.6 
 
35 
G96488 
15 17 0.7 0.7 6.2 6.0 
 
36 
H35170 
21 18 0.7 0.8 4.8 4.8 
 
37 
H27777 
19 18 0.7 0.7 3.4 3.3 
 
38 
H20486 
14 20 0.6 0.7 4.5 4.5 
 
39 
H36263 
11 16 0.8 0.9 2.9 2.8 
 
40 
H00601 
16 14 0.7 0.6 4.2 4.1 
124 
 
 
S.N
O 
 
OP.NO Total Bilirubin 
mg/dl 
Direct 
Bilirubin 
mg/dl 
 
Indirect 
Bilirubin 
mg/dl 
SGOT IU SGPT IU Alk.phos 
mg/dl 
BT 
 
AT BT AT BT AT BT AT BT AT BT AT 
 
1 
G91843 
0.6 1.0 0.3 0.5 0.3 0.5 16 20 07 22 43 43 
 
2 
G99429 
0.4 0.5 0.2 0.2 0.2 0.3 14 19 16 20 111 93 
 
3 
H00862 
0.4 0.3 0.2 0.0 0.2 0.3 19 21 14 11 98 72 
 
4 
H08939 
0.4 0.6 0.2 0.2 0.2 0.4 26 14 32 16 53 50 
 
5 
G92647 
0.4 0.4 0.2 0.2 0.2 0.2 22 22 25 22 113 100 
 
6 
G93856 
0.4 0.6 0.2 0.2 0.2 0.4 31 32 44 42 69 59 
 
7 
H08424 
0.4 0.6 0.2 0.3 0.2 0.3 23 13 19 08 66 54 
 
8 
H08496 
0.2 0.3 0.1 0.1 0.1 0.2 16 19 08 16 56 61 
 
9 
H01889 
0.7 1.1 0.3 0.4 0.4 0.7 18 20 14 20 58 53 
 
10 
H13948 
0.5 0.4 0.2 0.1 0.3 0.3 18 19 18 19 79 86 
 
11 
H14793 
0.3 0.3 0.1 0.1 0.2 0.2 17 33 16 41 69 75 
 
12 
H15049 
0.6 0.4 0.2 0.2 0.4 0.2 15 14 4 4 48 41 
 
13 
H16320 
0.4 0.4 0.2 0.2 0.2 0.2 17 17 16 14 79 80 
 
14 
H16297 
0.3 0.3 0.1 0.1 0.2 0.2 21 20 15 14 102 100 
 
15 
H08207 
0.4 0.5 0.2 0.2 0.2 0.3 17 21 20 19 61 50 
 
16 
H19521 
0.4 0.4 0.2 0.2 0.2 0.2 20 21 20 15 102 100 
 
17 
G49654 
0.3 0.2 0.1 0.1 0.2 0.1 17 23 14 26 91 111 
 
18 
H08313 
0.8 0.6 0.4 0.3 0.4 0.3 13 15 03 10 81 81 
 
19 
H07725 
0.4 0.4 0.2 0.2 0.2 0.2 21 22 12 10 91 92 
 
20 
H16246 
0.5 0.5 0.2 0.2 0.3 0.3 16 20 07 17 71 65 
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S.N
O 
 
OP.NO Total Bilirubin 
mg/dl 
Direct 
Bilirubin 
mg/dl 
 
Indirect 
Bilirubin 
mg/dl 
SGOT IU SGPT IU Alk.phos 
mg/dl 
BT 
 
AT BT AT BT AT BT AT BT AT BT AT 
 
21 
G97934 
0.8 0.8 0.3 0.3 0.5 0.5 18 17 18 25 69 78 
 
22 
H26029 
0.4 0.5 0.2 0.2 0.2 0.3 14 19 16 20 111 93 
 
23 
H25763 
0.8 0.5 0.4 0.2 0.4 0.3 18 21 24 13 63 66 
 
24 
H26007 
0.3 0.6 0.1 0.2 0.2 0.4 17 14 24 16 69 50 
 
25 
H28179 
0.4 0.4 0.2 0.2 0.2 0.2 13 20 10 16 56 50 
 
26 
H05923 
0.3 0.6 0.2 0.2 0.1 0.4 13 23 07 10 64 59 
 
27 
H28333 
0.6 0.6 0.3 0.3 0.3 0.3 17 13 13 08 102 84 
 
28 
H31190 
0.7 0.3 0.3 0.1 0.4 0.2 14 19 16 16 105 81 
 
29 
H19738 
0.3 1.1 0.2 0.4 0.1 0.7 17 20 18 20 61 53 
 
30 
H08744 
0.3 0.4 0.1 0.2 0.2 0.2 14 15 12 9 90 87 
 
31 
H30678 
1.0 0.3 0.5 0.1 0.5 0.2 23 33 17 41 90 75 
 
32 
H24781 
0.7 0.4 0.3 0.2 0.4 0.2 28 14 26 24 66 41 
 
33 
H30919 
0.8 0.4 0.3 0.2 0.5 0.2 23 17 69 58 81 80 
 
34 
G91734 
0.4 0.3 0.1 0.1 0.3 0.2 28 20 35 14 98 90 
 
35 
G96488 
0.5 0.5 0.2 0.2 0.3 0.3 21 21 36 18 64 50 
 
36 
H35170 
0.3 0.4 0.1 0.2 0.2 0.2 14 21 12 15 28 46 
 
37 
H27777 
0.3 0.2 0.1 0.1 0.2 0.1 21 23 17 26 55 62 
 
38 
H20486 
0.6 0.6 0.3 0.3 0.3 0.3 31 15 30 10 50 61 
 
39 
H36263 
0.4 0.6 0.1 0.3 0.3 0.3 15 08 12 12 55 56 
 
40 
H00601                                                                                                                              
0.7 0.3 0.3 0.2 0.4 0.1 17 15 10 10 47 48 
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S.N
O 
 
OP.NO Total 
cholestrol 
HDL LDL VLDL TGL 
BT AT BT AT BT AT BT AT BT AT 
 
1 
G91843 
120 133 53 64 62 67 12 08 62 39 
 
2 
G99429 
169 165 38 52 106 93 11 27 158 133 
 
3 
H00862 
111 141 38 45 71 79 26 33 131 162 
 
4 
G92647 
168 160 38 42 72 70 48 27 158 132 
 
5 
H08939 
196 207 40 43 129 122 71 43 353 213 
 
6 
G93856 
195 231 42 49 126 120 48 27 239 136 
 
7 
H08424 
168 178 62 58 104 100 25 12 127 58 
 
8 
H08496 
167 186 45 42 106 102 25 31 124 157 
 
9 
H01889 
163 152 51 46 99 90 12 12 59 58 
 
10 
H13948 
222 237 56 51 141 139 12 29 83 146 
 
11 
H14793 
175 195 64 71 105 110 12 21 60 105 
 
12 
H15049 
198 177 62 54 117 105 23 31 113 157 
 
13 
H16320 
184 175 47 44 103 98 68 60 341 300 
 
14 
H16297 
162 160 46 40 92 90 31 31 154 150 
 
15 
H08207 
135 150 65 70 72 75 12 18 84 91 
 
16 
H19521 
247 160 34 45 213 139 39 17 197 180 
 
17 
G49654 
232 223 43 45 146 134 21 35 105 177 
 
18 
H08313 
126 128 47 40 72 72 12 25 58 123 
 
19 
H07725 
228 150 58 70 149 73 46 25 228 180 
 
20 
H16246 
169 161 59 63 91 88 13 23 65 113 
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S.N
O 
 
OP.NO Total 
cholestrol 
HDL LDL VLDL TGL 
BT AT BT AT BT AT BT AT BT AT 
 
21 
G97934 
147 157 41 48 87 92 17 25 84 126 
 
22 
H26029 
157 140 42 45 84 82 17 24 86 120 
 
23 
H25763 
184 169 62 51 97 93 1 1 28 57 140 
 
24 
H26007 
157 150 44 51 83 80 19 20 93 110 
 
25 
H28179 
146 200 51 51 82 80 20 19 99 99 
 
26 
H05923 
169 150 53 50 99 80 18 17 89 90 
 
27 
H28333 
165 160 53 63 90 70 32 19 162 150 
 
28 
H31190 
135 130 47 57 99 82 12 19 62 60 
 
29 
H19738 
133 120 57 58 75 70 14 12 68 66 
 
30 
H08744 
135 130 30 29 80 79 13 16 67 82 
 
31 
H30678 
144 140 60 62 90 70 08 12 39 118 
 
32 
H24781 
117 115 56 55 82 80 06 12 28 90 
 
33 
H24781 
192 190 43 44 113 80 37 30 184 150 
 
34 
H30919 
144 150 40 50 100 82 30 22 132 122 
 
35 
G96488 
124 130 39 61 70 68 15 20 73 120 
 
36 
H35170 
143 140 39 42 70 68 35 20 176 150 
 
37 
H27777 
179 160 59 62 82 70 16 20 80 140 
 
38 
H20486 
115 143 59 62 70 73 07 25 33 125 
 
39 
H36263 
163 158 55 47 103 104 27 44 134 136 
 
40 
H00601 
162 165 57 56 98 90 19 24 94 120 
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6.0 OBJECTIVES  
       6.1 Primary Objective:  
           To study the therapeutic efficacy of  siddha drug  “Garpa vaayu ilagam” 
(Internal medicine)  in  the  treatment  of  Garpa vaayu  (polycystic ovarian 
syndrome)  assessed through clearance of cysts in the ovary by USG abdomen and 
resumption of Regular menstrual cycle. 
      6.2 Secondary Objective: 
 To study the comorbid factors related to the disease such as Irregular 
menstruation, Amenorrhoea, Oligomenorrhoea, Obesityetc... 
7.0 STUDY DESIGN 
Study type: An Open Clinical trial 
Study Place:  OPD & IPD Of theAyothidass Pandithar Hospital , 
                       National Institute of Siddha, 
                       Tambaram sanatorium, 
Chennai-47. 
Study Period     : 12 months  
Sample size     : 40 patients 
8.0 TREATMENT 
                  Drug : Garpavaayu ilagam 
                  Dosage          : Kottai pakkalavu (6gm), morning,before food 
       Duration        : like wise 7days medicine -7 days drug holiday 
                  Study period  : 3months/ Patient 
                  Total duration of drug administration :  42 days  
                  Reference       : Aathmarakshamirtham ennum Vaithiya saarasangiragam  
                  Book               : Pg-59, September 2011  
                  Urai aasiriyar  : Kanthasamy mudhaliyar. 
Patthiyam(Dietry restriction)   :  Avoid Karapan inducing foods⃰⃰⃰⃰  
Note  ⃰:Karapan inducing foods: Solam(Maize), Kambu(Pear milet), Varagu 
(Kodo millet),  Kaar Arici(rice) ,  Vaazaikai(Unriped banana), Paagal(Bitter 
gourad),  and   kelitrumeen(fish). 
 
 
 
130 
 
 
9.0 STANDARD OPERATING PROCEDURE: 
 The  required  raw  drugs  are  purchased  from  a  well  reputed  
indigenous        drug shop.   
  The raw drugs will be  authenticated  by  the  Botanist  in NIS  and  
SCRI , Arumbakkam, Chennai.  
 The raw drugs will be purified and the medicine will be prepared as per 
SOP in Gunapadam Laboratory of National Institute of Siddha.  
9.1 Purification of raw drugs 
The following drugs will be purified as per siddha literature ; 
1. Root of Sivathai (Operculina turpethum.Linn.- steamed with milk  and 
dried. 
 
2. Root of Nilavagai (Cassia senna,Linn -  steamed with milk  and dried.  
3. Koraikizhangu (Cyperus rotandus) - Remove the outer skin  and  shadow 
dry.  
4. Sukku (Zingiber officinalis.Rosc)- Peel off the outer skin 
5. Milagu (Piper nigrum.Linn)-Soak it in butter milk for three hours and dry it. 
6. Thippili(Piper longum.Linn) -Soak it in butter milk for three hours and dry 
it. 
7. Kadukkai (Terminalia chebula.Retz)-Discard the seed and collect the rinds  
alone for use. 
8. Thaantrikkai (Terminalia bellarica.Roxb)- Discard the seed and collect the 
rinds alone for use. 
9. Nellikkai (Phylanthus embilica.Linn)- Remove the seed and collect the rinds 
alone for use. 
10. Kanda Thippili(Piper longum.Linn)-Soak it in butter milk for three hours &  
dry.   
11. Indhuppu (Sodium chloride impura)-soaked in viniger for three days and 
dried in sunlight.  
12. Omam (Carum coptium.Benth&Hook.f)-Soak it in clear calcium carbonate 
filtrate and dry it. 
13. Kadugu Rogini (Picrorhiza scrophulariflora,Pennell)-Dry it in shade. 
14. Vaaivilangam (Embelia ribes.Burm) -Remove the waste from it and dry it in 
shade. 
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15. Athividayam (Aconitum heterophyllum Wall-ex Royle)-Dry it in shade 
16. Maasikai (Quercus infectoria.Oliver)-Dry it in shade. 
17. Raipur Sugar (Brown sugar)-Dissolved in water and filter it. 
18. Sitramanakku ennai (Ricinus communis.Linn)-Filter it. 
19. Water-Filter it. 
9.2 Preparation:
 
Garpa vaayu ilagam: Ref:Vaithiya saarasangiragam,P.no-59 
9.3 Ingredients: 
1.   Sivathai vaer  (Operculina turpethum.Linn)   - 150 varagan (630 gm)  
2. Nilavagai vaer (Cassia senna,Linn)                 -150 varagan (630 gm) 
3. Koraikizhangu (Cyperus rotandus,Linn)         -33 varagan (132 gm) 
4. Sukku (Zingiber officinalis.Rosc)                     - 1.7 gm 
5. Milaghu (Piper nigrum.Linn)                 - 1.7gm 
6. Thippili (Piper longum.Linn)                            - 1.7 gm 
7. Kadukai (Terminalia chebula.Retz)                   - 1.7 gm 
8. Thaantrikkai (Terminalia bellarica.Roxb)       - 1.7 gm 
9. Nellikkai ( Phylanthus embilica.Linn)             - 1.7 gm 
10. Kanda Thippili(Piper longum.Linn)                - 1 kazhanju (5.1 gm) 
11. Indhuppu (Sodium chloride impura)              - 1 kazhanju (5.1 gm) 
12. Omam (Carum coptium.Benth&Hook)            - 1 kazhanju (5.1 gm) 
13. Kadugu Rogini (Picrorhiza scrophulariflora,Pennell) - 1 kazhanju (5.1gm  
14. Vaaivilangam (Embelia ribes.Burm)              - 1 kazhanju  (5.1gm) 
15. Athividayam (Aconitum heterophyllum Wall-ex Royle- 1 kazhanju (5.1 gm) 
16. Maasikai (Quercus infectoria.Oliver)             - 1 kazhanju (5.1 gm) 
17. Raipur Sugar(Brown sugar)     - 5 palam (175 gm) 
18. Sitramanakku ennei (Ricinus communis,Linn)    -1 padi (1.3 litre) 
19. Water                                                                    - Suffiecient quantity   
20.  
9.4 METHOD OF PREPERATION: The purified raw drugs from 1 to 16 will be 
made into fine powder. The powder will be added to the sugar syrup (i.e 175 gms of 
powdered sugar required quantity of water will be added and boiled till it reaches 
syrup consistency) and mix it well until it reach to ilagam consistency. Then Castor 
oil-1.3litre  will be added to the above mixture.              
9.5 Drug Storage: 
    The prepared drug will be stored in clean and dry air tight glass container. 
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9.6 Dispensing:                                                                                                                           
  The Ilagam  will be dispensed  in a glass container per visit.  
10.0 Subject selection: 
     Patients reporting at OPD of maruthuvam with the symptoms of inclusion 
criteria will be subjected to screening test and documented using screening 
proforma. 
11.0 INCLUSION CRITERIA: 
 Age: 20-40 years 
 Patients who are having the clinical symptoms of Oligomenorrhoea (or) 
Amenorrhoea (or) Dysmenorrhoea. 
 Patient willing to undergo Ultrasound abdomen &  routine blood 
investigation. 
 USG pelvis showing polycystic ovaries.   
 Patient  willing to participate in trial and signing in consent form  
12.0 EXCLUSION CRITERIA: 
 H/O hypertension  
 H/O Diabetes mellitus 
 H/O cardiac disease 
 Pregnancy and lactation 
 H/O thyroid dysfunction  
 Chronic kidney disease  
 Fibroid uterus 
 H/O use of HRT in one year before. 
 Presence of any systemic illness (e.g.Anaemia,)  
13.0 WITHDRAWAL CRITERIA: 
 Intolerance to the drug and development of adverse reactions during the 
drug trial. 
 Poor patient compliance & defaulters 
 Patients turned unwilling to continue in the course of clinical trial 
 Severe abdominal pain 
 Heavy menorrhagia  
 14.0TEST AND ASSESSMENTS: 
     14.1 Clinical assessment 
     14.2 Siddha assessment 
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     14.3 Routine Investigations  
     14.4 Specific investigation 
14.1 Clinical Assessment: 
 Irregular menstruation 
 Amenorrhoea 
 Oligomenorrhoea 
 Obesity 
 Hirsuitism 
 Acanthosis nigricans  
 Obesity 
 Infertility 
 Constipation 
14.2 Siddha Assessment 
 Naadi 
 Sparisam 
 Naa 
 Niram 
 Mozhi 
 Vizhi 
 Malam 
 Moothiram 
o Neerkuri 
o Neikuri 
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14.3 Routine Tests and Investigations  
Blood:  
 Hb  (gms/dl)          
 Total RBC (million/cu.mm) 
 Total WBC (cubic mm) 
 Differential count :(%) 
Polymorphs  
Lymphocytes   
Monocytes      
Esinophils       
Basophils 
 ESR(mm/hr) 
 Blood sugar level  - Fasting (mg/dl) 
                                  Post prandial (mg/dl) 
                                       Random (mg/dl) 
 Lipid profile        
 Renal function test     
 Liver function test     
 Urine  
 Thyroid function test  
 
14.4 Specific Investigations 
Ultra Sonography:USG Pelvis  
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PATIENT SCREENING 
Inclusion/Exclusion 
 
INCLUSION CRITERIA EXCLUSION CRITERIA 
EXCLUDED FROM TRIAL 
METHODOLOGY 
       STUDY NUMBER 
     HISTORY TAKING 
LAB INVESTIGATION 
 TRIAL DRUG  
CLINICAL ASSESSMENT 
OUTCOME 
INFORM ABOUT STUDY 
AND TRIAL DRUG 
 
INFORMED CONSENT FORM 
 
ADVERSE REACTION 
ADVICED TO TAKE 
TREATMENT IN OPD 
ABNORMAL VALUES 
VALUES 
         REFERRED TO 
PHARMACOVIGILANCE            
DEPARTMENT,    NIS 
 ADVISED TO TAKE 
TREATMENT IN OPD 
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15.0STUDY ENROLMENT: 
              Patient reporting at the NIS, OPD with clinical features of Amenorrhoea, 
Oligomenorrhoea, obesity, Irregular menstruation, infertility are chosen for 
enrolment based on the inclusion criteria. The patients who are enrolled are 
informed about the study trial drug, possible outcomes and the objectives of the 
study in their own language and terms understandable to them and the informed 
consent would be obtained from them in the consent form. 
16.0 CONDUCT OF THE STUDY: 
              On the first day  the trial drug Garpa vaayu ilagam was   given for 7 days 
medicine-7 days drug holiday for 3 months.  The trial drug was given by the 
investigator in the OP department of Maruthuvam, NIS, Chennai. The patients will 
be asked to have a regular treatment in the OP department once in 14 days . In 
every visit the clinical assessment will be recorded in the prescribed Proforma 
(form no:II A). The laboratory investigation will be done before and after treatment 
and recorded in the prescribed format (form no: III).  
                At the end of the trial the patients will be advised to come for follow up 
for 2 months for observation.   
17.0 Data Management: 
 After enrolling the patient in the study, a separate file for each patient will 
be opened and all forms will be filed in the file. Study No. and Patient No. 
will be entered on the top of file for easy identification.  Whenever the study 
patient visits OPD during the study period, the respective patient’s file will 
be taken and necessary recordings will be made at the assessment form or 
other suitable forms. 
 The screening forms will be filed separately. 
 The Data recordings will be monitored for completion by Guide (HOD, 
Dept. of Maruthuvam), SRO (Statistics) and the adverse event will be 
monitored by the members of the Pharmacovigilance department of NIS. All 
forms will be further scrutinized in presence of Investigator by Sr.Research 
Officer (Statistics) for logical errors and incompleteness of data to avoid any 
bias. No modification in the results is permitted for unbiased reports.   
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18.0STATISTYCAL ANALYSIS : 
           All collected data will be entered into computer using MS access / MS excel 
software by the investigator. The data will be analyzed using STATA software 
under the guidance of SRO(stat),NIS. The level of significance will be 0.05 
Descriptive analysis will be made and necessary tables/graphs generated to 
understand the profile of the patients included in the study. Student ‘t’ test and 
chisquare test are proposed to be performed for quantitative and qualitative data. 
19.0OUTCOME OF TREATMENT 
19.1PRIMARY OUTCOME:  
It is assessed by the changes of the ovaries in USG pelvis and  improvement in the 
score of intermenstrual period   before and after treatment. 
 
INTERMENSTRUAL PERIOD  
 
 
19.2 SECONDARY OUTCOME : 
To reduce the clinical symptoms such as Irregular menstruation Amenorrhoea, 
Oligomenorrhoea, Obesity, etc. 
20.0Adverse effect and Serious effect Management: 
      If the trial patient develops any adverse reactions the patient will be referred to 
the Pharmacovigilance department of NIS and documented. For any adverse effect 
the investigator will give the proper management in the OPD. 
21.0ETHICAL ISSUES:  
1. Informed consent will be obtained from the patients after explaining about 
the clinical trial in an understandable language. 
2. After the consent of the patient (through consent form) they will be enrolled 
in the study. 
3. Treatment will be provided free of cost 
4. No other medicines will be used except the trial drug 
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5. USG- Abdomen will be taken in the NABL certified laboratories and 
charges      will be borne by the patient. 
6. To prevent any infection, while collecting blood sample from the patient, 
only 
 Disposable syringes, disposable gloves, with proper sterilization of lab  
equipments will be used.  
7. The data collected from the patient will be kept confidentially. The patient 
will be informed about the diagnosis, treatment and follow up. 
8. The patients who are excluded (as per the exclusion criteria) are given 
proper treatment with full care at OPD. 
9. In conditions of treatment failure, adverse reactions patients will be given 
alternative treatment at the OPD with full care through the end. 
 
22.0  DATA COLLECTION FORMS: 
Required information will be collected from each patient by using the 
following forms  
Forms: 
FORM l : Screening & Selection Proforma  
FORM ll  :Clinical Assesment form 
FORM lll :Laboratory Investigation form 
FORM IV: Drug compliance form 
FORM V  : PatientInformation Sheet 
FORM VI :InformedConsent Form 
FORM VII: Withdrawal Form/ Adverse reaction form (Pharmacovigilence 
form) 
FORM VIII : Dietary advice Form  
 
 
 
 
 
 
139 
 
 
CASE REPORT FORM 
 
 
DISSERTATION TITLE 
CLINICAL EVALUATION OF SIDDHA DRUG GARPAVAAYU ILAGAM 
IN THE TREATMENT OF GARPAVAAYU  
(POLYCYSTIC OVARIAN SYNDROME)  
 
 
CENTRE 
AYOTHID0SS PANDITHAR HOSPITAL 
NATIONAL INSTITUTE OF SIDDHA 
CHENNAI-47 
 
 
INVESTIGATOR 
DR.S.SHAGILA MD(S)  
PG SCHOLAR 
DEPARTMENT OF MARUTHUVAM 
NATIONAL INSTITUTE OF SIDDHA 
CHENNAI-47 
 
 
GUIDE 
DR.T.LAKSHMI KANTHAM, M.D(S) 
LECTURER, 
DEPARTMENT OF MARUTHUVAM 
NATIONAL INSTITUTE OF SIDDHA 
CHENNAI-47 
 
 
 
Signature of the Guide                                           Signature of the HOD
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                     FORM l - SCREENING AND SELECTION PROFORMA 
1.SERIAL NO:                        2.OP/IP NO: ……………………                          
3.NAME: ………………………..             4.AGE: …… 5.GENDER: M / F     6.RELIGION: H/C/M/O  
7. ADDRESS: 
 
8.CONTACT NO:              
INCLUSION CRITERIA  
 Age:20-40 yrs                                                                           Yes / No 
 Patients who are having the symptoms of  Oligomenorrhoea (or) Amenorrhoea (or) 
Dysmenorrhoea                                                                                 Yes / No 
 Patient willing to undergo USG pelvis & routine blood investigation         Yes / No 
 USG pelvis shows polycystic ovaries                 Yes / No 
 Patient  willing to participate in trial and signing in consent form              Yes / No 
 
EXCLUSION CRITERIA:  
 History of hypertension         Yes / No 
 History of diabetes mellitus         Yes / No 
 History of cardiac disease                    Yes / No 
 Pregnancy and lactation                     Yes / No 
 History of thyroid dysfunction                       Yes / No                                                                                 
 History of recent hormone therapy (Past one year)                             Yes / No               
 Presence of any systemic illness (e.g.Anaemia,)Yes / No               
 Chronic kidney disease                                                                                   Yes / No               
 Fibroid uterus                                                                                                  Yes / No               
ADMITTED TO TRIAL  
              YES           NO  
 If Yes Serial NO: 
Signature of the Investigator with date:                                                          
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FORM II-CLINICAL ASSESSMENT FORM 
 
1.  Patient ID:   _________                                  2. S.NO:   _______________ 
 
3. Occupation:     ______________                     4.Income: _______________ 
 
5. Educational Status:   A) Illiterate                  B) Literate  
 
6. Date of informed consent signed: ______________ 
 
7. Height:  ________cms             8.Weight: ____ kg            9.BMI: ______ 
 
10. COMPLAINTS&DURATION: _______________________________________________ 
                                                             _______________________________________________ 
11. DIET:A.Pure vegetarian                  B.Non-vegetarian        If yes,   No of times ____per month                                                           
                   C.Mixed diet             
12. HABIT OF 
  A) Smoking              1. Yes; duration ________ years; number _____   2.No 
 B) Tobacco chewing 1. Yes; duration ________ years   2.No                                         
  C) Betel chewing      1. Yes; duration ________ years   2.No 
  D) Alcoholism          1.Yes; duration ________ years; Quantity____ml   2.No 
  E) Coffee or Tea        1.Yes; No of times ______ per day.          2.No 
13.DRUG HISTORY: Had the patient been treated before with allopathy drug for 
                                                 anaemia or any other ailments? 
                                      A.YES       B.NO             IF YES : :   _______________ 
 
14. MARITAL STATUS:    1.Married   2.Unmarried        
 
 
                                              No of children:             male:          female:       
 
15. FAMILY HISTORY: 
 
      Whether this problem runs in family?                      1.Yes                             2.No       
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       If yes, mention the relationship of affected person(s)        ------------------------- 
 
16. MENSTURAL AND OBSTETRIC HISTORY: 
1. Age at menarche _______ year 
 
       2. Regularly of cycle     Regular                              Irregular 
      3. Length of cycle [Days] 
      4. Duration of flow [Days] 
      5. Level of flow       Low                   Moderate                          Heavy 
      6.LMP : 
      7. Passage of big clots                           Yes / No 
8. Dysmenorrhoea started at age _______ years 
      9. Onset of abdominal pain 
      Starts at the time of menstruation           Prior by _____ hours 
                                                                          At that time 
                                                           After _____ hours 
     10. Presence of abdominal pain other than around the time of menstruation 
 
     1. Yes                     2.No 
 
   11. Presence of hirsuitism       1.Yes                        2.No 
   12. Drug history:       H/O Previous hormonal therapy   1. Yes                          2.No 
 
17. BOWEL HABITS & MICTURITION:  Normal  
 
            Historyof habitual constipation    1.Yes                           2.No                                                       
 
            History of frequent diarrhoea        1.Yes                            2.No                                                         
 
            History of frequent dysuria           1.Yes                             2.No                
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18. PSYCHOLOGICAL STATE:  Normal Anxiety                Depression 
 
19. THEGI: [ TYPE OF BODY CONSTITUTION] 
        
1.Vatham                 2.Pitham                                   3.Kabam                           IF NO 4. ____________ 
  
20. NILAM: [LAND WHERE PATIENT LIVED MOST]  
 
Kurinji                    Mullai                        Marutham                   Neithal                        Paalai   
 
21. KAALAM: [SEASON] 
 
  Kaarkalam                                         Koothirkalam                         Munpanikalam     
  Pinpanikalam                                      Ilavenil                                   Muthuvenil  
22. GUNAM:[CHARACTER] 
 
 Sathuvam                           Rasatham                      Thamasam 
  
23.SIDDHA SYSTEM OF EXAMINATION: 
 
 ENVAGAI THERVU:[EIGHT-FOLD EXAMINATION] 
 
I.NAADI: [PULSE PERCEPTION] 
 
 BEFORE TMT AFTER TMT       
 Vali   
Azhal   
Iyyam   
Vali Azhal   
Azhal vali   
Iyya vali   
Vali Iyyam   
Azhal Iyyam   
Iyya Azhal   
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II.NAA: [TONGUE] 
 
 BEFORE TMT AFTER TMT      
Colour normal/Red pale/yellow normal/Red 
pale/yellow 
Taste Sweet/Sour/ 
Pungent/Bitter/ 
None 
Sweet/Sour/ 
Pungent/Bitter 
/None 
Coating Present/Absent Present/Absent 
Fissure Present/Absent Present/Absent 
Saliva Normal/Increased/ 
Decreased 
Normal/Increased/
Decreased 
Dryness Present/Absent Present/Absent 
Glossitis Present/Absent Present/Absent 
Baldness Present/Absent Present/Absent 
 
III.NIRAM:[COMPLEXION]    
 
 
BEFORE TMT 
 
AFTER TMT 
 
Dark/pale/Yellow 
tinted/wheatish brown 
 
Dark/pale/ 
Yellow tinted/ 
wheatish brown 
 
IV.MOZHI:[VOICE] 
 
BEFORE TMT AFTER TMT 
Medium/High/ 
Low pitched 
Medium/High/ 
Low pitched 
 
V.VIZHI:[EYES] (Lower palpebral conjunctiva)     
 
BEFORE TMT AFTER TMT 
normal/Red 
pale/yellow 
normal/Red pale/yellow 
 
 
 
   
145 
 
VI. MALAM:[BOWEL HABITS / STOOLS] 
 
 BEFORE TMT AFTER TMT 
Colour Dark/pale/yellow/Red Dark/pale/yellow/Red 
Consistency Solid/Semisolid/Watery Solid/Semisolid/Watery 
stool  bulk                          Normal/Reduced Normal/Reduced 
Constipation   Present/Absent Present/Absent 
Diaarhoea Present/Absent Present/Absent 
 
VII.MOOTHIRAM:[URINE EXAMINATION] 
 
Neerkkuri  Neerkkuri BEFORE TMT AFTER TMT Neikkuri  BEFORE  TMT AFTER TMT 
Niram[Colour]   Yellow/Red/White/ 
Straw coloured/ 
Crystal clear 
Yellow/Red/White 
/Straw coloured/ 
Crystal clear 
Serpentine fashion   
Manam[Odour
] 
Present/Absent Present/ Absent Annular/Ringed 
fashion 
  
Nurai[Froth] Nil/Reduced/Increasd Nil/Reduced/Increased Pearl beaded 
fashion    
  
Edai[Sp.gravity
]                                
Normal/Increasd/Red
uced  
Normal/Increased/ 
Reduced 
Mixed fashion   
Enjal[Deposits] Present/ Absent Present/ Absent Other fashion   
Volume   Normal/Increasd/ 
Reduced 
Normal/Increased/ 
Reduced 
   
 
VIII. SPARISAM:[PALPATORY  PERCEPTION] 
BEFORE TMT AFTER TMT 
Warmth/Hot/ 
cold/ Sweat 
Warmth/Hot 
/cold/ Sweat 
 
24.IYMPORIGAL:[SENSORY ORGANS] 
 BEFORE TMT AFTER TMT 
 Normal/ Affected       Normal/ Affected       
Mei [Skin]   
Vaai 
[Buccalcavity] 
  
Kan [Eyes]   
Mooku[Nose]   
Sevi [ear]   
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25.IYMPULANGAL:[MOTOR ORGANS] 
 
 BEFORE TMT AFTER TMT 
 Normal/ Affected       Normal/ Affected       
Kai [upperlimb]   
Kal [lowerlimb]   
Vai[Buccal 
cavity] 
  
Eruvai[excretory 
organ] 
  
Karuvai 
[Reproductive 
organ] 
  
 
26.KOSAM:[SHEATHS] 
 BEFORE TMT AFTER TMT 
 Normal/ Affected       Normal/ Affected       
Annamaya kosam   
Pranamaya Kosam   
Manonmayakosam   
Vingyanamaya 
kosam 
  
Anandhamaya 
kosam 
  
 
27. MUKKUTRAM:[AFFECTION OF THREE HUMORS] 
A)VATHAM:    
 BEFORE TMT AFTER TMT 
 Normal/ Affected       Normal/ Affected       
Praanan   
Abaanan    
Samaanan   
Udhaanan   
Viyaanan   
Naahan   
Koorman   
Kirukaran   
Devathathan   
Dhananjeyan   
147 
 
B) PITHAM: 
 BEFORE 
TMT 
AFTER  TMT 
 Normal/ 
Affected       
Normal/ Affected       
Analapitham   
 Prasakam   
Ranjakam   
Aalosakam   
Saathakam   
 
C) KABAM: 
 
 BEFORE 
TMT 
AFTER TMT 
 Normal/ 
Affected       
Normal/Affected       
Avalambagam   
Kilethagam   
Pothagam   
Tharpagam    
Santhigam   
 
28.SEVEN DHATHUS:[SEVEN SOMATIC COMPONENTS] 
  
 BEFORE TMT AFTER TMT 
 Normal/ Affected       Normal/ Affected 
Saaram[chyme]   
Senneer[Blood]    
Oon[Muscle]   
Kozhuppu[Fat]   
Enbu[Bones]   
Moolai[Bonemarrow]   
Sukkilam/Suronitham  
[Genital discharges] 
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29.GENERAL EXAMINATION: 
 
 BEFORE TMT AFTER TMT 
Height (cms)   
Weight (kg)   
Temperature(°F)      
Pulse rate (per min)   
Heart rate (per min)   
Respiratory rate(per min)   
Blood pressure(mm/Hg)   
Pallor   
Jaundice   
Cyanosis   
Lymphadenopathy   
Pedal edema   
Clubbing   
Jugular vein pulsation   
 
 
30.SYSTEMIC EXAMINATION: 
 
 BEFORE TMT AFTER 
TMT 
CardioVascular 
system          
  
Respiratory System   
Gastrointestinal 
system    
  
CentralNervous 
system        
  
Endocrine System   
 
 
 
 
 
 
 
 
149 
 
CLINICAL SYMPTOMS: 
 
 0th day 14th day 28th day 42nd day 56th day 70th day 84 th day 
Irregular menstruation        
Oligomenorrhoea        
Amenorrhoea        
Dysmenorrhoea        
Constipation        
Weight gain        
Infertility        
Acanthosis nigricans        
Hirsuitism        
 
 
Signature of the Investigator with date:        
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FORM III   LABORATORY INVESTIGATION FORM 
1. Serial No: ________                     2 .Patient ID:                                  3.Date:                     
BLOOD INVESTIGATION 
Before 
treatment 
Date: 
After 
treatment 
Date: 
NORMAL VALUES 
HB (gms %)    11-15 
T.RBC(milli/cu.mm)   3.5-5.5 
ESR (mm) 
½ hr.    
1 hr.     0-20 
T.WBC (cu.mm) 
 
  
 
 4000-11,000 
 
 
DIFFERENTIAL COUNT 
(%) 
Polymorphs   40-75 
Lymphocytes   20-35 
Monocytes   2-10 
Eosinophils   1-6 
Basophils   0-1 
Blood glucose (mg/dl) 
Fasting   80-120 
PP   <130 
Random   <140 
Lipid profile (mg/dl) 
Serum cholesterol             150-250 
HDL             30-60 
LDL          Upto 130 
VLDL               40 
TGL         Upto 160 
RFT (mg/dl) 
Blood urea 
 
          16-50 
Serum creatinine 
 
          0.6-1.2 
Serum Uric acid 
 
          2.5-7.5 
LFT (mg/dl) 
Total bilirubin            0.2-1.2 
Direct bilirubin             0.1-1.2 
Indirect bilirubin             0.2-0.7 
Serum total protein              6-8 
Serum Albumin             3.5-5.5 
Serum globulin             2-3.5 
Serum fibrinogen    
Serum calcium             9-11 
Serum phosphorous             2-5 
SGOT   IU/L             0-40 
SGPT  IU/L              0-35 
Alkaline phosphatase  IU/L             80-290 
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URINE INVESTIGATION 
 
Before TMT 
Date: 
After TMT  
Date: 
Albumin   
Fasting sugar   
PP sugar   
Random Sugar   
Deposits   
Bile salts   
Bile pigments   
Urobilinogen 
  
 
 
         USG PELVIS 
Before treatment 
Date: 
After treatment 
 Date: 
 
  
 
 
 
 
 
Signature of the Investigator with date: 
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FORM IV   (DRUG COMPLIANCE FORM) 
 
PATIENT ID : --------------     SERIAL NO :----------- DRUG NAME:GARPAVAYU ILAGAM 
 
On0thday-Date: ______; Drugsissued:42gm    Drugs returned:____gm 
On14thday-Date:______; Drugsissued:42gm    Drugs returned:____gm 
On28thday-Date:______; Drugsissued:42gm    Drugs returned:____gm 
On42rdday-Date:______; Drugsissued:42gm    Drugs returned:____gm 
On56thday-Date:______; Drugsissued:42gm    Drugs returned:____gm 
On70thday-Date:______; Drugsissued:42gm    Drugs returned:____gm 
 
Day Date  Morning Day    Date   Morning 
Day1   Day43   
Day2   Day44   
Day3   Day45   
Day4   Day46   
Day5   Day47   
Day6   Day48   
Day7   Day49   
Day8 to Day14-Drug holiday Day50 to Day 56-Drug holiday 
Day15   Day57   
Day16   Day58   
Day17   Day59   
Day18   Day60   
Day19   Day61   
Day20   Day62   
Day21   Day63   
Day22 to Day28-Drug holiday Day64 to Day70-Drug holiday 
Day29   Day71   
Day30   Day72   
Day31   Day73   
Day32   Day74   
Day33   Day75   
Day34   Day76   
Day35   Day77   
Day36 to Day 42-Drug holiday Day78 to Day84-Drug holiday 
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FORM V- PATIENT INFORMATION SHEET 
Name of the Principal Investigator: Dr.S.SHAGILA (PG Scholar)  
Name of the Institution                   :  National Institute of Siddha, Chennai-47. 
            IDr.S.Shagila  studyingM.D (Siddha) in National Institute of Siddha, Chennai. I am doing a 
clinical trial on the study of Garpa vaayu(Polycystic ovarian syndrome).It is the most common 
gynaecological endocrinopathy with ovarian expression of metabolic disturbances. Nowadays the 
incidence of PCOD is much higher because of changes in life style like dietary habits, lack of physical 
work, stressful work.It includes symptoms of irregular menstruation like absence of mensturation, painful 
mensturation, and increased body weight .This condition is being treated in NIS with many siddha 
formulations. As a part of M.D(S) research programme and developing new efficacious medicine, I have 
proposed to study the drug Garpavayu ilagam for treating this condition. This formulation has been 
mentioned in siddha literature and empirical evidence with contemporary tools is required for 
documentation. You can receive medicines free of cost. The duration of treatment period is 3months. You 
have to visit NIS 15 days once and collect drugs for 7 days. The diagnosis tests will be carried out free of 
cost. However, a particular test USG Abdomen has to be taken from outside lab and charges to be borne 
by you. We will assess the effect of treatment after completion of 3months of treatment using clinical and 
lab parameters. 
              In this regard, I need to ask you few questions. I will maintain confidentiality of your comments 
and data obtained from you. There will be no risk of disclosing your identity and no physical, 
psychological or professional risk is involved by taking part in this study. 
 Taking part in this study is voluntary. No compensation will be paid to you for taking part       in this 
study. You can choose not to answer any specific question. There is no specific benefit for you if you take 
part in the study, but you will be under our clinical monitoring and specific attention will be given for 
your health. Taking part in the study may be of benefit to the community, as it may help us to develop 
medicine for Garpa vaayu. In case of any adverse symptoms like severe abdominal pain, menorrhagia 
during the treatment shall be reported to me and care will be taken in NIS for relief. You can withdraw 
from the study at the midst of treatment period, if you are not interested to continue and you will receive 
our usual treatment without condition.      
            The information collect in this study, will remain between you and me as a principal investigator. I 
will ask you a few questions through questionnaire. I will not write your name on different forms which 
sent to different investigating/analysis sections and I will use a code instead given by the principal 
investigator. Only the principal investigator will know the key to this code which will be kept in safe 
custody. If you agree to be a participant in this study, you will be screened as per the study protocol.  
  If you wish to find out more about this study before taking part, you can ask me all the questions you 
want or contactDr.S.Shagila, PG scholarprincipal investigator of this study, attached to the National Institute 
of Siddha, Chennai (Mobile phone no:9787646890). You can also contact the Chairman/Member-
secretary of Ethics committee, National Institute of Siddha, Chennai – 600047, Tel no: 91-44-22411611, 
for rights and participation in the study. 
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FORM V- ¾¸Åø ÀÊÅõ 
Ó¾ý¨Á ¬Ã¡öîº¢Â¡Ç÷ ¦ÀÂ÷ :  Dr. Í.„¸¢Ä¡   
¿¢ÚÅÉò¾¢ý ¦ÀÂ÷                  :  §¾º¢Â º¢ò¾ ÁÕòÐÅ ¿¢ÚÅÉõ 
                                                  ¾¡õÀÃõ º¡Éð§¼¡Ã¢Âõ 
                                                  ¦ºý¨É 47 
 
Dr.Í.„¸¢Ä¡  ¬¸¢Â ¿¡ý §¾º¢Â º¢ò¾ ÁÕòÐÅÁ¨ÉÂ¢ø Àð¼ §ÁüÀÊôÒ ÀÂ¢ýÚ ÅÕ¸¢§Èý. ¦¸÷ôÀ Å¡Ô ±ýÛõ 
§¿¡Â¡ÉÐ º¢¨Éô¨ÀÂ¢ø ¿£÷¸ðÊ¸¨Ç ²üÀÎòÐõ ´Õ §¿¡Â¡Ìõ. þó§¿¡Â¡ÉÐ ´Øí¸üÈ 
Á¡¾Å¢¼¡ö,Ý¾¸¾¨¼,Ý¾¸ÅÄ¢,¯¼øÀÕò¾ø,¸÷ôÀò¾¢¨É «Æ¢ò¾ø,Ó¸ò¾¢ø §¾¡ýÚõ §¾¨ÅÂüÈ ÓÊ 
ÅÇ÷îº¢,ÁÄîº¢ì¸ø §À¡ýÈ ÌÈ¢Ì½í¸¨Çò §¾¡üÚÅ¢ìÌõ. þó§¿¡öìÌ §¾º¢Â º¢ò¾ ÁÕòÐÅÁ¨ÉÂ¢ø ÀÄ º¢ò¾ 
ÁÕóÐ¸û ÀÂýÀÎò¾ôÀðÎ ÅÕ¸¢ýÈÐ. º¢ò¾ ÁÕòÐÅ Àð¼ §ÁüÀÊôÀ¢ø, ¬öÅ¢ý ´Õ ÀÌ¾¢Â¡¸ Ò¾¢Â ÁÕóÐ¸¨Ç 
ÀÂýÀÎòÐõ §¿¡ì¸¢ø ¦¸÷ôÀÅ¡Ô þÇ¸õ ±ýÛõ ÁÕó¾¢¨É þó§¿¡öìÌ ÅÆí¸ ÀÃ¢óÐ¨Ã ¦ºö¸¢§È¡õ. þó¾ 
ÁÕó¾¢ý ¦ºöÓ¨È, «Ç×, «ÛÀ¡Éõ ÁüÚõ ÁÕòÐÅ ÀÂý¸û «¨ÉòÐõ «í¸£¸Ã¢ì¸ôÀð¼ º¢ò¾ ÁÕòÐÅ áÄ¢ø 
ÜÈôÀðÎûÇÐ. ±ó¾Å¢¾ ¸ð¼½ÓÁ¢ýÈ¢ ¾¡í¸û þó¾ ÁÕó¾¢¨É ¦ÀüÚì¦¸¡ûÇÄ¡õ. þó¾ ¬öÅ¢ø ÁÕóÐ 
¯ð¦¸¡ûÙõ ¸¡Äõ 3 Á¡¾í¸û ¬Ìõ. 14 ¿¡û¸ÙìÌ ´ÕÓ¨È §¾º¢Â º¢ò¾ ÁÕòÐÅÁ¨ÉìÌ §¿Ã¢ø ÅóÐ 
ÁÕó¾¢¨É ¦ÀüÚì¦¸¡ûÇ §ÅñÎõ. þó¾ ¬ö× ºõÀó¾Á¡É ¬öÅ¸ ÀÃ¢§º¡¾¨É¸û ¸ð¼½Á¢ýÈ¢ ¦ºöÂôÀÎõ. 
§ÁÖõ þó§¿¡öì¸¡É, ÌÈ¢ôÀ¢ð¼ USG ABDOMEN ÀÃ¢§º¡¾¨É ¦ÅÇ¢ ¬ö×ìÜ¼ò¾¢ø ¾í¸û ¦ºÄÅ¢§Ä§Â 
¦ºöÐ ¦¸¡ûÇ §ÅñÎõ. 3 Á¡¾í¸û ÁÕóÐ ¯ð¦¸¡ûÙõ ¸¡Äõ ÓÊó¾ À¢ÈÌ §¿¡öì¸¡É ÌÈ¢Ì½í¸û ÁüÚõ 
¬öÅ¸ ÀÃ¢§º¡¾¨É¸û þÅüÈ¢ý ÓÊ×¸Ç¢ý «ÊôÀ¨¼Â¢ø ÁÕó¾¢ý ÀÃ¢¸Ã¢ôÒò¾¢Èý ¸ñ¼È¢ÂôÀÎõ. 
 
 þó¾ ¬ö× ºõÀó¾Á¡¸ º¢Ä §¸ûÅ¢¸¨Ç ¾í¸Ç¢¼õ §¸ð¸ þÕì¸¢§Èý. ¾í¸Ç¢¼Á¢ÕóÐ ¦ÀÈôÀÎõ 
¸ÕòÐì¸û ÁüÚõ ÌÈ¢ôÒ¸û «¨ÉòÐõ ¿õÀ¢ì¨¸Â¡¸ À¾¢× ¦ºöÂôÀÎõ.þó¾ ¬öÅ¢ø ¾í¸¨Ç 
¯ðÀÎò¾¢ì¦¸¡ûÅ¾¢ý ãÄõ ±ó¾ Å¨¸Â¢Öõ À¡¾¢ôÒìÌûÇ¡¸ Á¡ðË÷¸û ±É ¯Ú¾¢ «Ç¢ì¸¢§Èý. 
 
 ±ó¾Å¢¾ ÅüÒÚò¾ÖÁ¢ýÈ¢, þó¾ ¬öÅ¢ø Àí§¸ü¸×õ, þó¾ ¬ö× ºõÀó¾Á¡¸ §¸ð¸ôÀÎõ §¸ûÅ¢¸ÙìÌ 
À¾¢ø ÜÈ×õ ¾í¸ÙìÌ ÓØ Í¾ó¾¢Ãõ «Ç¢ì¸ôÀÎ¸¢ÈÐ. þó¾ ¬öÅ¢ø Àí§¸üÀ¾üÌ ±ó¾ ºýÁ¡ÉÓõ 
ÅÆí¸ôÀ¼Á¡ð¼¡Ð.  ¬É¡ø, ¬ö× ÓØÅÐõ ±ÉÐ §ÁüÀ¡÷¨ÅÂ¢Öõ, ¾í¸û ¯¼ø¿Äý ÌÈ¢ò¾ ¾É¢ ¸ÅÉò¾¢Öõ 
¬ö× §Áü¦¸¡ûÇôÀÎõ. ¦¸÷ôÀ Å¡Ô §¿¡öì¸¡É Ò¾¢Â ÁÕó¾¢ý ÀÃ¢¸Ã¢ôÒò¾¢È¨É ºã¸ò¾¢üÌ ¯½÷òÐõ 
Å¨¸Â¢ø þó¾ ¬ö× §Áü¦¸¡ûÇôÀÎ¸¢ÈÐ. þó¾ ¬öÅ¢ø, ÁÕóÐ ¯ð¦¸¡ûÙõ ¸¡Äò¾¢ø º¢ÄÕìÌ ¦ÀÕõÀ¡Î, 
¾¡í¸ÓÊÂ¡¾ ÅÂ¢üÚ ÅÄ¢ §À¡ýÈ Á¡ÚÀð¼ ÌÈ¢Ì½í¸û ¦¾¡¼÷óÐ þÕìÌõ Àðºò¾¢ø, Ó¾ý¨Á 
¬Ã¡öîº¢Â¡ÇÃ¡É ±ýÉ¢¼õ ¦¾Ã¢Å¢ì¸ôÀðÎ, §¾º¢Â º¢ò¾ ÁÕòÐÅÁ¨ÉÂ¢ø «¾üì¸¡É ¾£÷× ÅÆí¸ôÀÎõ. þó¾ 
¬öÅ¢¨Éò ¦¾¡¼Ã ¾í¸ÙìÌ Å¢ÕôÀõ þø¨Ä¦ÂÉ¢ø, ±ô¦À¡ØÐ §ÅñÎÁ¡ÉÖõ ¬öÅ¢ý þ¨¼Â¢ø 
Å¢Ä¸¢ì¦¸¡ûÇ×õ, þõÁÕòÐÅÁ¨ÉÂ¢ø ÅÆí¸ôÀÎõ þó§¿¡öì¸¡É ÅÆì¸Á¡É ÁÕóÐ¸¨Ç ¦ÀüÚì¦¸¡ûÇ×õ 
«È¢×Úò¾ôÀÎ¸¢È£÷¸û. 
 
 þó¾ ¬öÅ¢ø §º¸Ã¢ì¸ôÀÎõ Å¢ÀÃí¸û «¨ÉòÐõ ¾í¸ÙìÌõ Ó¾ý¨Á ¬Ã¡öîº¢Â¡ÇÃ¡É ±ÉìÌõ 
þ¨¼Â¢ø þÃ¸º¢ÂÁ¡¸ ¨Åì¸ôÀÎõ. §¸ûÅ¢ À¾¢ø ÅÊÅò¾¢ø ¾í¸Ç¢¼õ §¸ûÅ¢¸û §¸ð¸ôÀÎõ. «¨ÉòÐô 
ÀÊÅí¸Ç¢Öõ ¾í¸Ç¢ý ¦ÀÂ÷ ¾Å¢÷ì¸ôÀðÎ ¬öÅ¡ÇÃ¡ø ¾í¸Ùì¦¸É ¾É¢ì ÌÈ¢Â£Î ÅÆí¸ôÀÎõ. «ó¾ì ÌÈ¢Â£Î 
¬öÅ¡ÇÕìÌ ÁðÎ§Á ¦¾Ã¢ó¾¾¡¸ þÕìÌõ. ¿£í¸û þó¾ ¬öÅ¢ø Àí§¸ü¸ Å¢ÕôÀôÀð¼¡ø, ¾¢ð¼ Å¨Ã× ÀÊ 
§¾÷× ¦ºöÂôÀÎÅ£÷¸û. 
 
 ¿£í¸û þó¾ ¬öÅ¢ø Àí§¸üÌõ Óý, þó¾ ¬öÅ¢¨Éô ÀüÈ¢Â §ÁÖõ Å¢ÀÃí¸û ¦ÀÈ §ÅñÎ¦ÁÉ 
Å¢ÕôÀôÀð¼¡ø, þó¾ ¬öÅ¢ý Ó¾ý¨Á ¬Ã¡öîº¢Â¡Ç÷ ÁüÚõ §¾º¢Â º¢ò¾ ÁÕòÐÅÁ¨É, Àð¼ §ÁüÀÊôÒòÐ¨È 
Á¡½Å÷ Dr.Í.„¸¢Ä¡  ¬¸¢Â ±ý¨É 9787646890 ±ýÈ ±ñ½¢ø ¦¾¡¼÷Ò ¦¸¡ûÇÄ¡õ. §ÁÖõ, ¿£í¸û þó¾ 
¬öÅ¢ø, ¯í¸ÇÐ Àí§¸üÒ ÁüÚõ ¯Ã¢¨Á ÀüÈ¢ ¦¾Ã¢óÐ ¦¸¡ûÇ §¾º¢Â º¢ò¾ ÁÕòÐÅÁ¨É, ¾¨ÄÅ÷/¦ºÂüìÌØ 
¯ÚôÀ¢É÷ «Å÷¸¨ÇÔõ 91-44-22411611 ±ýÈ ±ñ½¢ø ¦¾¡¼÷Ò ¦¸¡ûÇÄ¡õ.   
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FORM VI –INFORMED CONSENT FORM 
 “I have read the foregoing information, or it has been read to me. I have had the opportunity to ask 
questions about it and any questions I have asked have been answered to my satisfaction.  
            I   consent voluntarily to participate in this study and understand that I have the right to 
withdraw from the study at any time without in any way it affecting my further medical care”. 
 
"I have received a copy of the information sheet/consent form". 
Date: 
Signature of the participant:                                                         Signature of the investigator: 
IN CASE OF ILLITERATE PARTICIPANT 
  “I have witnessed the accurate reading of the consent form to the potential participant, and 
the individual has had the opportunity to ask questions. I confirm that the individual has given consent 
freely.”                                                   
 
 
Date: 
 
 Signature of a witness :                                           Left thumb Impression of the Participant:     
 
Signature of the Investigator & Date: 
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FORM  VI-´ôÒ¾ø ÀÊÅõ 
                ¿¡ý §ÁüÜÈ¢Â  ¾¸Åø  ÀÊÅò¨¾ ÀÊòÐ «øÄÐ ÀÊì¸ §¸ðÎ ¦¸¡ñ§¼ý. 
þÐ ¦¾¡¼÷À¡É Å¢Çì¸í¸¨ÇÔõ §¸ðÎ ¦¾Ã¢óÐ ¦¸¡ñ§¼ý.±ó¾ Å¢¾ ÅüÒÚò¾Ä¢ýÈ¢, 
±ý ¦º¡ó¾ Å¢ÕôÀò¾¢ý §ÀÃ¢ø ±ý¨É þó¾ ¬Ã¡öîº¢ìÌ ¯ðÀÎò¾ ±ý ÓØÁÉ§¾¡Îõ 
ÍÂ¿¢¨É§Å¡Îõ ºõÁ¾õ ¦¾Ã¢Å¢ì¸¢§Èý.±ÉìÌ Å¢ÕôÀÁ¢øÄ¡¾ Àðºò¾¢ø ó¾ 
¬Ã¡öîº¢Â¢ø ÕóÐ ±ý¨É ±ô§À¡Ð§ÅñÎÁ¡É¡Öõ Å¢ÎÅ¢òÐ ¦¸¡ûÙõ ¯Ã¢¨Á¨Â 
¦ÀüÚû§Çý ±ýÀ¨¾Ôõ «È¢§Åý. 
 
§¾¾¢:                                                                             
¼õ:                                                                             º¡ðº¢ì¸¡Ã÷ ¨¸¦Â¡ôÀõ: 
                                                                                       ¦ÀÂ÷: 
¨¸¦Â¡ôÀõ:                                                                     ¯È×Ó¨È         :                                                                                      
¦ÀÂ÷     : 
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FORM VII- (WITHDRAWAL FORM/ADVERSE DRUG REACTION FORM/ 
PHARMACOVIGILANCE FORM) 
1. DATE OF TRIAL COMMENCEMENT: ………………... 
2. DATE OF WITHDRAWAL FROM TRIAL: …………….. 
3. REASONS FOR WITHDRAWAL: 
Long absence at reporting:              Yes/ No 
Irregular treatment:                          Yes/ No 
Shift of locality:                                    Yes/No 
Increase in severity of symptoms:    Yes/No 
Development of severe adverse drug reactions:  Yes/No 
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NATIONAL PHARMACOVIGILANCE PROGRAMME FOR  SIDDHA 
DRUGS 
 
Please note:  i. All consumers / patients and reporters information will remain confidential. 
ii. It is requested to report all suspected reactions to the concerned, even if it does not have complete 
data, as soon as possible. 
Peripheral Center code:        State:  
 
 
1. Patient / consumer identification (please complete or tick boxes below as appropriate) 
 
Name  Father name 
 
Patient / Record No. 
Ethnicity  Occupation 
Address  
Village / Town 
Post / Via 
District / State    
Date of Birth / Age: 
 
Sex:     Male / Female  
Weight : 
Degam: 
 
2. Description of the suspected Adverse Reactions (please complete boxes below) 
 
Date and time  of 
initial observation 
 Season: 
Description of reaction   
 
 Geographical area: 
 
3. List of all medicines / Formulations including drugs of other systems used by the patient during the 
reporting period: 
 
Medicine Daily dose Route of 
administration 
& Vehicle – 
Adjuvant 
Date  Diagnosis for which 
medicine taken  Starting Stopped 
Siddha 
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Anyother 
systemofmedic
ines 
 
     
 
4. Brief details of the Siddha Medicine which seems to be toxic: 
 
Details Drug – 1 Drug – 2 Drug – 3 
a) Name of the medicine    
b) Manufacturing unit and batch 
No. and date 
   
c) Expiry date    
d) Purchased and obtained from    
e) Composition of the 
formulation / Part of the drug 
used 
   
 
 
b) Dietary Restrictions if any 
c) Whether the drug is consumed under Institutionally qualified medical supervision or used as self 
medication.  
d) Any other relevant information. 
 
5. Treatment provided for adverse reaction: 
 
6. The result  of the adverse reaction / side effect / untoward effects (please complete the boxes below) 
 
Recovered:           Not 
recovered: 
 Unknown: Fatal: If Fatal 
Date of death: 
Severe:   Yes   /   No. Reaction abated after drug stopped or dose reduced: 
 
Reaction reappeared after re introduction: 
 
 
Was the patient admitted to hospital? If yes, 
give name and address of hospital 
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7. Any laboratory investigations done to evaluate other possibilities?  If Yes specify:  
 
8. Whether the patient is suffering with any chronic disorders? 
Hepatic    Renal   Cardiac    Diabetes    Malnutrition  
 
Any Others  
9. H/O previous allergies / Drug reactions:  
 
10. Other illness (please describe): 
11. Identification of the reporter: 
 
Type (please tick):  Nurse / Doctor / Pharmacist / Health worker / Patient / Attendant / Manufacturer 
/                                                                      
                                Distributor / Supplier / Any others (please specify) 
Name: 
 
Address: 
 
Telephone / E – mail if any : 
 
 
Signature of the reporter:        Date: 
Please send the completed form to:  
Name & address of the RRC-ASU / PPC-ASU 
    The Director 
            National Institute of Siddha, 
                                                           (Pharmacovigilance Regional Centre For Siddha Medicine), 
Tambaram Sanatorium, Chennai-600 047. 
                                                            (O) 044-22381314  Fax : 044 – 22381314 
Website :www.nischennai.org 
        Email: nischennaisiddha@yahoo.co.in 
 
* * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * ** * *  
This filled-in ADR report may be sent within one month of observation /occurrence of ADR 
 
Signature of the Investigator with date: 
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FORM VIII- DIETARY ADVICE FORM 
The following diet to be taken: 
  Drink adequate water 
 Goose berry 
 Green vegetables 
 Fish   
 Sprouted black gram 
 Butter milk 
 Fig fruit 
 Honey 
 Tender brinjal 
 Bananna 
 Pome granate 
 Dates 
The following food should be avoided: Karapan inducing foods : 
 Solam(Maize),  
  Kambu(Pear milet),   
 Varagu (Kodo millet),  
  Kaar Arici(rice) ,   
  Vaazaikai(Unriped banana),  
  Paagal(Bitter gourad),          
 kelitrumeen(fish).      
 
 
 
Signature of the Investigator &Date:                                                       
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FORM VIII – DIETARY ADVICE FORM 
 
§º÷ì¸ ÜÊÂ ¯½× Å¨¸¸û                                                          
 ¦¿øÄ¢ì¸¡ö                                                                                                                                                                      
 Àî¨º ¸¡ö¸È¢¸û  
 §Á¡÷   
 «ò¾¢ôÀÆõ 
 §ÀÃ£î¨º                    
 ¸ò¾¢Ã¢ À¢ïÍ  
 Á¡Ð¨Ç                        
 ÀôÀ¡Ç¢  
 «ýÉ¡º¢ôÀÆõ              
 ¦¸¡ð¨¼ÔûÇ ¸ÕôÒ ¾¢Ã¡ð¨º 
 À¡º¢ôÀÂ¢÷                     
 §º¡Â¡ À£ýÍ 
¾Å¢÷ì¸ ÜÊÂ ¯½× Å¨¸¸û:¸ÃôÀ¡ý À¾¡÷ò¾í¸û  
 §º¡Çõ   
 ¸õÒ   
 ÅÃ¸Ã¢º¢   
 ¸¡ÃÃ¢º¢   
 Å¡¨Æì¸¡ö  
 À¡¸ø  
 ¦¸Ç¢üÚÁ£ý 
 
 
 
Signature of the Investigator &Date:                                                       
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  VENSIVATHAI                         NILAVAGAI                             KORAIKIZANGU 
      
 
 
  CHUKKU                                 MILAGU                                   THIPPILI 
   
 
         KADUKKAI                               NELLIKKAI                        THANDRIKKAI 
                
  
] 
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  KANDATHIPPILI                      OMAM                                    KUROSANI OMAM 
                
      VAIVILANGAM                    ATHIVIDAYAM                    MAASIKKAI 
               
   KADUGUROGINI                               INDHUPPU                        BROWN  SUGAR 
                           
SITRAMANAKKU ENNEI 
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GARPA VAAYU ILAGAM 
 
 
 
 
 
Dosage  : 6 gm, morning, before food 
Duration :  like wise 7days medicine – 7days drug holiday 
Study Period : 3 months /patient 
Total duration of drug administration : 42 days  
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